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Self-assembling peptides have emerged as new nanobiomaterials in the areas of nanoscience and 
biomedical engineering. In this category are self-assembling, ionic-complementary peptides, which 
contain a repeating charge distribution and alternating hydrophobic and hydrophilic residues in the 
amino acid sequence, leading to a unique combination of amphiphilicity and ionic complementarity. 
These peptides can self-assemble into stable nanostructures or macroscopic membranes that can 
withstand conditions of high temperature, extreme pH, many digesting enzymes and denaturation 
agents. Moreover, they exhibit good biocompatibility with various cultured mammalian cells, and do 
not have detectable immune responses when introduced into animals. These properties make them 
ideal materials for tissue scaffolding, regenerative medicine and drug delivery. 
This thesis focuses on the utilization of self-assembling peptides for hydrophobic anticancer 
drug delivery. The hydrophobic anticancer agent ellipticine was selected as a model drug. The studies 
include: (i) characterization of the photophysical properties of ellipticine in different environments; 
(ii) study of the formation of peptide-ellipticine complexes and the release kinetics; (iii) investigation 
of the cellular toxicity of the complexes and ellipticine uptake; (iv) study of the peptide sequence 
effect on the complex formation and in vitro delivery. 
Prior to applying ellipticine to the peptide-based delivery system, the fundamental studies on 
the effect of solution conditions, especially solvent polarity and hydrogen bonding, on the 
fluorescence of ellipticine were carried out. Ultraviolet (UV) absorption and fluorescence emission of 
ellipticine were found to be solvent/environment dependent. The absorption and emission maxima 
shifted to higher wavelengths (red shift) with increased solvent polarity. Large Stokes’ shifts were 
due to intramolecular charge transfer (ICT), which was enabled by large solvent polarity and 
hydrogen bonding of ellipticine with the solvents. The photophysical response of ellipticine to 
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changes in solvent polarity and hydrogen bond formation could be used to infer the location of 
ellipticine in a heterogeneous medium, such as liposomes and cultured cells. 
EAK16-II, a model self-assembling peptide, was found to be able to stabilize ellipticine in 
aqueous solution. The equilibration time required to form peptide-ellipticine complex suspensions 
was found to be peptide concentration-dependent and related to the peptide critical aggregation 
concentration (CAC, ~0.1 mg/mL). With different combinations of EAK16-II and ellipticine 
concentrations, two molecular states (protonated or crystalline) of ellipticine could be obtained in the 
complexes. The release kinetics of ellipticine from the complex into egg phosphatidylcholine (EPC) 
vesicles (cell membrane mimics) was also affected by the peptide concentration used in the drug 
formulation. A higher peptide concentration resulted in a faster transfer rate, in relation to the size of 
the resulting complexes. Subsequent cellular studies on two cancer cell lines, A549 and MCF-7, 
showed that the complexes with protonated ellipticine were more effective against both cell lines, but 
their dilutions were not very stable. In addition, it was found that ellipticine uptake in both cell lines 
was very fast and through direct membrane permeation. 
Three peptides, EAK16-II, EAK16-IV and EFK16-II, either having a different charge 
distribution (EAK16-II vs. EAK16-IV) or hydrophobicity (EAK16-II vs. EFK16-II), were tested for 
the complexation and in vitro delivery of ellipticine. It was found that EAK16-II and EAK16-IV were 
able to stabilize protonated or crystalline ellipticine depending on the peptide concentration; EFK16-
II, on the other hand, could stabilize neutral ellipticine molecules and ellipticine (micro)crystals. The 
viability results showed that the charge distribution of the peptides seemed not to affect the complex 
formation and its therapeutic efficacy in vitro; however, the increase in hydrophobicity of the peptides 
significantly altered the states of stabilized ellipticine and increased the stability of the complexes. 
This work provides essential information for peptide sequence design in the development of self-
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Cancer is the second most common cause of death in the developed countries after heart disease, 
causing over 70,000 fatalities each year in Canada.1 It is a type of genetic disease, resulting from the 
mutation of genes in a normal cell and causing it to malfunction, especially in cell growth and 
recognition with the adjacent cells.2,3 Such a malfunction leads to uncontrollable cell growth and cell 
metastasis. Since cancerous cells originate from the normal cells in the body, they are barely “seen” 
by our immune systems in early stages, leading to challenges for early cancer diagnoses. This 
immune “invisibility” of the cancerous cells in combination with their uncontrollable growth and 
metastasis makes cancer one of the most difficult diseases to fight.  
By far, there have been three major types of cancer treatments practically used in clinics: 
surgery, radiotherapy and chemotherapy.3 Surgery and radiotherapy are local treatments to remove or 
sterilize defined solid tumor masses. They often prove successful for locally confined, primary solid 
tumors. Chemotherapy, on the other hand, is a systemic therapy to kill tumor cells throughout the 
body, which is especially useful for metastatic tumors. It is also applied as the adjuvant treatment 
after surgery or radiotherapy. Other cancer treatments have been emerging from a better 
understanding of the cellular and molecular biology of cancer.2,4 They include adoptive 
immunotherapy, cancer vaccine, gene therapy, antisense and RNAi therapy, hormone and growth 
factor antagonists, antiangiogenesis therapy, inhibitors for cell cycle and cancer-promoting 
proteins.2,4-12 Although some of these new strategies have shown promise in preclinical tests, they still 
have a long way toward clinical applications. Nevertheless, at present, about 50% of cancer patients 
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can be cured, with chemotherapy contributing to cures in 10-15% of the patients. This indicates that 
the chemical control of neoplasia plays an important role in cancer treatment and the development of 
advanced chemotherapy will benefit more cancer patients. 
However, two main obstacles exist in the conventional cancer chemotherapy. One is the severe 
side effects of the cytotoxic chemicals; the other is the development of drug resistance.13 The harmful 
side effects can result in patient non-compliance and cause damage to healthy tissues/organs 
(especially fast replicating tissues including the bone marrow and the gastrointestinal tract mucosa), 
which in turn greatly limits the applicable dosage.8,13-15 This is because most chemotherapeutic agents 
lack specificity in reaching tumor tissue; such poor specificity at the cellular level also significantly 
reduces the therapeutic efficacy. The “cellular” drug resistance arises from a defence mechanism of 
cancer cells in response to the chemotherapeutic agents, known as the multidrug resistance (MDR) 
phenotype, which involves active efflux of a broad range of cytotoxic drug molecules out of the 
cytoplasm by membrane-bound transporters.4,13 In addition, massive solid tumors can create various 
drug permeation barriers (comparing to non-aggregating cancer cells), leading to a relatively low 
intratumoral drug concentration in solid tumors, referred as “non-cellular” drug resistance. These 
limitations may be overcome with delivery devices, e.g., nanocarriers, capable of passive or active 
targeting.8,15-19 The nanocarriers are small enough (< 200 nm) to extravasate out of tumor 
microvasculature and accumulate in the tumor interstitium, known as the enhanced permeability and 
retention (EPR) effect.15,20 They can also be linked to targeting molecules that can recognize and bind 
specifically to cancer cells. This further improves the delivery efficacy and significantly reduces 
undesired side effects. 
Many delivery devices have been developed to improve solubility, transport, safety, targeting 
and efficacy of chemotherapeutic agents. These delivery constructs include liposomes,21,22 polymeric 
and surfactant micelles,23-26 nanoparticles,13,15,27-29 polymeric vesicles,30,31 microemulsions,32 
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micro/nano-encapsulation,33 emulsification,34 cyclodextrans,35 dendrimers36 and carbon nanotubes.37 
The basic principle of these delivery vehicles for chemotherapeutics is to provide an enclosed, 
protective, hydrophobic interior that can molecularly solubilize hydrophobic anticancer drugs, and 
circulate in the blood steam. They can be made to achieve controlled release, active targeting and/or 
passive targeting (EPR) delivery by appropriate material design, post surface modification and control 
of the vehicle size. Although they all have achieved varying degrees of success in delivering 
chemotherapeutics, some challenges still remain in their biocompatibility, biostability and toxicity of 
the vehicles after degradation.38,39 
In addition to polymers, lipids, surfactants and some inorganic materials, self-assembling 
peptides have drawn much attention in drug delivery due to their desirable chemical/physical 
properties and biological functionalities. First, the peptides can be easily engineered to form a variety 
of stable nanostructures such as fibers,40,41 rod,42 tubes,43 nanovesicles44  and globules,45,46 which can 
be readily used as delivery constructs. Second, the peptide sequence can be designed to incorporate 
natural binding motifs to inorganic materials,41,47,48 oligonucleotides (e.g., antisenses),49,50 siRNA and 
hydrophobic compounds.51 Third, they can possess the natural propensities for cell penetration and 
targeting.52,53 Fourth, some peptide sequences possess therapeutic effects.54,55 With such features, self-
assembling peptides have great potential as delivery constructs for nanomedicines.56-58 
In this research, a special class of ionic-complementary, self-assembling peptides is used to 
explore the capability of such peptides in stabilizing hydrophobic anticancer drugs in aqueous 
solution and delivering them in vitro. This sets up the basis to develop self-assembling peptide-
mediated delivery of cancer chemotherapeutics in vitro. The selection of this particular class of self-
assembling peptides is based on the following reasons. First, these peptides have a simple sequence 
and unique structure for the study and possible control of peptide assembly.59 In the case of EAK16-
II, as an example, the peptide contains 16 amino acids in sequence, but is made of only three different 
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amino acids: glutamic acid (E), lysine (K) and alanine (A). These three amino acids are arranged in a 
special manner with hydrophobic (A) and hydrophilic residues (K or E) alternating in the sequence, 
rendering the peptide amphiphilic. In addition, the charged amino acid residues of EAK16-II alternate 
in a regular fashion ( ++−−++−− ), resulting in ionic complementarity.60,61 Second, most of these 
peptides have been found to form stable, β-sheet-rich nanostructures in aqueous solution.60-62 In a β-
sheet arrangement, all hydrophilic residues of the peptide are arranged on one side and the 
hydrophobic residues are on the other side. This unusual amphiphilic property allows the peptide to 
interact with both hydrophilic and hydrophobic (drug) molecules. Third, the unique molecular 
structure of EAK16-II enables various interactions (hydrogen bonding, electrostatic and hydrophobic 
interactions) to stabilize the assembled nanoconstructs, which can withstand extreme pHs, high 
temperature, many digestion enzymes and denaturation agents.61,62 Fourth, these peptides have non-
detectable immune response when introduced into animals, indicating good biocompatibility.61,63,64 
Fifth, fundamental aspects of peptide self-assembly have been explored by our research group for 
several years. Previous studies have shown that many factors such as peptide sequence45,46 and 
concentration,40,65 salt type and concentration,41,65,66 solution pH,45 surfaces67,68 and mechanical force69 
affect the self-assembled micro-/nanostructures of these peptides and their derivatives. These 
fundamental studies provide essential information for physicochemical control over peptide self-
assembly and nanostructure. The combination of the simple structure, unique properties, good 
(bio)stability and biocompatibility, as well as our previous knowledge of these peptides make them 
ideal candidates as delivery vehicles for hydrophobic anticancer drug. In fact, such a potential for 
hydrophobic anticancer drug delivery was first explored by our group and elaborated in this study. 
A hydrophobic compound, pyrene, was first used to demonstrate the capability of self-
assembling peptides in delivering hydrophobic cargos in the early studies.51,56 Following the success 
in pyrene delivery, a hydrophobic anticancer agent, ellipticine, was applied for developing self-
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assembling peptide-based delivery system here for the following reasons: first, the photophysical 
properties of ellipticine enable us to monitor the interaction of ellipticine with the peptide and locate 
it in different micro-environments;70 its characteristic fluorescence can be used to monitor cellular 
uptake, by fluorescence imaging and fluorescence-activated cell sorting (FACS) techniques. Second, 
ellipticine is extreme hydrophobic with a low water solubility of ~0.62 μM at neutral pH,71 
comparable to that of the model hydrophobic compound pyrene.72 Third, its great anticancer activity 
makes ellipticine one of the promising candidates in cancer chemotherapy.73 Fourth, the discovery of 
severe side effects of ellipticine derivatives during early clinical trials suggests that a novel delivery 
system is required.73,74 
This research project focuses on the complexation and in vitro delivery of the hydrophobic 
anticancer drug ellipticine using self-assembling, ionic-complementary peptides. In order to apply 
fluorescence techniques to investigate the complexation of ellipticine with the peptides, the release 
kinetics of ellipticine from the complexes, and cellular uptake of ellipticine, the photophysical 
properties of ellipticine in different environments were systematically studied. The self-assembling 
peptide EAK16-II was first used to stabilize ellipticine in aqueous solution. The kinetics of complex 
formation, molecular states of stabilized ellipticine and its release into a cell membrane mimic were 
investigated, and related to the peptide and ellipticine concentrations. The peptide-ellipticine 
complexes with certain combinations of peptide and ellipticine concentrations were further tested on 
their cellular toxicity and uptake into two cancer cell lines (A549 and MCF-7) to obtain the in vitro 
therapeutic effect. This information will be critical to the next phase of in vivo studies. In addition to 
EAK16-II, other two self-assembling peptides were used here to gain information of peptide sequence 
effects on the formation of peptide-ellipticine complexes and their anticancer activity in vitro. Based 
on the results reported in this work, strategies could be developed to design appropriate self-
assembling peptides to construct functional nanocarriers for advanced cancer chemotherapy.  
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1.2 Research Objectives 
The goal of this research is to develop self-assembling peptide-mediated delivery of hydrophobic 
anticancer drugs. To achieve this goal, the hydrophobic anticancer agent ellipticine is selected as the 
delivery cargo to test the principles of complexation with self-assembling peptides, release kinetics 
and the anticancer activity in vitro. The specific objectives of this thesis are listed in the following: 
1. Characterization of the photophysical properties of ellipticine in different solution 
environments; these properties provide essential information for studying the complexation, release 
and possibly cellular delivery, using fluorescence and/or UV absorption techniques. 
2. Study of the complex formation of ellipticine with a model self-assembling peptide, EAK16-
II, and the release kinetics of ellipticine from the resulting complexes. 
3. Evaluation of the therapeutic efficacy of the complexes in vitro with two cancer cell lines, 
non-small cell lung cancer cell A549 and breast cancer cell MCF-7. 
4. Investigation of the peptide sequence effect on the complex formation and its anticancer 
activity in vitro; the results will aid to the peptide design in the development of the self-assembling 
peptide-mediated delivery.  
1.3 Outline of the Thesis 
This thesis consists of seven chapters. The scope of each chapter is listed as follows: 
Chapter 1 gives an overview of the thesis, including a brief introduction to cancer 
chemotherapy, hydrophobic drug delivery systems, self-assembling peptides and their potential 
applications in drug delivery. The objectives and the scope of the thesis are also given in this chapter. 
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Chapter 2 provides a review of delivery systems for hydrophobic anticancer drugs, the 
hydrophobic anticancer agent ellipticine and its delivery methods. The properties of self-assembling 
peptides and their recent developments in drug delivery are also reviewed. 
Chapter 3 presents a thorough investigation of the photophysical properties of ellipticine in 
different solvent environments. Of particular interest is the solvent-dependent fluorescence of 
ellipticine for the characterization of complexation with peptides and its release. 
Chapter 4 deals with the complex formation of ellipticine with a self-assembling peptide, 
EAK16-II, and the release kinetics of ellipticine from the complexes. The concentration effect of both 
the peptide and ellipticine on complexation and release is investigated. 
Chapter 5 reports the anticancer activity of the peptide-ellipticine complexes in vitro and the 
cellular uptake of ellipticine. The importance of the peptide-to-ellipticine ratio (by mass) to the 
efficacy of in vitro delivery is also described. 
Chapter 6 investigates the peptide sequence effect on the complex formation of ellipticine and 
the cellular toxicity of the complexes. The effects of charge distribution and hydrophobicity of three 
different self-assembling peptides are studied. 
Chapter 7 presents the conclusions of studies in the thesis, contributions of this research and 




Chapter 2                                                                    
Literature Review 
2.1 Current Advances in Hydrophobic Anticancer Drug Delivery 
Nearly 40% of new drug candidates discovered today are hydrophobic compounds, possessing poor 
water solubility.75-77 These hydrophobic, potent compounds are often involved in various essential 
clinical treatments, especially in cancer chemotherapy. Unfortunately, their solubility problem in 
aqueous solution limits their clinical use since this prevents them from dissolving in the bloodstream, 
circulating in the host body and reaching their intended targets.76,78 In addition, the clinical dosage 
cannot be reached due to the poor drug solubility. For cytotoxic drugs, administration of bare drugs 
can cause serious side effects; other common problems associated with free drugs include fast drug 
degradation, unfavourable pharmacokinetics and poor biodistribution.79 Therefore, drug delivery 
systems, capable of solubilizing and carrying a hydrophobic drug to the intended targets, are being 
avidly studied and developed to supply additional therapies and new chemotherapeutics for clinical 
use.14,39,79 Some examples of problems that can be ameliorated by using a drug delivery system are 
listed in Table 2.1. 
Many delivery systems for hydrophobic anticancer drugs have been developed. They can be 
briefly categorized into five classes: polymeric conjugates, (micro)emulsions, micellar systems, 
liposomes and nanoparticles.80-82 The primary goal of these systems is to improve the solubility of the 
hydrophobic entities so that they can be properly administered and circulated in the body. The 
optimal goal is to achieve targeted delivery, a concept of the “magic bullet” proposed by Ehrlich in 
the early 20th century, through either active or passive mechanisms as the ideal cancer 
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chemotherapy.80,83 The advances in each class of the hydrophobic drug delivery systems are briefly 
reviewed in the following sections. 
 
Table 2.1 Non-ideal properties of drugs and their therapeutic implications.79 
Problem Implication Effect of DDS 
Poor solubility A convenient pharmaceutical format 
is difficult to achieve, as hydrophobic 
drugs may precipitate in aqueous 
media. Toxicities are associated with 
the use of excipients such as 
Cremphor® EL (the solubilizer for 
paclitaxel in Taxol). 
DDS such as lipid micelles or 
liposomes provide both hydrophilic 
and hydrophobic environments, 
enhancing drug solubility. 
Tissue damage on 
extravasation 
Inadvertent extravasation of cytotoxic 
drugs leads to tissue damage, e.g., 
tissue necrosis with free doxorubicin. 
Regulated drug release from the DDS 
can reduce or eliminate tissue 
damage on accidental extravasation. 
Rapid breakdown of 
the drug in vivo 
Loss of activity of the drug follows 
administration, e.g., loss of activity of 
camptothecins at physiological pH. 
DDS protects the drug from 
premature degradation and functions 
as a sustained release system. Lower 
doses of drug are required. 
Unfavorable 
pharmacokinetics 
Drug is cleared too rapidly, by the 
kidney, for example, requiring high 
doses or continuous infusion. 
DDS can substantially alter the PK of 
the drug and reduce clearance. Rapid 
renal clearance of small molecules is 
avoided. 
Poor biodistribution Drugs that have widespread 
distribution in the body can affect 
normal tissues, resulting in dose-
limiting side effects, such as the 
cardiac toxicity of doxorubicin. 
The particulate nature of DDS lowers 
the volume of distribution and helps 
to reduce side effects in sensitive, 
nontarget tissues. 
Lack of selectivity 
for target tissues 
Distribution of the drug to normal 
tissues leads to side effects that 
restrict the amount of drug that can 
be administered. Low concentrations 
of drugs in target tissues will result in 
suboptimal therapeutic effects. 
DDS can increase drug 
concentrations in diseased tissues 
such as tumors by the EPR effect. 
Ligand-mediated targeting of the 
DDS can further improve drug 
specificity. 
DDS: drug delivery system; EPR: enhanced permeability and retention; PK: pharmacokinetics 
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2.1.1 Polymeric Conjugates 
Polymeric conjugated systems have been widely used for the delivery of anticancer drugs. This 
concept was first clearly presented by Ringsdorf in 1975.84 The drug is covalently linked to a 
hydrophilic polymeric carrier to enhance the drug solubility in aqueous solution. In addition, the 
linkage of small hydrophobic molecules with a macromolecule can alter the pathway of cellular 
uptake. It has been found that the soluble macromolecular conjugates preferentially enter cells via 
endocytosis, which can significantly reduce the unspecific uptake by healthy tissue through direct cell 
membrane permeation.85 Such a mode of entry can bypass some of the common mechanisms of 
multidrug resistance (e.g., cell membrane efflux pumps).86 Three endocytosis mechanisms can occur 
for the soluble macromolecules: i) fluid-phase endocytosis, ii) adsorptive endocytosis, and iii) 
receptor-mediated endocytosis. By introducing cell recognition moieties to the conjugates, receptor-
mediated endocytosis can be achieved, consequently affecting the biodistribution, also known as 
active targeting.15 Even without such cell-specific targeting moieties, the polymeric conjugates are 
found to preferentially localize in the tumor tissue due to the EPR effect.84,85 These advantages make 
the polymeric conjugates attractive in anticancer drug delivery. 
The materials used to conjugate anticancer drugs can be broadly divided into synthetic and 
natural systems. The synthetic polymers are nonimmunogenic, but many of them are not 
biodegradable. These include poly(N-[2-hydroxypropyl]-methacrylamide) (HPMA), poly(styrene-co-
maleic anhydride) (SMA), poly(divinylether-co-maleic anhydride) (DIVEMA) and poly(ethylene 
glycol) (PEG).80,84 Natural biodegradable materials used for conjugation are poly(L-glutamic acid) 
(PG), some proteins, dextran and chitoson.80,85 The anticancer drugs Doxorubicin, Paclitaxel and 
Camptothecin can be successfully delivered using HPMA copolymer, PG and PEG conjugates; some 




Table 2.2 Polymer-drug conjugates in clinical trials.84 
Polymer Polymer-Drug Conjugate Phase of Clinical Trials 
HPMA HPMA-Doxorubicin (PK1) 
HPMA-Doxorubicin-Galactosamine (PK2) 
HPMA-Paclitaxel (PNU166945) 











PEG PEG-Camptothecin (PEG-CPT) II 
 
An important issue for polymeric-conjugate delivery systems is the proper release of the drug, 
which depends on the carrier-drug linkage. The ideal linkage should be broken only when the 
conjugates are internalized by the cells inside the endosomes or lysosomes.84 However, the commonly 
used pH-sensitive linkers, such as ester bonds, cis-aconityl spacers and hydroazone linkages, can also 
be hydrolyzed in the blood stream. Also, the degradation of disulfide bonds is relatively nonspecific 
in the blood stream and on the cell membranes. Such nonspecific release of the free drug results in the 
development of side effects. To overcome this obstacle, special linkers that are stable in the 
circulation and can be specifically cleaved in the lysosome are used. Amide bonds, usually from a 
short peptide spacer, perform this function. One example is the glycylphenylalanylleucylglycyl 
(GFLG) linker, which is susceptible to lysosomal cathepsin B (a cysteine protease), while remaining 
stable in the blood stream.87 
In addition to the passive targeting of the conjugates, active targeting can be achieved by 
linking a targeting moiety to enhance the specificity of internalization.15,88 This is especially useful for 
spreading tumors, metastases, and types of cancer that do not form solid tumors. The targeting 
moieties are usually antibodies, vitamins or analogs, and proteins/peptides. Recently, a PEG-
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camptothecin conjugate system was developed to incorporate a targeting moiety/penetration enhancer 
using a synthetic analogue of luteinizing hormone-releasing hormone (LHRH) peptide.89 In addition, 
a synthetic analogue of BCL2 homology 3 domain (BH3) peptide was introduced as a suppressor of 
cellular antiapoptotic defense. Such a combination of active targeting and inhibition of cellular 
antiapoptotic defense significantly enhances the antitumor activity compared to the individual 
components applied separately. Although the conjugated system has shown great promise in 
advanced cancer chemotherapy, the synthesis of a multicomponent conjugate involves a series of 
chemical reactions and purifications, which in turn greatly complicate the manufacturing processes. 
2.1.2 (Micro)emulsions 
(Micro)emulsions are stable mixtures of oil, water and surfactants, frequently in combination with a 
cosurfactant. Such systems are useful for drug delivery due to their ease of preparation, capability of 
solubilizing large amounts of hydrophobic drugs and sustained release of the drugs. Although 
microemulsions and emulsions are usually treated as similar drug delivery systems, they are, in fact, 
fundamentally different.82 Microemulsions are thermodynamically stable systems but emulsions are 
merely kinetically stable, i.e., emulsions will eventually undergo phase separation. Accordingly, 
microemulsions form spontaneously without the application of external work; the preparation of 
emulsions, on the other hand, requires energy and usually involves the use of high-pressure 
homogenization. A distinguishable difference between the two systems is the size of the droplets and 
their visual appearance: microemulsions contain small droplets (typical 10-100 nm) and are 
transparent while emulsions consist of relatively large droplets (typically 0.1-10 μm) and look milky. 
Nevertheless, both systems can form various oil-in-water (o/w), water-in-oil (w/o) or bicontinuous 
microstructures depending on the properties of surfactants and the water-oil composition. 
 
 13
Although (micro)emulsions have great ability to solubilize diverse drug molecules ranging 
from hydrophilic proteins/peptides to hydrophobic drugs, their use in parenteral delivery (including 
anticancer drug delivery) has been much less explored and is very challenging. This is often related to 
the instability of the (micro)emulsions upon dilution after intravenous administration. Also, the 
toxicity and biodegradability issues greatly limit the selection of surfactants and cosurfactants in this 
administration route.90 Thus, searching for pharmaceutically acceptable excipients becomes important 
in order to apply (micro)emulsions to anticancer drug delivery. Examples include naturally occurring 
lecithins and glycerides, some non-ionic surfactants (e.g., polyoxyethylene sorbitan monooleate 
Tween 80 and polyoxyethylene sorbitan monolaurate Tween 20) and sugar surfactants (e.g., alkyl 
glucosides).90 In general, (micro)emulsions are often explored as the delivery systems for topical and 
oral administration.82,90,91 
Self-emulsifying drug delivery systems (SEDDS), which are very closely related to 
(micro)emulsions, have recently drawn much attention for oral delivery of hydrophobic drugs.91 The 
system contrains an isotropic mixture of oils, surfactants, or alternatively, one or more hydrophilic 
solvents and cosolvents/surfactants. When the mixture is diluted in aqueous media, it automatically 
forms a fine o/w emulsion or microemulsion. Such systems are expected to improve the rate and 
extent of drug absorption. SEDDS has been applied to the oral delivery of paclitaxel and shown to be 
promising compared to the comercial formulation.92 This may provide an alternative administration 
route for anticancer drug delivery. 
2.1.3 Micellar Systems 
Micelle-based carriers have been attracting many scientists in academia and the pharmaceutical 
industry. They provide a set of unique features in drug formulation and targeting for water insoluble 
drugs. Micelles, in general, are formed via molecular self-assembly of amphiphiles having a 
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core/shell structure when their concentration is above a threshold level referred to as the “critical 
micelle concentration” (CMC). Below the CMC, amphiphilic molecules exist as unimers. The 
hydrophobic core serves as a reservoir for solubilizing the hydrophobic drugs, while the corona 
provides hydrophilicity to the system so the micelles can be delivered in aqueous solution. The 
sequestration of anticancer drugs in the inner core can protect them from degradation, lower the 
cytotoxicity to the healthy tissues during circulation, and reverse MDR.26 Micelles may also increase 
the systemic half-life of drugs and passively enhance their accumulation at the tumor site via the EPR 
effect.26,83 
Micelles can be subdivided into two different groups according to the molecular weight of the 
materials: low-molecular-weight surfactant micelles and polymeric micelles. The pharmaceutically 
acceptable surfactant micelles (or FDA approved) for parenteral administration are poly(ethylene 
oxide) [PEO]-based amphiphiles. The most common commercial surfactants for anticancer drug 
delivery are polyethoxylated castor oil (Cremophor® EL), PEO 660 12-hydroxystearate (Solutol® 
HS15) and polysorbates (PEO-based sorbitan fatty ester, Tween®).83 They have been used in 
(micro)emulsions as well (see Section 2.1.2). Cremophor® EL has been used to solubilize several 
anticancer drugs. One famous example is paclitaxel, which has been clinically used as Taxol® in 
cancer chemotherapy for many years.35 Unfortunately, many of these surfactant micelles have major 
drawbacks due to their in vivo toxicity and biocompatibility. For instance, Cremophor® EL can 
extract plasticizers from the infusion bags and tubing sets, causing severe hepatotoxicity.93 In 
addition, it has been associated with acute hypersensitivity reactions, including dyspnea, rash, chest 
pain, tachycardia, hypotension, angioedima and generalized urticaria;94 it is also found to be 
neurotoxic and nephrotoxic.35 Furthermore, surfactant micelles are not very stable upon dilution due 




Polymeric micelles, on the other hand, offer several advantages over surfactant micelles in 
delivering hydrophobic anticancer drugs. First, they often have a low CMC, resulting in a higher 
stability upon dilution.26,77 Second, the hydrophobic core can be tailored for different drugs. Third, the 
hydrated outer shell can offer effective steric protection and minimize uptake by phagocytes. Fourth, 
the circulation time can be increased as well as the biodistribution. However, the long term toxicity 
still remains an unsolved issue although considerable preliminary data suggest that some polymeric 
micelles are biocompatible. Biodegradability of the polymeric micelles would be another issue to 
consider. 
Most polymeric micelles used for anticancer drug delivery are made of amphiphilic block or 
graft copolymers.26,95 The block copolymers consist of hydrophilic (A) and hydrophobic (B) blocks 
arranged in an AB di-block or ABA tri-block sequence. The graft copolymers are usually synthesized 
by grafting hydrophobic blocks onto a hydrophilic backbone. The hydrophilic block is usually non-
biodegradable poly(ethylene oxide) (PEO, similar to poly(ethylene glycol) PEG), whereas the 
hydrophobic blocks could be poly(propylene oxide) (PPO), poly(D,L-lactide) (PDLLA), poly(L-
amino acid), poly(ester) and phospholipid.25,76,77,83,96,97 They all have certain degrees of success in 
delivering anticancer drugs in vitro and/or in vivo.77,80,83 Recently, a multifunctional micellar system 
capable of cell targeting and distribution imaging was developed to deliver the anticancer drug 
doxorubicin in vitro.98 The system was made of a graft copolymer, a diblock copolymer and two 
functionalized diblock copolymers into a multifunctional micelle by carefully designing each 
component in the mixture (Figure 2.1). This indicates that functionalized polymeric micelles may 




Figure 2.1 Schematic representation of multifunctional micelle structure made of a graft copolymer, a 
diblock copolymer and two functionalized diblock copolymers. Dox: doxorubicin; P(NIPAAm-co-
MAAc)-g-PLA: poly(N-isopropyl acrylamide-co-methacryl acid)-g-poly(D,L-lactide); mPEG-PLA: 
methoxy poly(ethylene glycol)-b-poly(D,L-lactide); Gal-PEG-PLA: galactosamine-PEG-PLA; FITC-
PEG-PLA: fluorescein isothiocyanate-PEG-PLA.98 
 
2.1.4 Liposomes 
Among many drug carrier systems, liposomes represent a mature technology for gene and anticancer 
drug delivery.21,80 They are phospholipid vesicles composed of a bilayered lipid membrane, made 
from natural lipids such as phosphatidylcholine (PC), phosphatidylglycerol and cholesterol. These 
vesicles can carry hydrophilic drugs inside the core of the liposome (aqueous compartment) and 
hydrophobic drugs in the bilayered membrane. Depending on the preparation method (usually 
sonication or filtration) and the nature of the lipids, the size of liposomes ranges from 0.05 to 5.0 μm 
in diameter.80,99 There are three major types of liposomes: multi-lamellar vesicles (MLV, > 0.1 μm), 
small unilamellar vesicles (SUV, < 0.1 μm) and large unilamellar vesicles (LUV, > 0.1 μm). MLV 
and LUV can carry both hydrophobic and hydrophilic cargos while SUV is not suitable for 
hydrophilic drugs due to low encapsulation efficiency (~1%). By virtue of their biodegradable and 
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nontoxic nature, liposomes can be safely administered without severe side effects. However, 
conventional liposomes through parenteral administration are recognized as foreign particles and are 
taken up by the mononuclear phagocytic system (MPS or the reticuloendothelial system RES).80,99 
This leads to fast clearance of liposomes from the blood circulation and limits the use of liposomal 
delivery to the tumors in liver, spleen and the bone marrow. Another obstacle of conventional 
liposomes is the fast leakage of drugs. This can be overcome by introducing cholesterol or using 
certain lipids (e.g., distearoylphosphatidylcholine, DSPC) to increase the phase-transition 
temperature.99 A combination of cholesterol and DSPC, in fact, were used to construct the first 
comercial liposomal vehicle (DaunoXome®) to deliver daunorubicin. 
A significant advance in liposomal delivery is the development of long-circulating liposomal 
carriers by coating the outer shell with PEG.22,99,100 Other synthetic polymers that can serve the same 
purpose include poly(acrylamide) and poly(N-vinyl pyrrolidine).80 Another important factor to extend 
the blood circulation and enhance the EPR effect is the size of the liposomes;101 small-sized 
liposomes tend to have longer circulation time and avoid mononuclear phagocyte system (MPS) 
uptake. The optimal liposome size for longer blood circulation and higher tumor accumulation ranges 
from 50 to 200 nm.101 The pegylated liposome carrier leads to another clinical delivery method for 
doxorubicin (Doxil®).102 
Other advances in liposomal delivery include the incorporation of active cell targeting and 
design of pH/temperature-sensitive liposome vehicles. To achieve active targeting, the targeting 
moieties (e.g., antibodies, peptides and folates) are coupled to an anchor inserted into the bilayer or to 
the distal end of the PEG grafted to the liposome surface.22,100,103 The pH-sensitive liposomes are 
composed of a mixture of phosphatidyl ethanolamine (PE) with an acidic phospholipid.104 At pH < 
6.5, PE becomes protonated and undergoes a transition from the bilayer phase to a hexagonal phase, 
resulting in the destabilization of the liposomes to release the drugs. Such a mechanism is especially 
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useful for delivering hydrophilic molecules. Similarly, the induction of a rapid release of liposomal 
content can be achieved using temperature-sensitive liposomes made of lipids with a phase transition 
temperature of around 40°C.100 The transition can be triggered by local heating or hyperthermia. The 
triggered release of anticancer drugs from liposomes can also overcome the cancer-associated 
MDR.105 
2.1.5 Nanoparticles 
Due to the fast developing field of nanotechnology over the past decade, novel nanoparticles have 
been produced and benefited modern cancer chemotherapy and diagnosis.18,19,38,106 Nanoparticles are 
broadly defined as being submicronic (< 1 μm) colloidal systems.80,107 They may be classified as 
either nanospheres, where the drug is dispersed throughout the system, or nanocapsules, where the 
drug is entrapped in a cavity surrounded by a shell. According to this definition, most polymeric 
micelles and liposome vesicles can be regarded as nanoparticles, which have been reviewed in the 
previous sections. Other nano-particulated delivery systems include ceramic nanoparticles, chitosan 
nanoparticles, solid lipid nanoparticles (SLN), dendrimers and magnetic nanoparticles.13,38,80,108,109 
Each system has its advantages towards anticancer drug delivery. For example, the iron oxide 
magnetic nanoparticles coated with oleic acid and Pluronic polymers can deliver doxorubicin while 
simultaneously allowing magnetic targeting and/or imaging.110 Dendrimers, as another example, are 
nanospheres with unique structural features, well-defined size according to the generation and 
controlled surface functionalities.109 They can carry diverse molecules via hydrophobic interaction, 
ionic attraction and hydrogen bonding. 
The major attempt of using nanoparticles for cancer chemotherapy is to achieve targeted 
delivery – the “magic bullet”. Strategies involve passive and active targeting. Although some of these 
concepts have been mentioned in the previous sections, an overview is given hereafter. 
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Passive targeting is based on the unique properties of most tumor microenvironments: (i) leaky 
tumor vasculature, which is more highly permeable to macromolecules than normal tissue; (ii) a 
dysfunctional lymphatic drainage system, which results in enhanced fluid retention in the tumor 
interstitial space.15,111 These characteristics lead to 100 times higher accumulation of nanoparticles in 
tumor tissue than in normal tissue (Figure 2.2). This phenomenon of tumor-specific deposition is 
known as enhanced permeability and retention (EPR). The extent of nanoparticle extravasation 
depends on the size of open interendothelial gap junctions and trans-endothelial channels. The cutoff 
size has been reported to be 380-780 nm.107 In general, particles with diameters less than 200 nm and 
a molecular weight above 40 kDa are the most effective for extravasating tumor 
microvasculature.15,111 This approach has been widely applied to long-circulating delivery systems for 
cancer chemotherapy. 
Different from passive targeting, active targeting is achieved by the incorporation of targeting 
molecules, which can recognize specific cancer cells and deliver the particles to the targets 
efficiently.15-17 This approach can minimize the harmful side effects on healthy tissues while 
maximize the therapeutic efficacy. The targeting molecules include monoclonal antibodies (mAb), 
nucleic acid ligands (aptamers), peptides, folic acids (folates) and nanobodies.15 Monoclonal 
antibodies are the first and still the preferred class of targeting molecules. However, the use of mAb 
still has many challenges and limitations such as the large size, complicated conjugation procedures 
and high cost to manufacture compared to the drug cargos. Nanobodies are the fragments of 
antibodies and could be good alternatives. An attractive and promising alternative to antibodies are 
peptides due to their small size, low immunogenecity, higher stability and ease of manufacture.112 
Examples are cyclic RGD peptide (Cilengitide®), cell-surface hormone receptors (LHRH receptors 
and somatostatin receptors) and tumor vasculature antigens.15 The possibility of peptides in targeted 




Figure 2.2 Diagrammatic representation of the enhanced permeability and retention effect. Low 
molecular-weight (Mw) drugs (black spots) can diffuse freely in and out of the tumor blood vessels 
because of their small size; hence, the effective concentration of the drug in the tumor diminishes 
after 1 h when the drug concentration in plasma becomes low (i). The high Mw drug (green circles) 
cannot diffuse back into the blood stream because of its large size. Thus, there is progressive 
accumulation of macromolecular drug in the tumor tissues with time by the enhanced permeability 
and retention (EPR) effect (ii). 111 
 
2.2 Self-Assembling Ionic-Complementary Peptides 
In the past decade, short peptide sequences have attracted much attention for their use and design to 
construct functional nano/microstructures for various applications in nanoscience, surface engineering 
and biomedical technology.60,113-117 These peptides share a common feature of self-association in 
aqueous solution. They are either portions of natural proteins or derived by de novo biomolecular 
design. Short fragments of natural proteins, such as β-amyloid peptides and prion peptides, have been 
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found to self-assemble into fibril structures in various environments.118-120 On the other hand, 
synthetic peptides can be easily engineered to self-assemble into functional supramolecules, by taking 
advantage of the intrinsic properties of amino acids.41,121-123 The combination of various molecular 
interactions existing in the amino acids, including hydrogen bonding, ionic interaction and 
hydrophobic interaction, governs the self-assembly behavior. 
Among many self-assembling peptides is a special class of ionic-complementary peptides. 
These peptides have emerged as promising nanobiomaterials for many biomedical applications.59,60 
They are originally derived from a short segment (EAK16-II) of a Z-DNA binding protein in yeast by 
Zhang et al.61,124 These peptides contain a unique amphiphilic molecular structure and can self-
assemble into β-sheet-rich nanofibers and macroscopic membranes.61 With relatively good 
biocompatibility and biodegradability, such peptides have been used as scaffolds for tissue 
engineering and 3-D cell cultures, novel materials for regenerative medicine, and nanocarriers for 
therapeutic agents.58,60,125,126 Detailed information of their physical and biochemical properties, self-
assembly process and factors influencing the assembly, and their potential applications in drug 
delivery will be reviewed in the following sections. 
2.2.1 Molecular Structure and Physical/Biochemical Properties 
Molecular structure  
Self-assembling ionic-complementary peptides are characterized by an alternating arrangement of 
negatively and positively charged residues. In order to have ionic complementarity, the distribution of 
the charges should follow certain patterns. There are three types of charge distributions that are 
simplest and most widely studied. They are type I ( +−  or −+ ), type II ( ++−−  or −−++ ) and 
type IV ( ++++−−−−  or −−−−++++ ). Such ordered charge distribution could result in 
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unique electrostatic interactions, which promote molecular self-assembly in addition to the more 
usual hydrogen bonding and hydrophobic interaction, and stabilize the assembled nanostructures. 
Another feature of self-assembling ionic-complementary peptides is a special arrangement of 
hydrophobic and hydrophilic amino acid residues alternating in sequence. This leads to a “side-to-
side” amphiphilic structure, for a β-strand peptide, where hydrophobic residues are on one side of the 
peptide backbone and hydrophilic ones are on the other side. Such a structure is different from the 
“head-to-tail” one of a surfactant.82 As a result, the molecular self-assembly of these peptides is 
different from the micelle formation of surfactants. 
Table 2.3 lists the family of a special class of self-assembling ionic-complementary peptides 
that have been studied since 1993.60-62 The first peptide of its kind is EAK16-II, a 16-amino-acid 
peptide segment originating from a Z-DNA binding protein.61,124 Its derivatives, such as EAK16-I and 
EAK16-IV, have different charge distributions of type I and IV, respectively, from type II. Their 
molecular structures are shown in Figure 2.3. It has been found that most peptides in this family can 
self-assemble into β-sheet-rich fibril structures.60 The fibril formation of these peptides is believed to 
result from the combination of three different interactions: hydrogen bonding from the peptide 
backbone, the electrostatic interaction from the ionic-complementary residues, and the hydrophobic 
interaction from the hydrophobic side. The molecular structure of EAK16-II forms a basis to 
construct other similar self-assembling ionic-complementary peptides with different functionalities. 
An example is RADA16-I that has been designed to enhance the biocompatibility and cell adhesion 
for tissue scaffoldings.127 
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Table 2.3 The family of self-assembling ionic-complementary peptides60,128,129 
Name Sequence (n → c) Charge Distribution Type Structure 
KADA8-I n- KADAKADA -c −+−+  I r.c. 
KFE8-IT n- KFEFKFEF -c −+−+  I β 
KFE8-I n- FKFEFKFE -c −+−+  I β 
RADA8-I n- RADARADA -c −+−+  I r.c. 
RAEA8-I n- RAEARAEA -c −+−+  I r.c. 
EFK8-I n- FEFKFEFK -c +−+−  I β 
EAKA8-I n- AEAKAEAK -c +−+−  I r.c. 
KFE12-I n- FKFEFKFEFKFE -c −+−+−+  I β 
KIE12-I n- IKIEIKIEIKIE -c −+−+−+  I β 
KVE12-I n- VKVEVKVEVKVE -c −+−+−+  I β 
KLD12-I n- KLDLKLDLKLDL -c −+−+−+  I β 
KLE12-I n- KLELKLELKLEL -c −+−+−+  I β 
EFK12-I n- FEFKFEFKFEFK -c +−+−+−  I β 
RADA16-I n- RADARADARADARADA -c −+−+−+−+  I β 
RGDA16-I n- RADARGDARADARGDA -c −+−+−+−+  I r.c. 
RAEA16-I n- RAEARAEARAEARAEA -c −+−+−+−+  I β 
KADA16-I n- KADAKADAKADAKADA -c −+−+−+−+  I β 
KFE16-I n- FKFEFKFEFKFEFKFE -c −+−+−+−+  I β 
EAKA16-I n- AEAKAEAKAEAKAEAK -c +−+−+−+−  I β 
RAD8-II n- RARADADA -c −−++  II r.c. 
EAH8-II n- AEAEAHAH -c ++−−  II r.c. 
ELK8-II n- LELELKLK -c ++−−  II β. 
EAK8-II n- AEAEAKAK -c ++−−  II r.c. 
EAK12-a n- AKAKAEAEAKAK –c ++−−++  II r.c. 
RAD16-II n- RARADADARARADADA -c −−++−−++  II β 
EAH16-II n- AEAEAHAHAEAEAHAH -c ++−−++−−  II β 
EFK16-II n- FEFEFKFKFEFEFKFK -c ++−−++−−  II β 
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ELK16-II n- LELELKLKLELELKLK -c ++−−++−−  II β 
EAK16-II n- AEAEAKAKAEAEAKAK -c ++−−++−−  II β 
KAE16-IV n- KAKAKAKAEAEAEAEA-c −−−−++++  IV β 
RAD16-IV n- RARARARADADADADA -c −−−−++++  IV β 
EAK16-IV n- AEAEAEAEAKAKAKAK -c ++++−−−−  IV β 
DAR16-IV n- ADADADADARARARAR -c ++++−−−−  IV α/β 
DAR16-IVT n- DADADADARARARARA -c ++++−−−−  IV α/β 
DAR32-IV n- (ADADADADARARARAR)2 -c ++++−−−−  IV α/β 
EAK12-b n- AKASAEAEAKAK -c ++−−+  N/A r.c. 
EAK12-c n- AKAEAEAEAKAK -c ++−−−+  N/A r.c. 
EAK12-d n- AEAEAEAEAKAK -c ++−−−−  IV/II α/β 
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Figure 2.3 (a) Chemical structure of the ionic-complementary peptide EAK16-II. It contains 
alternating hydrophobic (alanine, A) and hydrophilic (glutamic acid, E and lysine, K) residues, with a 
type II charge distribution ( ++−−++−− ), where pairs of negatively (E) and positively (K) 
charged residues alternate. (b) Three-dimensional molecular model of EAK16s. The top, middle and 
bottom schemes represent the EAK16-I, EAK16-II and EAK16-IV structures, respectively.129 
 
Ionic-complementary peptides have several important features. First, their charge distribution 
can be altered through simple molecular design. For example, the sequence design based on the same 
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components can generate different charge distributions of type I, II and IV (i.e., EAK16-I, EAK16-II 
and EAK16-IV). The differences in charge distribution may determine the peptide secondary 
structure and influence peptide self-assembly. Second, specific peptide chain lengths are required to 
exhibit ionic complementarity. The length of these peptides varies from eight to thirty-two amino 
acids in sequence due to the alternating hydrophobic and hydrophilic residues in the peptide sequence 
(Table 2.3). The minimum number of amino acids required to build type I peptides is four, while the 
creation of type II and type IV peptides require eight and sixteen amino acids, respectively. The 
sequence of these short peptides can also be utilized for the design of polypeptides such as poly-
EAK.130 Third, the ionic-complementary peptide family can be easily expanded by using different 
amino acids. For example, DAR can be derived from EAK by replacing the residues glutamic acid 
(E) and lysine (K) with aspartic acid (D) and arginine (R), respectively. Similarly, the replacement of 
the hydrophobic residue alanine (A) of EAK with phenylalanine (F) or leucine (L) will create two 
other similar peptides EFK and ELK, respectively. Such simple replacement maintains the intrinsic 
properties of ionic-complementarity and self-assembly. In some cases, it can also strengthen the 
propensity of the peptides to form the desired supramolecules (e.g., the introduction of more 
hydrophobic residues can reduce the peptide length required to form a predominant β-sheet structure).  
Unusually stable β-sheet formation 
An important characteristic of ionic-complementary peptides is the spontaneous formation of 
unusually stable β-sheets in aqueous solution.60,62,131 Once the β-sheets are formed, they remain 
unchanged under a broad range of physicochemical conditions (extreme pH, high temperature and 
dilution) and are even impervious to denaturing agents.62 The β-sheet character of EAK16-II exhibits 
a maximum ellipticity at 218 nm and a minimum ellipticity at 195 nm in the CD spectra, even at the 
very low peptide concentration of 0.612 μM.62 In addition, the CD spectra of EAK16-II show that β-
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sheets remain stable up to 90 °C, which are much more stable than most proteins (denatured above 65 
°C). Also, the β-sheets remain stable at extreme pH (1.5 or 11) since only a small change in the CD 
spectra at 218 nm can be observed.62 Unlike normal proteins that denature when the concentration of 
denaturation agents (e.g., guanidine-HCl and urea) is above 4 M, β-sheet structures of EAK16-II can 
withstand even 7 M guanidine-HCl and 8 M urea. Such high stability has also been found in 0.1% 
sodium dodecylsulphate (SDS) solution. 
The analysis of the molecular structures and interactions in the self-assembling ionic-
complementary peptides may explain the formation of such unusually stable β-sheet structures. The 
β-sheet formation is mainly caused by the hydrogen bonding between individual peptide backbones, 
which is evidently found in protein folding and aggregation.132,133 In addition, charged residues can 
also interact with each other to stabilize the β-sheets by means of electrostatic intermolecular 
interactions and hydrogen bonding. Similarly, the hydrophobic interactions from the nonpolar 
residues also play a role in stabilizing the structure. 
Stable and biocompatible supramolecular structure 
The self-assembled nano/microstructures of these peptides are also found to be stable under various 
physiological conditions.61,62 They have been shown to resist degradation by acidic or basic 
environments ranging from pH 1.5-11,61 sodium dodecyl sulfate (SDS)/urea and a number of 
proteolytic enzymes including trypsin, protease K and pronase.61,62 In addition, no detectable immune 
responses are observed when these peptides are injected into rabbits, rats and goats.61,134 The unusual 
stability of the peptides in serum, combined with their high resistance to proteolytic digestion, simple 




2.2.2 Peptide Self-Assembly and Control 
The understanding and precise control of peptide self-assembly is important to regulate the formation 
of nano/microstructure, formulate peptide-drug complexes, and further control the complex size. 
There are many internal and external factors that can influence peptide self-assembly. These factors 
include (a) amino acid sequence, (b) molecular size, (c) peptide concentration, (d) solution pH, (e) 
ionic strength, (f) solvent, (g) presence of denaturation agents, (h) temperature, (i) time, (j) surface 
and its property and (k) mechanical force. The effects of amino acid sequence, peptide concentration, 
pH, the presence of surface and mechanical force on peptide nanostructure formation, which are most 
relevant to this thesis work, are discussed below.40,45,65,67-69,128,136  
Effect of amino acid sequence 
Peptide sequence serves as an internal factor that tunes peptide self-assembly. The type, number and 
arrangement of amino acids in the sequence play important roles in determining the secondary 
structures and self-assembled nanostructures of the peptides. For example, EFK8-I, containing eight 
amino acids in the sequence, forms β-sheet secondary structure in aqueous solution. However, when 
phenylalanine (F) is replaced with alanine (A) and maintains the same charge distribution, the 
resulting peptide EAKA8-I forms random coils instead (Table 2.3). The reason for this phenomenon 
is still not clear. A possible explanation could be that the steric hindrance of the hydrophobic 
phenylalanine may help form β-sheets. 
In addition to the type of amino acid, the length of the peptide sequence has significant impact 
on nano/macrostructure formation.61,62,128,130 EAK16-II (16 amino acids) spontaneously associates to 
form a macroscopic membrane when dissolved in a salt solution such as phosphate buffer saline 
(PBS). EAK12 (12 amino acids) can also form membranes, but to a much lesser degree (< 50%). In 
contrast, EAK8-II (8 amino acids) does not form membranes under the same condition. This might be 
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due to the fact that peptides with a shorter chain length have fewer ionic-complementary pairs that 
can assist/stabilize peptide self-assembly. 
The difference in charge distribution due to the arrangement of amino acids can alter peptide 
self-assembly into different nanostructures. For instance, EAK16-I and EAK16-II form fibril-like 
nanostructures, while EAK16-IV forms globular aggregates at neutral pH (Figure 2.4).45 Further 
studies have found that EAK16-IV tends to form β-turn secondary structure via strong intramolecular 
electrostatic attraction. The assembly of β-turns may result in the formation of globular aggregates. 
On the other hand, EAK16-II prefers a stretched β-strand, resulting in the formation of linear fibrils. 
The experimental results are supported by Monte Carlo simulations.46 
 
   
Figure 2.4 AFM images of peptide self-assembled nanostructures from EAK16-I (a), EAK16-II (b) and 
EAK16-IV (c).45,65 
 
Effect of peptide concentration  
Another factor that triggers peptide self-assembly and further controls the nanostructure formation is 




molecules is usually concentration dependent and has a critical concentration that governs the 
assembly process.82 As with the micelle formation of surfactants at a concentration above the critical 
micelle concentration (CMC), self-assembling ionic-complementary peptides are amphiphilic and 
also have a critical aggregation concentration (CAC). This is expected since the CAC has been 
reported for many proteins and amphiphilic peptides.137-141 However, the concentration-dependent 
self-assembly of most biomolecules follows a nucleation and growth mechanism,141-145 whereas the 
CMC represents a threshold concentration above which micellization of surfactants occurs. 
The self-assembling ionic-complementary peptide EAK16-II has been found to have a CAC of 
~0.1 mg/ml (60 μM) by surface tension measurements.40 AFM studies of the nanostructure of 
EAK16-II reveals that nanofiber networks are formed when the peptide concentrations exceed the 
CAC, while isolated filaments and globules are observed at concentrations below the CAC.40 In 
addition, the fibril size and network density are related to the peptide concentration as well. Similarly, 
EAK16-I has a critical concentration of 0.3 mg/ml (180 μM).65 Unlike EAK16-II, EAK16-I assembly 
has been shown from AFM studies to undergo two nanostructure transitions.65 The first transition 
from globules to fibril morphology occurs when the peptide concentration is about 0.05 mg/ml (30 
μM); the second transition involves dramatic increase in the fibril size as the concentration rises 
above 0.3 mg/ml (180 μM). 
Effect of solution pH 
In biological systems, the solution pH is an important environmental factor affecting protein and 
peptide structures. A pH change will influence the ionic state of the charged residues as well as the 
net charge of peptides/proteins. This will further affect the self-assembly behavior of the peptide and 
protein folding/aggregation. Interestingly, the structure of self-assembling ionic-complementary 
peptides responds to the solution pH differently according to the peptide charge distribution. EAK16-
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IV has been found to undergo a nanostructural transition from globular aggregates to fibril-like 
nanostructures at different solution pH.45 The globular nanostructures occur at pHs between 6.5 and 
7.5, while nanofiber networks appear at pHs beyond this range. In contrast, EAK16-II forms 
nanofibers throughout the pH range from 4 to 11. These findings suggest that the charge distribution 
in sequence plays an important role in determining the self-assembled peptide nanostructures. With a 
type IV charge distribution, strong intramolecular electrostatic attractions occur at neutral pH, which 
may cause molecular bending and the formation of globular nanostructures. At extreme pHs such as 
pH 4 and 11, either glutamic acid or lysine residues are neutralized, resulting in weakened 
intramolecular electrostatic interaction and smaller tendency for the peptide to form a β-turn structure. 
Thus, nanofiber formation would be predominant.  
Effect of surface 
Surface/interface plays an important role in many biomolecular processes such as protein aggregation 
and peptide self-assembly.146-148 Recently, it has been found that a hydrophilic surface (mica) can 
assist the assembly of the self-assembling ionic-complementary peptide EAK16-II; the assembly 
kinetics of the peptide is significantly enhanced on the surface.68 The surface-assisted peptide 
assembly follows a nucleation and growth mechanism and involves two steps. First step is the 
adsorption of nanofibers and fiber clusters (formed in the bulk solution) on the surface to serve as 
nuclei or seeds. The second step is the fiber elongation from the active ends of the seeds. Nanofibers 
or fiber clusters that have reached or are close to equilibrium in bulk solution can continually grow on 
the surface. This surface-induced peptide assembly may provide information to understand and 
control protein aggregation associated with conformational diseases.133,149  
Further studies have shown that the adsorption and assembly kinetics of peptide nanofibers on 
the surface are strongly dependent on the surrounding environment such as solution pH.68 The amount 
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of the adsorbed nanofiber “seeds” decreases with increasing solution pH, while the nanofiber growth 
rate under different solution conditions follows the order: pure water > 1 mM HCl > 1 mM NaOH > 
10 mM HCl ≈ 10 mM NaOH ≈ 0. This indicates that solution pH can regulate the adsorption of the 
“seeds” to the surface as well as the fiber growth rate by affecting the peptide-surface and peptide-
peptide interactions, respectively. This provides a way to control peptide assembly and the resulting 
nanostructures on surfaces (Figure 2.5). 
 
   
1 mM HCl Pure water 1 mM NaOH 
Figure 2.5 AFM images of EAK16-II on mica in various solutions after 30 min: (a) 1 mM HCl; (b) pure 
water; (c) 1 mM NaOH. Scan area is 2000 nm × 2000 nm.68 
 
Surface properties, in some cases, can influence molecular assembly to produce ordered 
nanostructures.147,150 It has been found that EAK16-II forms randomly deposited nanofiber networks 
on the hydrophilic mica surface, whereas well patterned nanostructures on a hydrophobic surface 
(HOPG) (Figure 2.6).67 These well-ordered nanofiber patterns on HOPG have preferential 
orientations at angles of 60° or 120° to each other, resembling the crystallographic structure of the 




significantly affected by the solution pH. In acidic environment (e.g., pH ≤ 3), the peptide does not 
adsorb and assemble on the HOPG surface. However, it can form patterned nanofibers on HOPG in 
pure water and basic environments. This pH-dependent adsorption of peptides to HOPG is attributed 
to the changes in peptide hydrophobicity at different pHs.69 
 
  
Figure 2.6 AFM images of EAK16-II on mica (a) and on HOPG (b) in various solutions after 30 min.
The inset in (b) shows the 2-dimensional Fourier transform of the AFM image and characteristic 6-fold 
symmetry. Scan areas are 2000 nm × 2000 nm for mica and 1000 nm × 1000 nm for HOPG.67 
 
Effect of Mechanical Force 
More recently, Yang et al.69 have reported a mechanochemical approach using AFM to control the 
assembly of EAK16-II over desired regions of a substrate. It has been found that the mechanical force 
applied by a tapping AFM tip can break the peptide assembled nanostructures. These broken 
fragments would serve as new nuclei for subsequent assembly to form new nanostructures. The total 




amplitude of the tip oscillation, the size of the scan area and scan speed. Such an approach could 
allow one to locally grow nanofibers that densely cover specific regions of the surface (Figure 2.7). 
 
   
   
Figure 2.7 AFM images of EAK16-II nanofibers formed on HOPG in pure water (a and b) and 4 μM 
EAK16-II solution (c and d) under a mechanical force applied by a tapping AFM tip: (a) large-scale 1 ×
1 μm2 scan; (b) 4th zoom-in scan of dotted area in (a); long peptide nanofibers are broken into short 
nanofiber segments under the mechanical force; (c) 1st and (d) 10th 1 × 1 μm2 scan of the same location 
as (c); amount of peptide nanofibers on HOPG increases with the number of repeated scans; (e) zoomed-
in scan image after 10th scan reveals many truncated nanofibers formed on HOPG; (f) surface coverage 
of peptide nanofibers as a function of time; squares represent the coverage at one location with repeated 
scans and triangles correspond to that at different locations scanned only once. The scale bar corresponds 
to 200 nm.69 



















The process of breaking peptide assembled nanostructures by an AFM tip also forms the basis 
for a nanolithography method to pattern the surface. This method requires two steps. The first step is 
to allow peptides to assemble over the entire surface, forming densely coated peptide assemblies on 
the surface. The second step is to apply a mechanical force using a tapping AFM tip at desired 
locations to remove peptide assemblies and expose the surface underneath. This process is done in an 
environment (e.g., 10 mM HCl solution), where the broken peptides or their assemblies do not re-
adsorb to the surface. Such a method can create various patterns with different surface properties at 
both nano- and microscales.67,69 
2.2.3 Self-Assembling Peptide Carriers for Drug Delivery 
To date, few of the discoveries in molecular therapeutics can truly benefit the treatment and 
prevention of human disease without effective delivery systems. An ideal delivery system should be 
able to control pharmacokinetics and pharmacodynamics, avoid non-specific toxicity, have no 
immunogenicity, possess biorecognition and enhance drug efficacy.79,151,152 Among many emerging 
drug carriers, peptides have shown great promise to overcome some major problems in therapeutic 
delivery, such as safety, efficiency and targeting. The most attractive aspect of peptide-mediated drug 
delivery is the natural propensities of many peptides for cell penetration and targeting.112,153,154 
Peptide-based delivery systems have shown the potential to deliver therapeutic proteins, bioactive 
peptides, small molecules and nucleic acids.57,58,153,154 
Self-assembling ionic-complementary peptides could be a new and promising material as 
carriers for drug delivery. Their unique amphiphilic structure and ability to self-assemble allow them 
to encapsulate both hydrophobic chemotherapeutics and hydrophilic gene therapeutics. Moreover,  no 
detectable immune response is observed when these peptides are introduced into animals.61,64,134 
These peptides can spontaneously organize themselves into nano/micro structures that may provide a 
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protected and stable environment for drug/gene molecules. Another advantage of using peptide-based 
carriers is the ease of sequence modification and design for cell penetration and targeting. Some 
examples of using these peptides to deliver protein drugs and hydrophobic compounds are reviewed 
hereafter. 
Protein drug delivery 
Self-assembling ionic-complementary peptides have shown success in the local delivery and release 
of peptide/protein drugs in a controlled manner. A new peptide sequence is designed to incorporate a 
biotin molecule into a self-assembling peptide motif, RADA16-II. Such a biotinylated RADA16-II 
has been used to deliver insulin-like growth factor 1(IGF-1) to the myocardium.58 The biotinylation 
does not alter the self-assembly property of RADA16-II. Biotin-IGF-1 is then incorporated into the 
biotinylated RADA16-II by using tetravalent streptavidin to form a “biotin sandwich”. This approach 
allows specific and highly controlled delivery of IGF-1 to local myocardial microenvironments. After 
injection into the rat myocardium, the biotinylated nanofibers provide sustained IGF-1 delivery for 28 
days and increase activation of Akt in the myocardium, indicating an improved cell therapy. 
RADA16-II has also been used to locally deliver a platelet-derived growth factor, PDGF-BB, 
for myocardial protection.57 PDGF-BB can be directly loaded onto peptide nanofiber matrices via 
non-specific, weak molecular interactions. The binding capacity of PDGF-BB is found to be 1 ng per 
microgram of nanofibers. The embedded PDGF-BB within the nanofibers remains biologically active 
for a prolonged period of 14 days in vivo. Sustained release of PDGF-BB can be achieved using these 
nanofiber matrices compared with injection of PDGF-BB alone, which will be rapidly eliminated 
from the blood stream. These results show another successful example of using self-assembling ionic-
complementary peptides for the delivery of protein growth factor. 
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Potential in Hydrophobic Drug Delivery 
In addition to delivering protein drugs, self-assembling ionic-complementary peptides have been 
shown to readily encapsulate hydrophobic materials and increase their solubility in aqueous 
environments. Recent work using pyrene as a model hydrophobic compound has demonstrated the 
potential of these peptides for the delivery of hydrophobic anticancer drugs.51,56 The peptide EAK16-
II is found to stabilize hydrophobic pyrene microcrystals in aqueous solution at concentrations up to a 
ten-thousand fold increase beyond its solubility in water (0.7 μM).72 Since the encapsulated pyrene is 
in a crystalline form, more pyrene molecules are encapsulated per peptide, leading to high loading 
efficiency. The complexation of pyrene with EAK16-II is simply achieved by mixing pyrene crystals 
with peptide solution while continuously stirring mechanically;56 peptide monomers and/or small 
peptide assemblies seem to be more effective at stabilizing pyrene in aqueous solution than mature 
peptide fibers.  
The encapsulated pyrene in the complexes can be released into liposomes (as the cell 
membrane mimics) in a controlled manner.51 The complete release has been found to take a few 
hours, and the release rate is affected by the peptide-to-pyrene ratio during the complexation: the 
higher the ratio, the slower the release rate (Figure 2.8). This is due to the difference in the density of 
peptide nanostructures coated on the pyrene microcrystals, as revealed by scanning electron 
microscopy (SEM). The high peptide-to-pyrene ratio results in solid peptide coatings on the 
microcrystals, whereas porous coatings occur at low peptide-to-pyrene ratio. This example 
demonstrates that controllable release of hydrophobic compounds may be achieved by using these 
self-assembling peptide vehicles. The results also show the possibility of such peptides in the delivery 


























Figure 2.8 (a) The release of molecular pyrene from EAK16-II-pyrene complexes into liposomes. 
Hollow and solid symbols are for pyrene transfer experiments carried out with 0.1 mg/ml peptide 
coatings and 0.5 mg/ml peptide coatings, respectively. SEM images of the peptide-pyrene complexes 
with 0.5 mg/ml (b) and 0.1 mg/ml (c) peptide coatings.51 
 
Other novel peptide-based delivery systems have been developed via adopting peptide 





example is the design of TβP peptide using three functional blocks: a Tat cell penetrating peptide 
block (Tat48-60, GRKKRRQRRRPPQ), a flexible-linker block (GSGG), and a β-sheet assembly block 
(KFE12-I) (Figure 2.9).155 This peptide can self-assemble into stable β-sheet nanoribbons, carrying 
hydrophobic molecules inside the bilayered ribbons (stabilized by π-π stacking of phenylalanine 
residues); the cell penetrating motifs allow the nanoribbons to enter the cell and release the cargos 
into the cytoplasm. 
 
 
Figure 2.9 Representation of the nanoribbon formed by self-assembly of TβP and encapsulation of 




A similar strategy has been applied to design a cell targeting, self-assembling peptide 
amphiphile to deliver hydrophobic molecules.156 The peptide amphiphile contains a dioctadecyl 
moiety as hydrophobic segment, a spacer consisting of a glycine residue and five units of 8-amino-
3,6-dioxaoctanoic acid, and a sequence of peptide hormone cholecystokinin, CCK8 (DYMGWMDF), 
as bioactive hydrophilic peptide. The CCK8 peptide motif possesses dual functions as a 
biorecognition marker for tumor targeting and the hydrophilic portion of the amphiphile for self-
assembly. The nanoconstructs of this peptide amphiphile have been found to be able to encapsulate 
hydrophobic pyrene and the anticancer drug doxorubicin. All these examples have shown that 
peptides play an important role in the development of advanced functional drug carriers to achieve 
effective delivery. 
2.3 The Anticancer Agent Ellipticine 
Many anticancer agents have been discovered and developed from natural sources35,157-159 and from a 
better understanding of molecular genetics and cancer biology.3,39,160-162 The original strategy of the 
anticancer drugs was to eradicate the cancer cells. As a result, the conventional anticancer drugs are 
very cytotoxic. According to their mode of action related to cancer biology, these cytotoxic chemicals 
can be classified into five categories: antimetabolites, covalent DNA binding drugs, noncovalent 
DNA binding drugs, inhibitors of chromatin function, and drugs affecting endocrine function.3 Table 
2.4 lists some anticancer drugs in these five categories that have been clinically used. Although these 
cytotoxic drugs are very effective at killing cancer cells, various side effects can occur during their 
clinical use. Therefore, novel delivery systems are required to minimize the severe side effects while 





Table 2.4 Some anticancer drugs in clinics.3 
 
Classes Mode of Action Drugs in Clinics 
Antimetaboites Interfere with the 
production of 
nucleic acids 
Folate Antagonists: Methotrexate (MTX, amethopterin); 
Trimetrexate (TMQ) 
Pyrimidine Antagonists: Fluorouracil (FUra, 5-FU); 
Fluorodeoxyuridine (FdUrd, 5-FUdR); CB3717; 
Azacytidine (Aza-C, 5-AC) 
Purine Antagonists: Mercaptopurine (MP, 6-MP); 
Thioguanine (TG, 6-TG); Tiazofurin; 
Chlorodeoxyadenosine (CdA); Pentostatin (2’-
deoxycoformycin, dCF) 
Sugar-Modified Analogs: Cyhtarabine (ara-C); 
Fludarabine (F-ara-A) 
Ribonucleotide Reductase Inhibitors: Hydroxyurea (HU) 
Covalent DNA-
Binding Drugs 
DNA cross-linking Nitrogen Mustards: Mechlorethamine (NH2, nitrogen 
mustard); Chlorambucil; Melphalan (L-phenylalanine 
mustard, L-PAM); Cyclophosphaminde; Ifosfamide 
Aziridines: Thiotepa (thio-TEPA); Altretamine 
(hexamethylmelamine); Mitomycin (mitomycin C) 
Alkane Sulfonates: Busulfan 
Nitrosoureas: Carmustine (BCNU); Lomustine (CCNU); 
Semustine (methyl-CCNU); Streptozotocin 
Platinum Compounds: Cisplatin (cis-DDP); Carboplatin 
Methylating Agents: Dacarbazine; Procarbazine 
Noncovalent DNA-
Binding Drugs  
DNA intercalating Anthracyclines: Daunorubicin; Doxorubicin; Idarubicin; 






for the changes of 
chromosomes 
Topoisomerase Inhibitors: Etoposide (VP-16); 
Teniposide (VM-26); Amsacrine (m-AMSA); 
Camptothecin (CPT-11) 
Microtubule Inhibitors: Vinblastine; Vincristine; 




Hormone treatment Glucocorticoids: Prednisone; Prednisolone 
Estrogens: Diethylstilbestrol (DES); Ethinyl estradiol 
Antiestrogens: Tamoxifen 
Progestins: Medroxyprogesterone; Megestrol 
Androgens: Fluoxymestrone; Testosterone 
Antiandrogens: Cyproterone acetate; Flutamide 
LHRH (GnRH) Agonists: Goserelin; Leuprolide 
Aromatase Inhibitors: Aminoglutethimide 




Among these cytotoxic agents, ellipticine, a natural alkaloid, was isolated from an Australian 
evergreen tree of the Apocynaceae family in 1959.73,163 Later, it was found that ellipticine and its 
derivatives possess anticancer activity against various tumors. One of the ellipticine derivatives, 2-
methyl-9-hydroxyellipticinium (NSC 264137, HME) was used in preclinical, phase I and phase II 
studies in the 1980’s.74,164-166 Unfortunately, it exhibited severe side effects during clinical 
trials,73,74,167  and further attempts to develop ellipticine-based anticancer treatment were ceased until 
new delivery technologies were developed in the late 1990’s. The following sections will give a 
review of ellipticine, including its properties, mode of action in cancer biology and current advances 
in ellipticine delivery. 
2.3.1 Molecular Structure and Physical/Chemical Properties 
Ellipticine is a natural alkaloid containing two benzene rings, one pyrrole-like and one pyridine-like 
ring in the structure with two methyl groups at positions 11 and 5 as shown in Figure 2.10.73 The 
planar pyridocarbazole ring system is arc-shaped and appropriately sized for intercalation between the 
base pairs of DNA; its dimension is similar to the known intercalator proflavin. The molecule is pH 
sensitive with two protonable ring nitrogens at positions 2 and 6. The pKa of N-6 is less than 1, and 
that of N-2 is about 6 although it can vary from 4.5 to 7.4 depending on the nature and position of 
substituents on the ring system.73,168,169 Generally, both protonated and neutral species can coexist at 
physiological pH. 
According to its molecular structure, the neutral ellipticine is expected to be hydrophobic. The 
reported water solubility of ellipticine is ~0.6 μM.71 Such low water solubility makes the delivery of 
ellipticine in aqueous solution difficult, which limits its clinical applications. The first attempt to 
increase its water solubility was through chemical modification of N-6 with a methyl group so that 
the molecule could be protonated.73,164,167 However, the chemical modification was found to reduce 
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the anticancer activity of the resulting derivatives.167,170 Thus, current approaches to solubilize 















Figure 2.10 (a) Chemical structure of ellipticine; (b) Planar structure of ellipticine. H: white, N: blue, C: 
canyon. 
 
An attractive feature of ellipticine is its photophysical activity. This allows one to study the 
interaction of ellipticine with other molecules and its cellular distribution by monitoring the change in 
absorption and emission spectra of ellipticine. A few scattered studies in the literature have reported 
the photophysical properties of ellipticine and its derivatives.73,163,168,173,174 They are summarized 
hereafter. Ellipticine exhibits several UV absorption bands between 220 and 400 nm, with an 
extinction coefficient ranging from 3000 to 79000 1/(M·cm).163 The UV absorption and fluorescence 
emission is highly dependent on solution pH.163,168,174 Ellipticine exhibits a maximum of fluorescence 
at 520 nm in water (excitation at 304 nm), but an emission maximum at ~430 nm in ethanol 
(excitation at 294 nm), corresponding to protonated and neutral ellipticine, respectively. This solvent-
dependent photophysical property could be utilized to characterize the transfer mechanism of 
ellipticine in a given delivery system. However, a more systemic study on such a property is required. 
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2.3.2  Mode of Action 
The cytotoxicity of ellipticine is believed to be primarily related to two modes of action: (i) 
intercalation into DNA and (ii) inhibition of DNA topoisomerase II activity.73,175 The size and planar 
molecular structure of ellipticine closely resemble those of a purine-pyrimidine complementary base 
pair, providing favorable conditions for intercalation in DNA. The hydrophobic interaction between 
the polycyclic aromatic ring of ellipticine and the DNA bases may strengthen the intercalation. In 
addition, protonation of ellipticine appears to favor its binding to DNA, which in turn causes the 
unwinding of DNA.73,176 Intercalation may result in subsequent DNA breakage and cell death, 
although the detailed mechanism is still unclear. 
One pathway of ellipticine intercalation in DNA leads to the inhibition of topoisomerase II, 
leading to DNA strand breakage and causing cell death.177 This results from the formation of a ternary 
complex between topoisomerase II, DNA and ellipticine as proposed by Froelich-Ammon et al.178 
They found that ellipticine stimulates DNA breakage by enhancing the forward rate of cleavage. In 
addition, the ternary complex formation does not require the presence of a preformed topoisomerase-
II-DNA complex. 
Apart from these two modes of action, ellipticine has recently shown to be involved in the 
induction of cell cycle apoptosis. It can upregulate the tumor suppressor protein p53 in hepatocellular 
carcinoma cell (HepG2) and breast cancer cells (MCF-7 and MDA-MB-231).179-181 Besides, 
ellipticine can also trigger mitochondrial apoptotic pathway by regulating Bcl-2 family proteins 
expression, altering mitochondrial membrane potential, and activating caspase-9, caspase-8 and 
caspase-3. More recently, it has been found that ellipticine can covalently bind to DNA to form DNA 
adduct after being enzymatically activated.182-185 The adduct formation starts with oxidation of 
ellipticine by cytochrome P450 and/or peroxidase. This new mode of action may explain the selective 
cytotoxicity of ellipticine towards specific cancer cells. 
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2.3.3 Current Advances in Ellipticine Delivery 
As discussed earlier, low water solubility is one of the major challenges for the use of ellipticine. 
Although several ellipticine derivatives have shown enhanced water solubility via chemical 
modification without compromising the anticancer activity,164,170,186 none were successful during 
clinical trials.74,164-166 The early clinical trials with ellipticine and its derivatives (e.g., 2-methyl-9-
hydroxyellipticinium, NSC 264137) encountered severe side effects on the cardiovascular system, 
including hemolysis, rapid hypotension and a decrease in heart rate. This was thought to result from 
the propensity of ellipticine to bind to membranes, causing an increase in membrane surface area and 
osmotic fragility.173,187 Several other important toxicities to the patients were also displayed, such as 
xerostomia, vomiting, nausea, anorexia and immune-mediated hemolytic reactions.188,189 These 
obstacles greatly hamper the development of ellipticine in cancer chemotherapy. 
To overcome the low water solubility of ellipticine and possibly reduce its side effects, new 
approaches have emerged using polymeric micelle systems71,190,191 as well as polymeric/peptide 
conjugation.171,172,192,193 Vladimir et al.190 reported that ellipticine can be successfully incorporated 
into phosphatidylethanolamine-polyethyleneoxide (PE-PEO) micelles for long-circulating delivery. 
C. Allen and coworkers71 recently tested several polymeric systems for their compatibility with 
ellipticine. They compared different formulation characteristics regarding ellipticine solubility and 
release, and found that polycaprolactone (PCL)-based copolymer micelles (e.g., PEO-b-PCL) could 
be a promising delivery system for ellipticine. Such a system has a high ellipticine loading efficiency 
and can achieve controlled release. They also developed a new micelle system using methoxy 
(polyethylene glycol)-b-poly (5-benzyloxy-trimethylene carbonate) (MePEG-b-PBTMC), which had 
an enhanced ellipticine loading efficiency of 95%.191 With the presence of serum proteins, the 
ellipticine release was accelerated although the interactions between micelles and proteins were found 
to be minimal and insignificant. 
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In addition to micelle systems, conjugation with polymers or peptides provides an alternative 
approach to deliver ellipticine. Searle et al.172 prepared a series of novel N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer conjugates with the 6-(3-aminopropyl)-ellipticine derivative 
(APE, NSC176328) using GFLG or GG peptide linkage; the aqueous solubility of APE can be 
significantly increased (>10 fold). It was found that HPMA-APE conjugates could significantly 
reduce hemolysis ~10 times less when compared with free APE. Moreover, the cytotoxicity of these 
conjugates was found to be much less than free drug against B16F10 melanoma in vitro; the in vivo 
studies showed a higher antitumor activity than free APE, indicating the potential of such conjugates 
in cancer treatments. 
Peptides are attractive materials for conjugation because they often possess the capability of 
cellular recognition. An ellipticine derivative, 1-[3-[N-(3-aminopropyl)-N-methylamino]propyl] 
amino-9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b] carbazole, was conjugated with a heptapeptide 
and its derivative that targeted the gastrin/cholecystokinin type B receptor.192 The conjugated 
ellipticine derivative eradicated all receptor-positive tumor cells in vivo without producing any 
general toxicity. Another example was the vasoactive intestinal peptide (VIP)-ellipticine conjugates 
to selectively inhibit the growth of breast cancer cells MCF-7 and lung cancer cells NCI-H1299.171,193 
These peptide-ellipticine conjugates were internalized via receptor-mediated endocytosis, and active 
targeted delivery was achieved. 
  In summary, ellipticine has shown great anticancer ability since its discovery in 1959, but the 
clinical usage is limited due to intolerable side effects and lack of appropriate delivery systems. With 
fast development in nanobiotechnology, ellipticine and its derivatives could be a good choice for use 
in clinically applicable cancer chemotherapy. The fluorescence capability of ellipticine and its various 
modes of action enable its usage as a model drug for investigation of novel delivery vehicles for 
hydrophobic anticancer drug delivery. 
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Chapter 3*                                                                    
Solvent Effect on the Photophysical Properties of the Anticancer 
Agent Ellipticine 
3.1 Introduction 
Many anticancer agents have been discovered and developed from natural sources,35,157-159 as well as 
from the understanding of molecular genetics and cancer biology.39,160-162 Among them, ellipticine, a 
natural plant alkaloid, and its derivatives have been found to have anticancer activity since the 
1960’s.73,167,170,194 They are able to intercalate with DNA and inhibit topoisomerase II, leading to the 
inhibition of replication of DNA and transcription of RNA. While these compounds exhibit high 
cytotoxicity against tumor cells,167,170,186,195,196 only a few clinical trials of ellipticine and its 
derivatives were attempted in the 1980s.74,164-167 This is mainly due to the very low solubility of 
ellipticine and most of its derivatives in aqueous media and in many organic solvents.71,167,172 In 
addition, severe side effects have been observed during clinical trials, including intravascular 
hemolysis, xerostomia and the decrease of heart beat.73,74,167 
Recently, ellipticine and its derivatives have drawn renewed attention as new drug delivery 
technologies have emerged. Ellipticine can be covalently linked with polymers or peptides to form 
conjugates with significantly improved solubility.171,172,190,192,193 Such conjugates have the potential to 
target specific cancer cells, thereby reducing side effects.171,192,193 Micelles made of copolymers were 
also used to deliver ellipticine in vitro with some promising.71,191 More recently, a special class of 
self-assembling peptides has been found to be a good candidate for carrying and delivering 
hydrophobic compounds.51,59 These peptides were found to bind to ellipticine, showing great potential 
as a carrier of ellipticine. 
*This chapter is based on a paper “S.Y. Fung, J. Duhamel, P. Chen, Solvent effect on the photophysical properties of 
the anticancer agent ellipticine, J. Phys.Chem. A  2006, 110, 11446-11454”. 
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In order to characterize how ellipticine is transported to its target, it is useful to establish a 
relationship between the environment and photophysical properties of ellipticine. This will enable one 
to monitor the uptake of ellipticine by a given carrier and its release from the carrier to a target site by 
monitoring the change in absorption and emission spectra, as ellipticine migrates from the 
microenvironment of the carrier to that of the target site. Unfortunately, only a few scattered studies 
in the literature have reported the photophysical properties of ellipticine and its 
derivatives.73,163,168,173,174 Some studies focused on the binding of ellipticine to DNA;169,178,197 others 
monitored the ellipticine fluorescence inside cultured cells.198-200 These studies provided a limited 
understanding of the photophysical properties of ellipticine. They are summarized hereafter. 
Ellipticine exhibits several UV absorption bands between 220 and 400 nm, with an extinction 
coefficient ranging from 3000 to 79000 1/(M·cm).163 The UV absorption and fluorescence emission 
are highly dependent on solution pH.163,168,174 Ellipticine exhibits a maximum of fluorescence at 520 
nm in water (excitation at 304 nm), but an emission maximum at ~430 nm in ethanol (excitation at 
294 nm). This dramatic spectral shift is attributed to the different structures adopted by ellipticine in 
different solvents. The protonation of the pyridine-like nitrogen (pKa 6-7.4)73,168,169 results in an 
emission maximum at 520 nm while the neutral form of ellipticine emits fluorescence at ~430 nm.168 
The observation of the neutral form of ellipticine in ethanol and its protonated form in a more polar 
solvent (water) suggests that one may use the solvatochromic effects exhibited by ellipticine to 
determine its local environment. This would be a powerful investigation tool to describe the polarity 
of a medium in which ellipticine is located. Such a result would be expected to have immediate 
application to characterize the transfer mechanism of ellipticine in a given delivery system. 
In the present study, the photophysical properties of ellipticine were determined in a series of 
organic solvents with different polarities. The UV absorption and fluorescence emission spectra were 
obtained in each solvent and analyzed in terms of the position of their peak maxima. The position of 
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the peak maxima was correlated to the solvent polarity using the Lippert-Mataga equation.201,202 The 
extinction coefficient of ellipticine in each solvent was obtained by applying Beer-Lambert’s law. 
Time-resolved fluorescence experiments were conducted to determine the lifetime of ellipticine. The 
trends obtained for the absorption and emission of ellipticine as a function of the solvent polarity 
enable one to use the photophysical properties of ellipticine as a tool to determine its location in a 
heterogeneous medium. For instance, ellipticine was found to reside close to the surface of the lipid 
membrane of egg phophatidylcholine (EPC) liposomes. 
3.2 Materials and Methods 
3.2.1 Materials 
The solvents (Table 3.1) were obtained from Sigma-Aldrich (Oakville, Canada), Caledon 
Laboratories Ltd. (Georgetown, Canada) or EM Science (New Jersey, US) with a purity of 99+%. 
Dielectric constants (ε) and refractive indices (n) of the pure solvents were obtained from the 
literature,203 and used to estimate these properties of the mixed solvents (εmix and nmix) from Equations 
3.1 and 3.2,204-206 
bbaamix ff εεε +=         (3.1) 
222
bbaamix nfnfn +=         (3.2) 
where the subscripts a and b represent the two different pure solvents, and fa,b is the volume fraction 
of each solvent. The polarities of the pure and mixed solvents could be estimated using the definition 
















ε         (3.3) 
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Table 3.1 Photophysical properties of ellipticine in different solvents 










MeOH 0.308 32.70 1.3288 294 34014 434 23041 10972 62300 
ACN 0.305 36.64 1.3442 291.5 34305 420 23810 10495 43500 
EtOH 0.289 24.55 1.3611 294 34014 429 23310 10704 69900 
Hex15EtOH85 0.281 21.15 1.3703 294.5 33956 426 23474 10482  
iPrOH 0.277 20.18 1.3776 294.5 33956 424 23585 10371 71300 
DMF 0.274 36.70 1.4305 293.5 34072 425 23529 10543 53600 
Hex35EtOH65 0.271 16.62 1.3708 294.8 33921 425 23529 10392  
BuOH 0.264 17.50 1.3988 295 33898 427 23419 10479 71500 
DMSO 0.263 46.68 1.4793 295 33898 428 23364 10534 60000 
Hex50EtOH50 0.260 13.225 1.3712 295 33898 423 23641 10257  
Hex65EtOH35 0.242 9.819 1.3716 295 33898 422 23697 10201  
tBuOH 0.238 12.47 1.4255 294.5 33956 420 23810 10146 70400 
Hex75EtOH25 0.222 7.552 1.3718 295 33898 421 23753 10145  
THF 0.210 7.520 1.4050 293.3 34095 413 24213 9882 49600 
Hex1THF99 0.209 7.464 1.4047 293 34130 412 24272 9858  
Hex5THF95 0.207 7.238 1.4034 293 34130 412 24272 9858  
Hex80EtOH20 0.206 6.420 1.3720 294.8 33921 420 23810 10111  
Hex10THF90 0.204 6.957 1.4018 293 34130 411 24331 9799  
EAce 0.201 6.081 1.3723 291.5 34305 410 24390 9915 47400 
Hex20THF80 0.197 6.393 1.3986 293 34130 410 24390 9740  
Hex30THF70 0.188 5.830 1.3954 293 34130 410 24390 9740  
Hex85EtOH15 0.185 5.286 1.3721 294.8 33921 420 23810 10111  
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tAmOH 0.184 5.780 1.4052 294.5 33956 419 23867 10089 70000 
Hex40THF60 0.178 5.267 1.3922 293 34130 409 24450 9680  
Hex50THF50 0.165 4.703 1.3889 293 34130 409 24450 9680  
Ether 0.165 4.267 1.3526 291.5 34305 405 24691 9614 52100 
Hex90EtOH10 0.154 4.153 1.3722 294.5 33956 419 23866 10090  
Hex60THF40 0.148 4.140 1.3857 292.5 34188 407 24570 9618  
Hex70THF30 0.127 3.577 1.3825 292.5 34188 406 24631 9557  
Hex93EtOH7 0.126 3.473 1.3723 294.5 33956 419 23866 10090  
Hex95EtOH5 0.102 3.020 1.3724 294.5 33956 418 23923 10033  
Hex80THF20 0.099 3.013 1.3792 292.5 34188 405 24691 9497  
Hex97EtOH3 0.070 2.566 1.3724 294 34014 418 23923 10091  
Hex90THF10 0.059 2.450 1.3760 292.5 34188 403 24814 9374  
Hex98EtOH2 0.051 2.340 1.3724 293.3 34095 416 24038 10057  
Hex95THF5 0.033 2.168 1.3743 292 34247 402 24876 9371  
Hex99EtOH1 0.028 2.113 1.3725 291 34364 407 24570 9794  
Diox 0.021 2.219 1.4224 292.5 34188 410 24390 9798 51800 
Hex98THF2 0.014 1.999 1.3734 291.5 34305 401 24938 9367  
Tol 0.013 2.379 1.4961 293 34130 403 24814 9316 47400 
Hex99.6EtOH0.4 0.012 1.977 1.3725 290.5 34423 403 24814 9609  
Hex99THF1 0.007 1.943 1.3730 291 34364 401 24938 9426  
Hex99.8EtOH0.2 0.006 1.932 1.3725 290.3 34447 402 24876 9571  
CHex 0 2.024 1.4235 290 34483 392 25510 8973 37700 
Hex 0 1.887 1.3727 289.5 34542 390 25641 8901 32100 
EPC    295 33898 436 22936 10962  
SDS    307 32573 520 19231 13342  
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Notations: orientation polarizability, Δf; dielectric constant, ε; refractive index, n; absorption 
wavelength, λa; absorption wavenumber, νa; emission wavelength, λf; emission wavenumber, νf; 
extinction coefficient, e. 
 
The anticancer agent ellipticine (99.8% pure) was purchased from Sigma-Aldrich (Oakville, 
Canada) and used without further purification. Egg phosphatidylcholine (EPC) and sodium dodecyl 
sulfate (SDS) were purchased from Avanti Polar Lipids, Inc. (Alabama, US) and EM Science (New 
Jersey, US), respectively. Ethylenediaminetetraacetic acid (EDTA) was supplied by Bio-Rad 
Laboratories. Tris(hydroxymethyl)methylamine (Tris) and acetic acid were obtained from BDH Inc. 
(Toronto, Canada). 
The following abbreviations are used for the various solvents: methanol, MeOH; acetonitrile, 
ACN; ethanol, EtOH; iso-propanol, iPrOH; dimethylformamide, DMF; butanol, BuOH; 
dimethylsulfoxide, DMSO; tert-butanol, tBuOH; tetrahydrofuran, THF; ethyl acetate, EAce; tert-
amyl alcohol, tAmOH; diethyl ether, Ether; 1,4-dioxane, Diox; toluene, Tol; cyclohexane, CHex; 
hexane, Hex; egg phosphatidylcholine, EPC; sodium dodecyl sulfate, SDS; the subscripts for the 
mixture represent the volume percentage of the two solvents in the mixture (i.e., Hex99THF1: the 
mixture contains 99% of hexane and 1% of THF) 
The error for all absorption and emission data is within 0.2%, and that for extinction 
coefficients is less than 2.0%. 
3.2.2 Sample Preparation 
The ellipticine solutions were prepared from stock solutions (100 μM and 400 μM) dissolved in THF. 
Aliquots of the ellipticine stock solution (100 μM) in THF were transferred to a 20 mL vial. The vial 
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was then dried under a gentle flow of N2. Solvents (5 mL) were added to the vial to obtain a solution 
with a final ellipticine concentration of 2 μM for all fluorescence studies. The same procedure was 
used to prepare higher ellipticine concentrations (4, 8, 10 and 20 μM) from the 400 μM stock solution 
for UV absorption experiments. All solutions were degassed prior to performing a steady-state or 
time-resolved fluorescence experiment.  
A 25 mM Tris/acetic acid buffer at pH 7 with 0.2 mM EDTA was used in the dispersions of 
EPC liposomes. The preparation procedure was described in a previous publication:51 EPC in 
chloroform (75 g) was added to a 1 L round-bottom flask. The chloroform was then evaporated off 
using a rotary evaporator to produce a thin film inside the round-bottom flask. The film was dispersed 
at room temperature in 310 mL of the buffer solution. The mixture was then sonicated for 25-30 min 
in a sonifier cell disrupter (Heat Systems-Ultrasonic Inc, model W-225) set at about 20 W output. The 
round-bottom flask was kept near 0 °C on ice above the lipid phase transition temperature (Tc = -15 
°C to -7 °C) and nitrogen was bubbled into the mixture. This was followed by centrifugation at 7000 
rpm for 1 h to eliminate the larger membranes and eventual titanium particles from the sonifier probe. 
The supernatant was collected and stored at 5 °C before use. The prepared liposomes were 
characterized as large unilamellar vesicles (LUVs) in terms of their sizes (70-130 nm in diameter).51  
The lipid concentration was determined from the difference between the solid content of the 
vesicle solution and that of the buffer solution. The procedure was described in the following: three 
known masses of the vesicle solution were pipetted into preweighed 20 mL vials. Three aliquots of 
the buffer solution with masses close to the mass of the vesicle solution were also pipetted into 
preweighed 20 mL vials. This was done so that the solid content of the buffer solution could be 
withdrawn from the mass of the dried liposome and an accurate concentration of the EPC lipid could 
be determined. The three sets of vesicle and buffer solutions were set under a stream of nitrogen to 
obtain a film at the bottom of the vial. The vials were then placed in a vacuum oven overnight at 60 
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°C to remove any traces of water. The mass of the three sets of vesicle and buffer films were obtained 
to calculate the lipid concentration. The EPC concentration used in this study equaled 1.1 mM. 
Liposome dispersions (5 mL) were added to the sample vial containing a dry film of ellipticine to 
reach the set 2 μM ellipticine concentration. 
3.2.3 UV Absorption  
The extinction coefficient of ellipticine at the wavelength corresponding to the absorption maximum 
in each solvent was determined from the absorption of five ellipticine solutions (2, 4, 8, 10 and 20 
μM). The absorption spectra were acquired on a UV-Vis spectrophotometer (Biochrom Ultraspec 
4300 Pro, Cambridge, England) using a 1 cm path length quartz cell. The molar extinction coefficient 
(e) was obtained from Beer-Lambert’s Law as follows:202 
ecdAbsAbsorbance =)(        (3.4) 
where c is the molar concentration of ellipticine and d is the optical path length (cm). A plot of 
absorbance versus ellipticine concentration yields a straight line (R2 > 0.995) with slope equal to e for 
a 1 cm light path length. 
3.2.4 Steady-State and Time-Resolved Fluorescence 
All steady-state fluorescence emission spectra were acquired on a Photon Technology International 
QM-4 spectrofluorometer (London, ON, Canada) with a continuous xenon lamp as the light source. 
For each sample, approximately 3 mL of solution was transferred from the sample vial into a square 
quartz cell (1 cm × 1 cm) through a Pasteur glass pipette. The sample was then excited at the 
wavelength corresponding to the position of the absorption maximum in different solvents (289-305 
nm). The emission fluorescence spectra were collected at wavelengths ranging from 300 nm to 650 
nm. Each spectrum was normalized according to its peak maximum. In the case of solutions 
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exhibiting multiple fluorescence peaks, the position of the far left fluorescence peak was used in the 
Lippert-Mataga Equation. 
The time-resolved fluorescence decays were acquired on an IBH 5000U time-resolved 
fluorometer using the time-correlated single photon counting (TCSPC) technique. For each solvent, 
the excitation was set at the wavelength corresponding to the absorption maximum and the 
fluorescence was collected at the wavelength corresponding to the fluorescence maximum determined 
from the steady-state fluorescence spectra. All decay profiles were acquired over 1024 channels and 
the data collection was stopped when the peak maximum reached 20000 counts. A filter was applied 
with a cutoff of 370 nm to minimize potential light scattering leaking through the detection system. 
The decays were then fitted with a mono or bi-exponential function and the fitting parameters were 
optimized using the Marquardt-Levenberg algorithm.207 The quality of all fits was determined by the 
χ2 parameter, the random distribution of the residuals, and the autocorrelation function of the 
residuals. 
3.3 Results and Discussion 
3.3.1 Effect of Solvent on the Absorption Spectra 
Typical absorption spectra of ellipticine in various solvents are shown in Figure 3.1. Ellipticine 
absorbs over a wide range of wavelengths from 220 nm to 400 nm. In methanol, three major 
absorption peaks are found at 294 nm, 285 nm and 276 nm. The peak locations are very close to the 
reported values.163 When ellipticine is in a non-polar solvent, such as hexane, the absorption spectrum 
shifts toward the ultraviolet region (blue shift). The 294 nm peak (peak III) in methanol shifts to 
289.5 nm in hexane, but it does not change much in the solvents with medium polarity such as THF 
 
 56
(absorption spectra for other solvents are not shown). The position of the absorption peak III in all 

















Figure 3.1 Absorption spectra of ellipticine in hexane (open squares), THF (open triangles) and 
methanol (crosses). The ellipticine concentration is 2 μM. The position of peak III was chosen as the 
excitation wavelength of ellipticine in each solvent. 
 
The shift of the absorption spectrum with solvent polarity observed for a solvatochromic 
compound is a well-known phenomenon. The shift can be described as being hypsochromic or 
bathochromic depending on whether the absorption maximum occurs at a lower or higher 
wavelength, respectively. In the case of ellipticine, the absorption spectrum shifts to higher 
wavelengths with increasing solvent polarity, indicating a bathochromic shift. Normally, a 
bathochromic shift occurs when the dipole moment of the probe (ellipticine in the present case) 
increases during the electronic transition (i.e., the ground-state dipole moment μg < excited-state 
289.5 nm (Hex) 
293.3 nm (THF) 





dipole moment μe), and the excited state is formed in a solvent cage of already partly oriented solvent 
molecules.208 Thus, more polar solvents favor the stabilization of the excited state of the probe. By 
examining the structure of ellipticine (Figure 3.2), the electrons are expected to be delocalized 
between the nitrogen atoms of the pyridine-like ring (ring 4) and of the pyrrole-like ring (ring 2). In 
addition, hydrogen bonding between the solvent and both nitrogen atoms of ellipticine may induce 
electron redistribution. This might be the reason why, in all protic solvents with strong hydrogen 
bonding ability, peak III shifts to higher wavelengths, but it remains fixed at low wavelengths in 
hexane and cyclohexane where the formation of hydrogen bonds is prevented. The effect of specific 
solvent interactions will be discussed later. 
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Figure 3.3 Extinction coefficients of ellipticine as a function of solvent polarity (Δf) (alcohols, 
triangles). The ellipticine concentrations in hexane and cyclohexane varied from 1 to 5 μM (due to its 
low solubility in these two solvents) while those in other solvents varied from 2 to 20 μM. The data 
for each solvent followed a straight line, and the extinction coefficient was obtained through a linear 
fit of the data using Equation 3.4. 
 
The extinction coefficients (e) at peak III in pure solvents are listed in Table 3.1 and plotted 
against the solvent polarity (Δf) in Figure 3.3. It seems that there is no trend for the extinction 
coefficients as a function of solvent polarity. The values vary from 32000 in non-polar solvents up to 
~70000 in protic solvents (alcohols). Interestingly, ellipticine has the highest extinction coefficients in 
all protic solvents (solid triangles) except methanol, intermediate ones in aprotic polar solvents, and 
the lowest ones in non-polar solvents. This trend seems to follow the hydrogen bonding ability of the 






ability, but the non-polar solvents cannot form hydrogen bonds with ellipticine. The aprotic polar 
solvents contain either an ether group or an ester group, which can act as hydrogen acceptors for 
hydrogen bonding, resulting in an intermediate hydrogen bonding ability. These observations suggest 
that hydrogen bonding between the solvent and ellipticine affects its extinction coefficient. 
3.3.2 Effect of Solvent on the Fluorescence Emission Spectra 
Following the absorption experiments, steady-state fluorescence spectra of ellipticine were acquired 
in 16 different organic solvents. Some representative emission spectra are shown in Figure 3.4. The 
spectra were normalized with respect to their peak maxima. The peak maximum shifts to the right 
(red shift) as the solvent polarity increases (from hexane to methanol). Meanwhile, the spectra 
obtained in apolar solvents such as hexane exhibit several peaks which merged into a single broad 
peak when dissolved in more polar solvents. It is worth noting that the emission spectrum in methanol 
exhibits a red-shifted peak at ~510 nm. This peak is close to the one observed at 520 nm in SDS 
micelles and aqueous solutions, which has been identified as the protonated form of ellipticine 
(protonation of the nitrogen on the pyridine-like ring).168,169,199 This might be due to the fact that 
methanol, having a smaller pKa, is more acidic than other alcohols. However, the real mechanisms 























Figure 3.4 Fluorescence emission spectra of ellipticine (2 μM) in different solvents. All spectra were 
normalized with respect to the peak maximum. 
 
Further experiments were conducted to investigate whether the 510 nm peak in methanol could 
be attributed to the formation of an ellipticine excimer. The fluorescence spectra of a series of 
ellipticine solutions in methanol with concentrations ranging from 2 to 100 μM were acquired. The 
ratio of the fluorescence intensity at the 436 nm peak to that at the 510 nm peak was found to remain 
constant and equal to 2.16 ± 0.02 for all ellipticine concentrations. This result suggests that the 510 
nm peak is not due to the formation of an excimer since increasing the ellipticine concentration 






































Figure 3.5 Fluorescence emission spectra of ellipticine (2 μM) in methanol upon addition of 1 M 
NaOH ( top pure methanol, bottom 194 uL of 1M NaOH solution). All spectra were normalized with 
respect to their peak maxima. 
 
To confirm that protonation resulted in the appearance of the 510 nm peak, a 5 mL methanol 
solution containing 2 μM ellipticine was titrated by adding 1-194 μL of 1.0 M NaOH solution. As 
shown in Figure 3.5, the 510 nm peak decreased with the addition of NaOH due to the deprotonation 
of ellipticine. Thus, it was concluded that the protonated ellipticine causes the emission peak at ~510 
nm in methanol. This result is consistent with the earlier finding that ellipticine is protonated in SDS 
micelles giving a peak maximum at ~520 nm.168 
3.3.3 General Solvent Effect and the Lippert-Mataga Relation 
The position of the peak maximum (λf) for each fluorescence spectrum was plotted against the 




peak maximum shifts from 390 nm to ~430 nm with increasing solvent dielectric constant. It seems 
that the profile reaches a plateau when the dielectric constant is larger than 20. Since the dielectric 
constant is a parameter often taken to represent the solvent polarity, Figure 3.6a confirms that the 
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Figure 3.6 (a) Position of ellipticine fluorescence maximum as a function of solvent dielectric 
constants. (b) Lippert-Mataga plot of ellipticine in 16 pure solvents. The data are fitted to a straight 





























ellipticine in mixtures of hexane-THF (open circles) and hexane-ethanol (open triangles). The 
ellipticine concentration in each solvent and solvent mixture was set at 2 μM. 
 
To better understand the solvent polarity effect, the Lippert-Mataga relation was applied. This 
relation has been widely used to correlate the energy difference between absorption (hνa) and 
emission (hνf), also known as Stokes’ shift, with solvent polarity represented by Δf. This relation is 

































ενν     (3.5) 
In Equation 5, νa and νf are the wavenumbers (1/cm) corresponding to the absorption and the 
emission, respectively, h is Planck’s constant, c is the speed of light, and a is the radius of the solvent 
cavity in which the fluorophore resides. The term involving ε and n is called the orientation 
polarizability (Δf), which only accounts for the spectral shifts due to the reorientation of the solvent 
molecules. Therefore, the Lippert-Mataga relation is based on the assumption that the energy 
difference is only proportional to the solvent orientation polarizability (known as the general solvent 
effect). Inability of the Stokes’ shift to increase linearly with Δf usually implies that specific solvent 
effects are involved. 
Figure 3.6b shows the Lippert-Mataga plot of ellipticine in 16 organic solvents. The Stokes’ 
shift increases with increasing solvent polarity. When the solvent polarity (Δf) is larger than 0.15, the 
data appears to fall on a straight line. From the Lippert-Mataga equation, the slope of this line yields 
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slope μΔ=          (3.6) 
The estimated dipole moment difference is 12.2 D (debye) (slope 9700 ± 990, R2 > 0.92), based 
on the assumption that the Onsager cavity radius a equals 5.35 Å, which is half of the optimized 
distance between the two farthest atoms of the molecule in the direction of charge separation (10.7 
Å).210 Although this Δμ value was obtained with an approximated cavity radius, it is quite comparable 
with those reported for other solvatochromic compounds (3~20 D).210-217 This estimation from the 
Lippert-Mataga equation is based on the assumption that the photophysical properties of ellipticine 
can be described by the theory of general solvent effect; hence, it may not hold if specific solvent 
effects are involved. Actually, the Stokes’ shifts observed for solvents with a polarity smaller than 
0.03 do not follow the trend (Figure 3.6b). This suggests that the solvent polarity might not be the 
only factor affecting the spectral shifts. Specific solvent effects including hydrogen bonding, acid-
base chemistry and charge-transfer interactions, can also result in nonlinear Lippert-Mataga plots.202 
As mentioned before, ellipticine can form hydrogen bonds with the solvent, and it can shuffle 
electrons between its two nitrogen atoms (Figure 3.2). This complicates the interpretation of how the 
solvent affects the absorption and emission spectra of ellipticine. 
To better understand the factors that affect the Stokes’ shifts of ellipticine, the data points in 
Figure 3.6b can be roughly divided into two groups corresponding to Δf values smaller than 0.03 and 
larger than 0.15. In the more polar region (Δf > 0.15), a linear trend was found and the corresponding 
dipole moment difference was estimated to be 12.2 D. Such a large dipole moment difference usually 
indicates the occurrence of intramolecular charge transfer (ICT) induced by the solvent after 
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excitation.210,213-217 Figure 3.2 describes the mechanism by which the ICT occurs. In most cases, 
solvent polarity is believed to be the effect driving an ICT, but for ellipticine, another important factor 
– hydrogen bonding – should be considered as well. Most solvents used in this study can form 
hydrogen bonds with ellipticine except hexane and cyclohexane. Alcohols with a hydroxyl group 
(OH) together with solvents such as DMF and DMSO are expected to form strong hydrogen bonds 
with ellipticine, which, in addition to their large solvent polarity, may favor the occurrence of an ICT 
and result in the large 12.2D dipole moment difference. Although hydrogen bond formation may 
occur even in less polar solvents such as diethyl ether, THF and ethyl acetate, the strength of such 
hydrogen bonds is expected to be weaker;208 as a result, these solvents will be much less effective at 
inducing an ICT (see below). In the less polar region (Δf < 0.03), the data fell on a second, steeper 
straight line. However, this steeper straight line is probably a coincidence because an ICT should not 
occur in the non-polar hexane and cyclohexane where no hydrogen bonds can be formed with 
ellipticine. In addition, the relatively larger Stokes’ shift observed in toluene may be related to the 
presence of π-π staking, and that observed in 1,4-dioxane can be due to hydrogen bonding 
interactions (see below). 
In order to bridge the gap between the non-polar (Δf < 0.03) and semi-polar (0.15 < Δf < 0.2) 
solvents in the Lippert-Mataga plot, ellipticine solutions were prepared with solvent mixtures of 
hexane and THF. Such binary mixtures provide a simpler means of studying solvent effects because it 
reduces the possibilities of specific solvent effects generated by different solvents. The results are 
listed in Table 3.1 and plotted in Figure 3.6c (open circles). The Stokes’ shifts increases linearly with 
the solvent polarity, but the mixture containing the lowest volume fraction of THF (1 v/v %) exhibits 
a Stokes’ shift substantially larger than that of hexane. The dramatic increase in Stokes’ shift 
observed for 1 v/v % of THF in hexane cannot be due to an increase of the solvent polarity alone, but 
to specific interactions between THF and ellipticine. This statement is further illustrated in Figure 
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3.7a, where the position of the absorption and emission maxima is plotted as a function of solvent 
composition. Small addition of THF results in a substantial shift of the position of both the absorption 
and emission maxima. 
Volume % of THF in Hexane

















Volume % of EtOH in Hexane



















Figure 3.7 Position of the absorption peakIII and emission maximum of ellipticine (2 μM) in the 









One possible reason for this effect could be the formation of hydrogen bonds between THF and 
ellipticine. THF contains an ether group (C-O-C), which can serve as a hydrogen acceptor, so 
hydrogen bonds can be formed between the NH group on the pyrrole-like ring of ellipticine and the 
oxygen of THF. This interaction only requires minute amounts of THF since the ellipticine 
concentration is very low (2 μM), and that of THF in a 1 v/v % mixture is comparatively high (0.125 
M). The presence of minute amounts of THF also affects the absorption of ellipticine (Figure 3.7a), 
suggesting that hydrogen bonding between THF and ellipticine must be occurring in the ground 
state.202,208 When the amount of THF is greater than 5 v/v %, both absorption and emission shift 
gradually to lower wavenumbers due to the increase of solvent polarity.  
Combining the data generated from the hexane-THF mixtures with that from 16 pure solvents, 
a transition is clearly seen at a solvent polarity around 0.2 (Figure 3.6c). This transition is thought to 
be an indication that an ICT happens when Δf is above 0.2. However, it is worth noting that the 
position of this transition is not fixed, and depends on different systems of solvent mixtures (see 
below). Furthermore, solvents with Δf values close to 0.2 (THF, ethyl acetate and diethyl ether) may 
be less effective at inducing an ICT as they are very close to the transition region. 
The results obtained so far suggest that the Stokes’ shift of ellipticine in solvents is governed 
by three factors: solvent polarity, hydrogen bonding and ICT. In the case of solvent mixtures between 
an alkane and a H-bond forming solvent, hydrogen bonding is expected to cause a sudden increase of 
the Stokes’ shift in non-polar mixtures followed by a slight increase mainly due to the increase of the 
mixture polarity (0.01 < Δf < 0.2); an ICT induced by both hydrogen bonding and solvent polarity 
occurs when Δf is greater than ~0.2. To validate the transition described above, a series of binary 
mixtures of hexane and ethanol was prepared, covering a wider range of polarities from 0 to ~0.3. The 
resulting profile is shown as open triangles in Figure 3.6c. The previously described transitions are 
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also apparent in this profile. Comparing this profile to that generated with the series of mixtures of 
hexane and THF, one observes that both display a sudden increase of the Stokes’ shift upon small 
addition of the polar cosolvent due to hydrogen bonding, followed by a slight increase for 
intermediate solvent polarities (0.05 < Δf < 0.2). When the solvent polarity of the hexane-ethanol 
mixtures is higher than 0.25, a steeper increase is observed due to an ICT. Overall, the profile 
obtained from the hexane-ethanol mixtures exhibits a much larger Stokes’ shift in the apolar solvent 
region (Δf < 0.05) and reflects the occurrence of an ICT in the more polar solvent region (Δf > 0.25).  
The relatively larger Stokes’ shift observed with the hexane-ethanol mixtures comparatively to 
the hexane-THF mixtures is probably due to stronger hydrogen bond formation between ellipticine 
and ethanol than between ellipticine and THF. This can also be seen by comparing Figure 3.7a and b. 
As for THF, the hydrogen bonds were formed in the ground state with the presence of minute 
amounts of ethanol (less than 5 v/v % in Figure 3.7b). For Δf values between 0.05 and 0.25, the 
Stokes’ shifts remains almost constant regardless of increasing solvent polarity. This result suggests 
that, in the moderate polarity range, the Stokes’ shift of ellipticine in the hexane-ethanol mixtures is 
predominantly determined by hydrogen bonding rather than by solvent polarity. When the polarity is 
larger than 0.25, ellipticine undergoes an ICT resulting in a large increase of the Stokes’ shift. 
The above discussion rationalizes why some of the data points in Figure 3.6b, (i.e., hexane, 
cyclohexane, 1,4-dioxane, tert-amyl alcohol and acetonitrile), are scattered and away from the master 
line obtained for solvents with polarity between 0.15 and 0.32. The non-polar solvents, hexane and 
cyclohexane, do not have specific interactions with ellipticine; hence the Stokes’ shift in these non-
polar solvents is small. A similar observation was reported from Pal and his group when studying 
coumarin and its derivatives.218-220 They found that the unusual behavior of coumarin and its 
derivatives in non-polar solvents is due to the absence of ICT (i.e., locally excited (LE) state). A 
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much larger Stokes’ shift observed in 1,4-dioxane, which is comparable to that obtained with THF 
and diethyl ether, is probably due to a similar ability of forming hydrogen bonds between ellipticine 
and the ether oxygen of 1,4-dioxane, THF or diethyl ether. Similarly, the OH group of tert-amyl 
alcohol may induce stronger hydrogen bonding with ellipticine, so that a larger Stokes’ shift than 
expected from the Δf value is observed. In fact, both 1,4-dioxane and tert-amyl alcohol yield Stokes’ 
shifts that fall on the profile generated by the hexane-ethanol mixtures, suggesting the presence of 
stronger hydrogen bonds between ellipticine and these two solvents. In the region of polar solvents, 
the Stoke’s shift of acetonitrile is somewhat lower than its value expected from the linear trend line 
shown in Figure 3.6b. This effect may be a result of the weaker hydrogen bonds formed between 
ellipticine and the CN group than the hydroxyl group (OH) of alcohols, even though acetonitrile is the 
second most polar solvent in this study. 
3.3.4 Solvent Effect on Fluorescence Lifetime 
The lifetimes of ellipticine in pure solvents are listed in Table 3.2. Most decay curves can be well 
fitted with a single exponential with a χ2 smaller than 1.3. The others are fitted with a sum of two 
exponentials. The solvents in which ellipticine has two lifetimes are methanol, toluene, cyclohexane 
and hexane. These “abnormal” solvents are either very polar (methanol) or non-polar (toluene, 
cyclohexane and hexane). The data in Table 3.2 indicate that the lifetime of ellipticine falls in two 
categories: the longer lifetime ranges from 15 to 29 ns depending on the solvent polarity; the shorter 
one is around 5 ns. In very polar methanol, ellipticine exhibits a decay time around 3 ns. The reason 
for the biexponential decay of ellipticine is still unclear. One may speculate that there exist two 
different forms of ellipticine in methanol, i.e., the protonated and neutral forms as mentioned before; 
however, such speculation does not hold in non-polar solvents where two lifetimes are observed 
because ellipticine cannot be protonated in non-polar solvents. 
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Table 3.2 Lifetime of ellipticine in different solvents 
Solvents Δf τ1 (ns) a1 τ2 (ns) a2 τavg (ns) χ2 
DMSO 0.263 24.4 1.00    1.23 
DMF 0.274 25.7 1.00    1.22 
MeOH(434) 0.308 3.4 0.70 5.3 0.30 4.0 1.10 
EtOH 0.289 29.8 1.00    1.21 
BuOH 0.264 28.3 1.00    1.10 
tBuOH 0.238 27.4 1.00    1.16 
THF 0.210 21.7 1.00    1.25 
EAce 0.201 23.5 1.00    1.19 
tAmOH 0.184 26.2 1.00    1.22 
Ether 0.165 15.4 1.00    1.17 
Diox 0.021 21.2 1.00    1.15 
Tol 0.013 18.3 0.83 13.2 0.17 17.4 1.24 
CHex 0 15.1 0.92 4.6 0.08 14.2 1.00 
Hex 0 16.5 0.87 4.4 0.13 14.9 1.16 
EPC  28.5 0.84 5.8 0.16 24.9 1.19 
MeOH(510)  9.2 0.89 2.0 -0.11 - 1.24 
SDS  8.5 1.00    1.20 
Note: the average lifetime is calculated from Equation 3.7. The subscripts for MeOH represent the 
wavelengths at which the fluorescence decay was collected. The time-resolved fluorescence data were 
fitted with the equation: ( ) )(2)(1 21 ττ tt eaeatI −− +=  
 
The effect of solvent on the lifetimes is illustrated in Figure 3.8, where the lifetimes are plotted 
as a function of solvent polarity. When two lifetimes were needed to fit the fluorescence decays, the 
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where a1 and a2 are the contributions of the two decay times obtained from the curve fitting. The 
average lifetime of ellipticine shown in Figure 3.8 is scattered between 15 and 30 ns. Interestingly, 
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Figure 3.8 Ellipticine lifetime as a function of solvent polarity. The lifetime increases with increasing 
solvent polarity. Ellipticine in methanol is an exception with a very short lifetime. Triangles represent 
alcohols. The ellipticine concentration was set at 2 μM 
 
It was shown in Figure 3.4 that ellipticine exhibits two fluorescence peaks in methanol. To 
further confirm whether the emission of ellipticine at the 434 nm and 510 nm peaks came from two 
different ellipticine species, a fluorescence decay experiment was carried out at 510 nm in addition to 
434 nm. The decay time of ellipticine at 510 nm was found to be ~9.2 ns, which is much longer than 




suggesting that the formation of the species that emitted with a 9.2 ns decay time was delayed. These 
results clearly show that the fluorescence emission at 434 nm and 510 nm comes from two different 
species of ellipticine in methanol. In addition, the species (species II) having a 9.2 ns decay time were 
formed after those (species I) with a shorter decay time (~4.0 ns) were excited. In fact, the excitation 
spectra acquired at both emission maxima of 434 nm and 510 nm overlapped after normalization, 
which supports the statement that species I of ellipticine is generated prior to species II. The decay 
time of the protonated form of ellipticine at 520 nm was found to equal ~8.5 ns in SDS micelles, 
which is comparable to that of ellipticine at 510 nm in methanol. Therefore, these results suggest that 
the 510 nm fluorescence maximum of ellipticine in methanol is due to the protonated form of 
ellipticine. 
3.3.5 Ellipticine in Lipid Bilayers 
The photophysical behavior of ellipticine was investigated in aqueous dispersions of EPC liposomes. 
Since ellipticine can be classified as being extremely hydrophobic considering its very low water 
solubility (6.2 × 10-7 M)71, it was expected to reside in the hydrophobic regions of the EPC liposomes. 
The location of ellipticine in the lipid bilayers might be inferred by comparing the spectral shift of 
ellipticine in the liposome dispersions with those obtained in organic solvents of known polarity.  
The emission spectra of ellipticine in different solvents and in the EPC liposomes were 
normalized to 1.0 and plotted in Figure 3.9. The emission band of ellipticine in the liposomes is 
located at 436 nm (λex = 295 nm), a wavelength very close to that obtained in methanol. The spectrum 
shows a relatively large red shift, suggesting that a more polar microenvironment is surrounding the 
ellipticine molecules. For comparison, the fluorescence spectrum of ellipticine in pH 7 Tris/acetic 
acid buffer solution was acquired. The intensity of this emission spectrum was normalized according 
to that of ellipticine in EPC liposomes. It is clearly seen that ellipticine in the buffer solution exhibits 
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an emission band at ~520 nm corresponding to its protonated form (Figure 3.9 inset), and does not 
dissolve well in aqueous solution resulting in a very low fluorescence signal. These results indicate 
that the EPC liposomes can efficiently dissolve ellipticine, but that the local environment experienced 
by ellipticine in the liposomes is rather polar, different from that expected of ellipticine located inside 
the hydrophobic lipid bilayer. Consequently, ellipticine dissolved in the liposomes must be located at 
or close to the interface between the lipid membrane and water. This could be due to the fact that the 
dipole and quadrupole moments of the indole ring (a combination of rings 1 and 2 in Figure 3.2) of 
ellipticine are more suited to interacting with charged and polar groups in the phospholipids than with 
the hydrophobic acyl chains; in addition, the flat rigid shape of ellipticine may limit its access to the 
hydrocarbon core. Such phenomena have also been found with the amino acid tryptophan (Trp), 
which consists of an indole ring and has a preference for membrane interfaces.221 The location of 
ellipticine at or close to the membrane surface combined with its sensitivity to the local environment 
suggests that ellipticine might also serve as a surface probe for studying biological phenomena 























Figure 3.9 Fluorescence emission spectra of ellipticine (2 μM) in different solvents and EPC 
liposomes. The spectrum of ellipticine in pH 7 buffer was normalized with respect to the peak 
maximum in EPC liposomes. The spectrum of ellipticine in buffer is enlarged in the inset. 
 
3.4 Conclusions 
The photophysical properties of the anticancer agent ellipticine were systematically studied in 16 
organic solvents and some of their mixtures. The UV absorption and fluorescence emission of 
ellipticine were found to be solvent dependent. As the solvent polarity increased, ellipticine exhibited 
a spectral shift to the red for both absorption and emission. The spectral shifts could be correlated 
with the solvent dielectric constants and the solvent polarity using the Lippert-Mataga equation. The 
presence of a non-linear trend in the Lippert-Mataga plot indicated the existence of specific solvent 
effects. Such effects were thought to result in an intramolecular charge transfer (ICT) due to the large 





450 490 530 570
 
 76
dipole moment difference between the ground state and the excited state. Hydrogen bonding between 
the solvent and ellipticine can also be related to the specific solvent effects. The formation of stronger 
hydrogen bonds in alcohols led to larger extinction coefficients and longer lifetimes, although 
methanol was an exception. Ellipticine exhibited an emission band at 436 nm in EPC liposomes. The 
emission band of ellipticine at 436 nm in the liposomes indicated that ellipticine is located in a rather 
polar environment, presumably close to the hydrophilic surface of the liposomes rather than buried in 
the hydrophobic interior of the liposome membrane. This study not only provides detailed 
information on the photophysical properties of ellipticine in many solvents, but also suggests that the 
dependence of the spectral shift of ellipticine with solvent can be a good indicator of where ellipticine 





Chapter 4*                                                                    
Complexation of Ellipticine with a Self-Assembling Peptide and Its 
Release into a Cell Membrane Mimic 
4.1 Introduction 
The slow progress in treating severe diseases such as cancer has suggested a growing need for novel 
approaches to the effective delivery of therapeutics to physiological targets. Drug delivery systems 
are essential to control pharmacokinetics, non-specific toxicity, immunogenecity, biorecognition, and 
drug efficacy.151 In order to develop novel drug delivery systems for clinical use, the design and/or 
discovery of effective delivery vehicles play an important role. The ideal delivery vehicle should have 
the following properties: biocompatibility, biodegradability, suitable size, high loading capacity, 
extended circulation time, and ability to accumulate at required pathological sites in the body.25 
Peptides have shown much potential for drug delivery. The most attractive aspect of peptide-
mediated drug delivery is the natural propensities of many peptides for cell penetration and 
targeting.112,153,154 As a result, many novel delivery systems involve peptides to achieve targeted 
delivery15,16,112,222 for anticancer therapeutics and to cross the cell membrane barrier223-226 for 
gene/siRNA delivery. Peptide-based delivery systems have also shown the potential to deliver 
therapeutic proteins, bioactive peptides, small molecules and nucleic acids.112,154,227  
A special class of self-assembling, ionic-complementary peptides228 could be a new and 
promising biomaterial for constructing drug delivery carriers. The unique amphiphilic structure and 
the ability of self-assembly of these peptides allow them to encapsulate both hydrophobic 
chemotherapeutics and hydrophilic protein and oligonucleotides.57,58,228 Moreover, no detectable 
immune response was observed when these peptides were introduced into animals.61,64,134 These 
*This chapter is based on a paper “S.Y. Fung, H. Yang, P. T. Bhola, P. Sadatmousavi, E. Muzar, M. Liu and P. Chen, 
Self-assembling peptide as a potential carrier for hydrophobic anticancer drug ellipticine: complexation and release, 
submitted to ACS Nano, 2007”. 
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peptides can spontaneously organize themselves into nano/micro structures that may provide a 
protected and stable environment for the therapeutic molecules. An additional advantage of using 
such peptide-based carriers is the ease of sequence modification and design to incorporate peptide cell 
penetration and targeting capabilities. 
A typical self-assembling, ionic-complementary peptide, EAK16-II, has been shown to readily 
encapsulate hydrophobic compounds and stabilize them in aqueous solution. Recent work using 
pyrene as a model hydrophobic compound demonstrated the promising potential of this peptide for 
the delivery of hydrophobic anticancer drugs.51,56 EAK16-II was shown to stabilize pyrene 
microcrystals in aqueous solution at a concentration ten-thousand fold beyond its solubility in water, 
indicating a very high loading efficiency. The encapsulated pyrene from the peptide coatings can be 
released into liposomes and the release rate can be controlled by changing the peptide-to-pyrene ratio 
during the encapsulation.51 More recently, this peptide has been used to stabilize microcrystals of the 
anticancer agent ellipticine in aqueous solution.56 The stabilized ellipticine microcrystals can have a 
concentration several hundred times larger than its solubility in water. 
Ellipticine is selected as the model hydrophobic anticancer drug in our studies for the following 
reasons: first, the fluorescence property of ellipticine enables us to monitor the interaction of 
ellipticine with the peptide and its location in different micro-environments (Chapter 3). Second, 
ellipticine is extremely hydrophobic with a low water solubility of ~0.62 μM at neutral pH,71 which is 
comparable with that of the model hydrophobic compound pyrene.72 Third, its great anticancer 
activity makes ellipticine one of the promising candidates in cancer chemotherapy.73 Fourth, the 
discovery of severe side effects of ellipticine derivatives during clinical trials suggests that a novel 
delivery system is required.73,74 
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In this study, we investigate the effect of peptide and ellipticine concentration on the formation 
of stable peptide-ellipticine complexes in aqueous solution over time. This will elucidate the kinetics 
of complex formation in relation to peptide self-assembly. A new methodology developed in our 
recent work51 is applied to study the release kinetics of ellipticine from the stable peptide-ellipticine 
complexes to egg phosphatidylcholine (EPC) vesicles as cell membrane mimics. The fluorescence 
technique is the primary tool to characterize the complex formation and the release kinetics, where 
the change of ellipticine fluorescence is monitored over time. A calibration curve is constructed to 
relate the fluorescence of ellipticine in vesicles to ellipticine concentration. The UV-Vis absorption as 
a complementary method is adopted to verify the trend of the calibration curve and the corresponding 
ellipticine concentration. Scanning electron microscopy (SEM) is applied to characterize the 
dimensions of the peptide-ellipticine complexes. This work will provide comprehensive knowledge 
on the formation of peptide-ellipticine suspensions and ellipticine release kinetics, paving the way for 
future cellular and animal studies in the development of self-assembling peptide-based delivery of 
hydrophobic anticancer drugs. 
4.2 Materials and Methods 
4.2.1 Materials 
The peptide EAK16-II (Mw = 1657 g/mol, crude) was purchased from CanPeptide Inc. (Montreal, 
Canada) and used without further purification. It has a sequence of AEAEAKAKAEAEAKAK 
(Figure 4.1), where A corresponds to alanine, E to glutamic acid and K to lysine. The N-terminus and 
C-terminus of the peptide were protected by acetyl and amino groups, respectively. The anticancer 
agent ellipticine (99.8% pure) was purchased from Sigma-Aldrich (Oakville, Canada) and used as 
received. Egg phosphatidylcholine (EPC, powder, 99+% pure) was obtained from Avanti Polar 
Lipids, Inc. (Alabaster, AL). Ethylenediaminetetraacetic acid (EDTA) was from Bio-Rad 
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Laboratories (Mississauga, Canada). Tris(hydroxymethyl)methylamine (Tris) and glacial acetic acid 
were bought from BDH Inc. (Toronto, Canada). Tetrahydrofuran (THF, reagent grade 99%) was 





















































Figure 4.1 Molecular structure of EAK16-II structure. 
 
4.2.2 Liposome Preparation 
EPC powders (~5 g) were weighed and dissolved in 125 mL of a buffer solution containing 25 mM 
Tris/acetic acid (pH = 7.0) and 0.2 mM EDTA.51 The mixture was then extruded using a LiposoFast-
Basic extruder (Avestin Inc., Ottawa, Canada) with a polycarbonate membrane (100 nm pore size) to 
obtain uniform liposome dispersions at room temperature. The dispersions were further diluted (4x) 
with the same Tris/acetic acid buffer. This was followed by centrifugation at 4000 rpm for 1 h to 
eliminate the larger vesicles and possible contaminants. The supernatant was collected and stored at 
4°C before use. The EPC concentration was determined to be 7.1 × 10-4 M using the method 
described in our previous publication (Also see Section 3.2.2).51 The size of the EPC liposomes was 
characterized by Dynamic Light Scattering (DLS).  
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4.2.3 Formation of Peptide-Ellipticine Complexes 
To make peptide-ellipticine complexes, certain amounts of ellipticine crystals were added into fresh 
EAK16-II solutions (0.05-0.5 mg/mL) to obtain ellipticine concentrations of 0.1-1.0 mg/mL. The 
fresh peptide solutions were prepared by dissolving peptide powder in pure water (18.2 MΩ, Milli-Q 
A10 synthesis), followed by sonication for 10 min. The peptide-ellipticine mixtures were stirred at 
900 rpm on a magnetic stir plate throughout the complexation experiment. At specified times, the 
mixtures were transferred to a quartz cuvette to acquire fluorescence spectra of ellipticine on a steady-
state spectrofluorometer (Photon Technology International, London, Canada). The test was performed 
once every hour for the first 20 h and less frequently for the remaining period until an equilibrium 
state was reached. A 1 mg/mL solution of ellipticine in pure water was prepared as a control. 
Since the peptide can self-assemble over time, it is expected that a competition may exist 
between the peptide-peptide association and the peptide-ellipticine complexation during the drug 
formulation. To better understand such a complicated process, peptide assembly without ellipticine 
was investigated. For this purpose, 0.2 mg/mL of fresh EAK16-II solution was prepared and stirred 
for 30 h at 900 rpm. The peptide assembly was characterized by static light scattering (at 400 nm) 
acquired on the steady-state spectrofluorometer and compared with the fresh peptide solution (0 h). 
The light scattering intensity of air was obtained as the standard to correct for the lamp fluctuations.  
For the ellipticine release experiments, the complexes were newly prepared with a fixed 
ellipticine concentration of 0.1 mg/mL and various peptide concentrations ranging from 0.05 to 0.5 
mg/mL. The samples were continuously stirred for 24 h to ensure that equilibrium was reached. They 
were then photographed with a digital camera (Cannon PowerShot A95). The steady-state 
fluorescence spectra of the complexes were acquired just before the release experiments (to show the 
states of ellipticine in complexes different from that in EPC vesicles). 
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4.2.4 Ellipticine Release into Liposome Vesicles 
The release of ellipticine from the complex into the EPC vesicles was continuously monitored on the 
spectrofluorometer over time. The experiments were conducted with the following procedure: 100 μL 
of the peptide-ellipticine dispersion were transferred into a quartz cuvette and mixed with 2.9 mL of 
EPC vesicles. The 30 times dilution of the complex upon mixing with the vesicles was to ensure that 
the final ellipticine concentration was low enough to be in the range of the calibration curve. The 
cuvette was then put in the spectrofluorometer with gentle magnetic stirring, covered with a parafilm 
(to eliminate water evaporation during the course of measurement) before collecting the fluorescence 
intensity over time. The time required to prepare the sample before starting a time-dependent 
fluorescence measurement was less than 30 s. 
4.2.5 Calibration Curve 
In order to relate the fluorescence signals of ellipticine in the EPC vesicles to the ellipticine 
concentration, a calibration curve of ellipticine fluorescence from the ellipticine-EPC suspensions is 
needed. The concentration range of ellipticine was selected to be 10-6-10-4 M based on our previous 
experience on pyrene release experiments.51 The ellipticine-EPC suspensions were prepared using the 
following procedure: ellipticine crystals were dissolved in THF to make the ellipticine-THF stock 
solution with ellipticine concentration of 1 mM. Aliquots of ellipticine-THF solution were put into a 4 
mL vial and THF was evaporated under a stream of filtered air (0.45 μm) to have a film of ellipticine 
at the bottom of the vial. 3 mL of the EPC dispersions were added and the samples were stirred for 
~24 h to allow the saturation of ellipticine in the EPC vesicles. The ellipticine fluorescence was then 
acquired. It should be noted that ellipticine at high concentrations may not completely dissolve in the 
vesicles made of 7.1 × 10-4 M EPC. Therefore, the UV-Vis absorption of the ellipticine-EPC 
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suspensions was acquired and plotted as a function of ellipticine concentration to show whether 
ellipticine was completely dissolved in the EPC dispersions. 
To ensure that the fluorescence signal of ellipticine-EPC dispersions was from the ellipticine in 
the vesicles, the fluorescence of a control sample made of the buffer saturated with ellipticine was 
acquired. The fluorescence of the control was found to be ~280 fold smaller than that of 1 μM 
ellipticine in the EPC dispersion. Such a small fluorescence signal can be neglected. Thus, the 
observed fluorescence of the ellipticine-EPC dispersions should represent the fluorescence of 
ellipticine in the vesicles.  
4.2.6 Dynamic Light Scattering (DLS) Measurements 
The hydrodynamic diameter of the EPC vesicles was obtained on a Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, U.K.) with the appropriate viscosity and refractive index settings, at a 
fixed temperature of 25 °C during the measurement. A small-volume (45 μL) black quartz cuvette 
with a 3 mm light path was used. The scattered light intensities of the samples at the angle of 173 
degree were collected. The intensity-based size distribution of the EPC vesicles was obtained with the 
multimodal algorithm CONTIN,229 provided in the software package Dispersion Technology 
Software 5.0 (Malvern Instruments, Worcestershire, U.K.). Six measurements were performed to 
generate the intensity-based size distribution plot reported herein. 
4.2.7 Steady-State Fluorescence Measurements 
The ellipticine fluorescence was acquired on the Photon Technology International spectrofluorometer 
(Type QM4-SE, London, Canada) with a continuous xenon lamp as the light source. For each sample, 
approximately 3mL of solution were transferred from a vial into a square quartz cell (1 cm × 1 cm) 
through a pasteur glass pipette. All samples containing ellipticine were excited at 294 nm and the 
 
 84
emission spectra were collected from 320 to 650 nm. The excitation and emission slit widths were set 
at 0.25 mm and 0.5 mm, respectively (0.25 mm corresponds to 1 nm band path). The fluorescence 
intensity at 468 nm and 520 nm were obtained by taking the average from 458 to 478 nm and 510 to 
530 nm, respectively. A standard (2 μM ellipticine in ethanol, sealed and degassed) was used in each 
run to correct for the lamp intensity variations. The standard fluorescence intensity Is was obtained by 
taking the average of the fluorescence signal from 424 to 432 nm (peak at ~428 nm).  
In order to generate an accurate calibration curve, the emission fluorescence of ellipticine in 
EPC vesicles was collected at 436 nm over 1 min and averaged to yield the intensity for each 
ellipticine concentration. The excitation and emission slit widths were set at 0.5 mm and 0.25 mm, 
respectively. The intensities were corrected with an ellipticine standard (2 μM in ethanol, sealed and 
degassed) to account for lamp fluctuations. The Is was obtained by taking the average of fluorescence 
at 428 nm over 1 min after each run. 
The kinetics of the ellipticine release from the complex into the EPC vesicles was monitored by 
acquiring the time-dependent ellipticine fluorescence at 436 nm over a 7 h time span at 5 s intervals. 
All solutions reached equilibrium within 7 h as the fluorescence intensities reached a plateau during 
the experimental time span. The same standard sample as described above was used to obtain Is (at 
428 nm over 10 min) to correct for the day-to-day fluctuations. For each release experiment, the 
fluorescence was recorded while the solution was gently stirred in the spectrofluorometer. 
4.2.8 Scanning Electron Microscopy (SEM) 
A LEO model 1530 field emission SEM (GmbH, Oberkochen, Germany) was employed to study the 
morphology and dimensions of the peptide-ellipticine complex. The SEM samples were prepared by 
depositing 20 μL of the complex suspensions on a freshly cleaved mica surface. The mica was affixed 
on an SEM stub using a conductive carbon tape. The sample was placed under a Petridish-cover for 
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10 min to allow the complexes to adhere to the mica surface. It was then washed once with a total of 
100 μL pure water and air-dried in a dessicator overnight. All samples were coated with a 20 nm 
thick gold layer prior to imaging; the images were acquired using the secondary electron (SE2) mode 
at 5 kV. 
4.3 Results and Discussion 
The self-assembling peptide EAK16-II has shown the capability of stabilizing a hydrophobic 
compound and the anticancer agent ellipticine in aqueous solution from our previous studies.56 Here 
we report the details of the complexation between EAK 16-II and ellipticine, concentration effects on 
the complex formation and the release kinetics of ellipticine from the complexes to the liposomes. 
4.3.1 Time-Dependence of the formation of Peptide-Ellipticine Complexes 
To investigate the details of the complexation kinetics, the change in the ellipticine fluorescence of 
the peptide-ellipticine dispersions was monitored over time. Figure 4.2a shows the fluorescence 
spectra of the complex suspension with 1.0 mg/mL ellipticine and 0.2 mg/mL EAK16-II at different 
times. Initially, the fluorescence spectrum exhibits the characteristics of protonated ellipticine with a 
peak located near 520 nm after 0.5 h stirring.168 This peak rises with time and reaches a maximum 
after 6 h before decreasing. Meanwhile, a shoulder located at ~468 nm becomes pronounced with 
time and eventually forms a peak after 9 h. The band at 468 nm is characterized as the crystalline 
form of ellipticine.56 Note that there was no trace of fluorescence at 468 nm (crystalline ellipticine) 
initially, although ellipticine was in crystalline form when just mixed with the peptide solution; the 
ellipticine crystals were large, unable to be suspended in solution, and thus settled to the bottom of the 








































Figure 4.2 The ellipticine fluorescence from the peptide-ellipticine suspension over time. (a) 
Fluorescence spectra of ellipticine as a function of time; (b) the normalized fluorescence intensities at 
468 nm (diamonds) and 520 nm (squares) as a function of time. The ellipticine concentration is 1.0 
mg/mL (4 mM) and the peptide concentration is 0.2 mg/mL (0.12 mM). 
 
The intensity changes of the two peaks at 468 and 520 nm are plotted with time in Figure 4.2b. 
It can be clearly seen that the intensity at 520 nm increases for the first 6 h to a maximum and then 
decreases to the initial level after 10 h. On the other hand, the intensity at 468 nm increases with time 
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and reaches a plateau after ~15 h. The latter indicates that ellipticine crystals or microcrystals are 
gradually stabilized in aqueous solution, to form peptide-ellipticine complexes with time. The final 
state of stabilized ellipticine is in crystalline form and equilibrium is reached after ~15 h (considering 
both I468 and I520 reaching equilibrium). 
The trend in the change of the fluorescence of protonated ellipticine shown in Figure 4.2b may 
indicate a special mechanism for complex formation. It is speculated that the fresh peptide solution 
could facilitate the formation of protonated ellipticine. Since ellipticine has a pKa of ~6 (pyridine-like 
nitrogen), it can be protonated in a weak acidic environment.73,168,169 A fresh 0.2 mg/mL EAK16-II in 
pure water has a pH value of ~4.6, which can cause the protonation of ellipticine. In addition, the 
peptide molecules consisting of negatively charged glutamic acid residues may help stabilize the 
protonated ellipticine upon interaction. A similar phenomenon has been reported that highly 
negatively charged SDS micelles can stabilize protonated ellipticine in pure water (Chapter 3).168 The 
amount of protonated ellipticine increases during the first several hours to a maximum and then 
disappears when the equilibrium is established. The diminishing of the protonated ellipticine prior to 
equilibrium may be related to the dynamics of peptide self-assembly and its associated events. As 
shown in Figure 4.3, the scattered light intensity of a 0.2 mg/mL EAK16-II solution can significantly 
increase 30 h after preparation to a level 6 fold higher than that of a fresh peptide solution. This is the 
evidence of peptide assembly over time under constant mechanical stirring. The formation of EAK16-
II assemblies may consume the negatively charged glutamic acid residues as they are complementary 
to the lysine residues in the assemblies. This in turn reduces the amount of free glutamic acid residues 
that are able to stabilize the protonated ellipticine. Meanwhile, the pH of the EAK16-II solution was 
found to increase from ~4.6 (fresh) to 6.4 (30 h after preparation), which is slightly above the pKa of 
ellipticine. The combination of these two effects can induce deprotonation of ellipticine, thereby 
explaining the disappearance of protonated ellipticine over time. Note that an occurrence of “inner 
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filter effect” due to the increase of protonated ellipticine concentration might also result in the 
decrease in fluorescence signals of the protonated ellipticine. However, more experiments are 















Figure 4.3 Static light scattering of 0.2 mg/mL (0.12 mM) EAK16-II solution at 400 nm before 
(diamonds) and after mechanical stirring for 30 h (squares). 
 
On the other hand, the peptide assembly does not likely inhibit the formation of stable 
ellipticine microcrystals. In fact, these peptide assemblies are mainly made of β-sheets, which are 
amphiphilic with hydrophobic and hydrophilic regions on the opposite sides.67,68 The hydrophobic 
region can still interact with hydrophobic ellipticine microcrystals to form stable peptide-ellipticine 
suspensions. It has been shown that EAK16-II can adsorb on hydrophobic surfaces and assemble into 
stable β-sheet rich nanostructures.56,67  
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4.3.2 Concentration Effect on the Complex Formation 
Figure 4.4 shows the peptide concentration effect on the formation of peptide-ellipticine complexes at 
a fixed ellipticine concentration of 1.0 mg/mL. The peptide concentration ranges from 0.05 to 0.5 
mg/mL. The fluorescence intensity at 468 nm (crystalline ellipticine) increases with time and reaches 
a plateau for all peptide concentrations used, but the time required to reach equilibrium is dependent 
on the peptide concentration (Figure 4.4a). The equilibration time is at minimum (~5 h) when the 
peptide concentration is around 0.1 mg/mL, which is the reported critical aggregation concentration 
(CAC) of the peptide.40 When the peptide concentration is above or below the CAC, the equilibration 
time increases (> 10 h). The change in the fluorescence intensity at 520 nm (protonated ellipticine) is 
also strongly dependent on the peptide concentration as shown in Figure 4.4b. Above the CAC, the 
protonated ellipticine can be seen to form over time and then disappear. The protonated ellipticine 
stays for a longer time (40 h) with a higher peptide concentration (0.5 mg/mL). At the CAC, the 
fluorescence of protonated ellipticine only appears in the first 2 h and quickly disappears afterwards. 














































Figure 4.4 Effect of peptide concentration on the complex formation. The normalized fluorescence 
intensities of peptide-ellipticine suspensions as a function of time at 468 nm (a) and 520 nm (b). The 
ellipticine concentration was fixed at 1.0 mg/mL (4 mM) with various EAK16-II concentrations 





The overall equilibration time of the peptide-ellipticine complexation at different EAK16-II 
concentrations is list in Table 4.1. The reported values were estimated from Figure 4.4, considering 
that both processes of ellipticine protonation and formation of stable ellipticine microcrystals have 
reached steady-state or equilibrium. Note that when the equilibrium of both processes is reached, the 
final state of the stabilized ellipticine is mainly in crystalline form. It can be clearly seen that the 
overall equilibration time is strongly dependent on the peptide concentration and approaches a 
minimum when the peptide concentration is close to the CAC. This phenomenon may be related to 
the solution pH at various peptide concentrations and the peptide self-assembly. 
 
Table 4.1 Peptide concentration-dependent equilibration time and solution pH 
 [EAK] (mg/mL) Estimated equilibration time (h) pH of fresh peptide solution 
0.50 40 3.9 
0.20 15 4.6 
0.10 7 5.2 
0.08 4 5.5 
0.05 12 6.0 
Notes: 
1. The equilibration time was estimated from Figure 4.4, considering that both I468 and I520 reach 
equilibrium. 





At peptide concentrations below the CAC, the peptide solution has a relatively high pH, which 
prohibits ellipticine protonation. But under such a condition, microcrystals of ellipticine can form 
over time. Such formation of ellipticine microcrystals becomes faster with increasing peptide 
concentration up to its CAC.  At the CAC, a low pH, below the pKa of ellipticine, is observed. Such a 
low pH allows protonated ellipticine to form (Figure 4.4b). However, over time peptide assemblies 
start to appear at this concentration; meanwhile the solution pH starts to increase and the number of 
available glutamic acid residues reduces. (Note that the glutamic acid residues can stabilize the 
protonated ellipticine.) As a result, deprotonation of ellipticine occurs shortly after the initial 
protonation.   
At peptide concentrations above the CAC, a longer equilibration time is observed.  This is 
probably due to the combined effects of the ellipticine protonation and microcrystal formation. The 
pH of a fresh peptide solution decreases with an increase in peptide concentration as shown in Table 
4.1. At a concentration above the CAC, the solution has a pH below 5, which can induce the 
protonation of ellipticine. The lower the solution pH is, the more ellipticine can be protonated. The 
protonated ellipticine will gradually disappear with time while more stable ellipticine microcrystals 
form. It takes a longer time for protonated ellipticine to disappear at a higher peptide concentration, 
leading to a longer equilibration time.  
The peptide EAK16-II is capable of stabilizing ellipticine microcrystals and protonated 
ellipticine in aqueous solution in a time-dependent and peptide concentration-dependent manner. The 
state of ellipticine could be critically important in its function as a therapeutic agent. It has been 
reported that the neutral form of ellipticine is active against various tumors.73,167 Further in vitro and 

















) 1.0 EPT, 0.2 EAK
0.5 EPT, 0.2 EAK
0.1 EPT, 0.2 EAK

















1.0 EPT, 0.2 EAK
0.5 EPT, 0.2 EAK
0.1 EPT, 0.2 EAK
0.1 EPT, 0.5 EAK
 
Figure 4.5 Effect of ellipticine concentration on the complex formation. The normalized fluorescence 
intensities of peptide-ellipticine suspensions as a function of time at 468 nm (a) and 520 nm (b). The 
0.2 (0.12 mM) and 0.5 mg/mL (0.3 mM) EAK16-II were used with different ellipticine 





The ellipticine concentration effect on the complex formation was investigated with 0.2 mg/mL 
EAK16-II and three ellipticine concentrations: 1.0, 0.5 and 0.1 mg/mL. The change in fluorescence of 
crystal and protonated ellipticine is shown in Figure 4.5a and b, respectively. At this peptide 
concentration, the ellipticine concentration does not seem to affect the overall equilibration time 
significantly. The time for the peptide-ellipticine suspension formation (both ellipticine protonation 
and formation of ellipticine microcrystals should reach equilibrium) is all ~10 h. 
Interestingly, a particular combination of 0.1 mg/mL ellipticine with 0.5 mg/mL EAK16-II, 
increased from 0.2 mg/mL, can stabilize protonated ellipticine for a prolonged time (Figure 4.5, 
crosses). The intensity at 520 nm decreases slightly at the beginning and reaches a plateau after 10 h, 
while that at 468 nm remains constant at a low value with time. The very low intensity at 468 nm has 
comparable level to that of the background noise, indicating that no ellipticine microcrystals can be 
detected. This result shows that most ellipticine is protonated and solubilized in the solution. The 
slight initial decrease in intensity of the protonated ellipticine is likely the results of inner-filter effect 
as the solution solubilizes more ellipticine with time. The protonated ellipticine is stable for at least 
50 h, the duration of the experiment, under continuous mechanical stirring. During this time period, 
the solution remains clear with a yellow-orange color. This particular combination of ellipticine and 
peptide concentrations suggests that a prolonged state of protonated ellipticine can be established. 
This will affect ellipticine release kinetics, and probably its therapeutic efficiency. 
4.3.3 Release of Ellipticine from the Complexes into EPC Vesicles  
So far, we have shown the formation of stable peptide-ellipticine dispersions in water, either in 
microcrystal or protonated form. It is important to investigate how ellipticine releases from the 
peptide complex, and the release kinetics. This was done by mixing the complex with liposome 
vesicles, which mimic the cell membrane.51 
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The EPC vesicles were made by manual extrusion passing a polycarbonate filter for 10 cycles. 
The sizes of the vesicles were determined by DLS to be ~200 nm in diameter as shown in Figure 4.6. 
















Figure 4.6 Intensity-based size distribution of the EPC vesicles. 
 
Four peptide concentrations (0.05, 0.1, 0.2 and 0.5 mg/mL) were used to form stable peptide-
ellipticine dispersions with 0.1 mg/mL of ellipticine in study of release kinetics. The samples were 
stirred for 24 h to ensure that equilibrium was reached. As shown in the photographs (Figure 4.7a), 
the stable complex suspensions are formed with the presence of EAK16-II compared to ellipticine 
only in water (far left vial). At 0.5 mg/mL of EAK16-II, the dispersion looks more yellow and less 
turbid compared to others at lower peptide concentrations. This exceptional appearance is the 
additional evidence to the results of Figure 4.5 that the 0.5 mg/mL EAK16-II solution can stabilize 
protonated ellipticine for a prolonged time. The different states of ellipticine at equilibrium are also 
shown in Figure 4.7b. The suspension with 0.5 mg/mL EAK16-II has a pronounced peak located 
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~525 nm (protonated state) while those with peptide concentrations ranging from 0.05 to 0.2 mg/mL 
exhibit a peak of ~468 nm (crystalline state) (Figure 4.7b, inset). The very different properties of the 
complex suspensions according to the peptide concentration could also have significant effects on the 




















Figure 4.7 (a) Photographs of the peptide-ellipticine suspensions after 24 h stirring with 0.1 mg/mL 
(0.4 mM) ellipticine and various peptide concentrations of 0-0.5 mg/mL (0-0.3 mM). (b) The 
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It is worth noting that the fluorescence of ellipticine, either protonated or in crystal form upon 
interaction with peptides, is very different from that of ellipticine in EPC vesicles. Ellipticine in the 
vesicles exhibits a strong fluorescence signal at ~436 nm, which is characterized as neutral, 
monomeric ellipticine (Chapter 3). Such a signal can be well distinguished from those of the 
protonated ellipticine (~520 nm) and ellipticine crystals (weak fluorescence at ~468 nm) (Figure 
4.7b). The transfer of ellipticine from the complex into the vesicles can be monitored by the change in 
ellipticine fluorescence at 436 nm over time. 
A typical transfer curve of ellipticine from the complex to the EPC vesicles, or liposomes, is 
shown in Figure 4.8a. The complex was made with 0.05 mg/mL EAK16-II and 0.1 mg/mL ellipticine 
in pure water after 24 h stirring (second vial to the left in Figure 4.7a). The fluorescence intensity at 
436 nm increases with time and approaches a plateau after 20,000 s. The reason that the initial point 
starts slightly above zero (t = 0) is probably due to the burst release of ellipticine into the vesicles 



















































Figure 4.8 (a) The time-dependent ellipticine fluorescence showing the release of ellipticine from the 
complex made of 0.05 mg/mL (0.03 mM) EAK16-II and 0.1 mg/mL (0.4 mM) ellipticine into the 
EPC vesicles. (b) Calibration curve of various ellipticine concentrations in the EPC vesicles. (c) 
Corresponding UV absorption of ellipticine in (b). 
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In order to relate the transfer curve based on the ellipticine fluorescence to the concentration 
accumulation of ellipticine in vesicles, a calibration curve was generated as shown in Figure 4.8b. 
The ellipticine fluorescence in EPC vesicles increases to a maximum with the increase of ellipticine 
concentration from 1 to ~20 μM; it then slightly decreases with a further increase in ellipticine 
concentration (up to 100 μM). Normally, the decrease of ellipticine fluorescence at high ellipticine 
concentrations can be related to the inner-filter effect. This usually occurs when the concentration of a 
fluorophore is high enough with right angle detection.51,202 However, the decrease of the fluorescence 
due to the inner-filter effect is usually more dramatic (~50%), which does not seem to match with the 
present case. 
Figure 4.8c shows the concentration-dependent UV absorption of the ellipticine in EPC 
vesicles used for generating the calibration curve. It can be seen that the ellipticine absorbance at 295 
nm increases initially and reaches a plateau when the ellipticine concentration is greater than 20 μM. 
This trend correlates well with that of the calibration curve. A plateau observed in Figure 4.8c 
indicates that ellipticine is saturated in the vesicles (formed at this particular lipid concentration of 7.1 
× 10-4 M). This confirms that the inner-filter effect is not the cause of the slight decrease in the 
calibration curve at ellipticine concentrations above 20 μM. In addition, the molar ratio of ellipticine 
to the EPC lipid can be roughly estimated to be 0.028. Such a small number reflects the fact that such 
liposomes may not be an effective carrier for ellipticine when loading capacity is concerned. 
However, the exact reason for the slight decrease in the ellipticine fluorescence at high ellipticine 
concentrations (> 20 μM) in Figure 4.8b is still under study. 
The rising region in the calibration curve can be used to convert the fluorescence signals from 
the transfer profile to the ellipticine concentration in vesicles. This can be done by using a simple 
exponential equation to fit the rising region in Figure 4.8b (1-20 μM): 
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( )][1 EPTBeAI −=         (4.1) 
The fitting parameters A and B are 17.5 ± 0.36 and 230000 ± 13400 (1/M), respectively. [EPT] 
represents the concentration of ellipticine within the range of 0-20 μM. For a given fluorescence 
intensity of ellipticine (I/Is < 17.5), one can obtain the corresponding ellipticine concentration using 
Equation 4.1. 
Figure 4.9 shows four transfer profiles of ellipticine concentration in the vesicles ([EPTv]) with 
time (h). Each curve corresponds to the transfer of ellipticine into the vesicles from different peptide-
ellipticine complexes made with various EAK16-II concentrations. All profiles have a similar trend 
with a fast increase initially and gradually approaching a plateau. The very high initial values of the 
transfer profile from the complexes with 0.5 mg/mL EAK16-II indicate a burst release of ellipticine 
from the complex into the vesicles within 30 s. This is reasonable since the 0.5 mg/mL EAK16-II 
solution can stabilize protonated ellipticine (Figures 4.5 and 4.7b). These protonated ellipticine 
molecules may easily migrate into the lipid bilayers, causing a sudden increase in the ellipticine 
concentration in the vesicles. On the other hand, other peptide concentrations (0.05-0.2 mg/mL) 
stabilize ellipticine microcrystals rather than protonated ellipticine. The migration of ellipticine 
molecules from the microcrystals to the vesicles involves the molecularly dissolving of ellipticine, 
which is time consuming. Therefore, their transfer profiles do not have a large sudden increase at the 






















Figure 4.9 The transfer profiles of ellipticine from different peptide-ellipticine complexes to the EPC 
vesicles. The complexes were made of 0.1 mg/mL (0.4 mM) ellipticine with various EAK16-II 
concentrations: 0.05 (triangles, 0.03 mM), 0.1 (crosses, 0.06 mM), 0.2 (squares, 0.12 mM) and 0.5 
mg/mL (circles, 0.3 mM). The solid lines represent the fitting curves to the data points using either 
Equation 4.2 or Equation 4.3. The excitation and emission wavelengths are 295 and 436 nm, 
respectively. 
 
To better compare the transfer kinetics for the four different EAK16-II concentrations, the 
profiles were fitted to one of the following exponential equations. The second equation was used if 
the first could not satisfactorily describe the dynamics:51 
( ) ( ) ktveqveqvv eEPTEPTEPTtEPT −−−= 0][][][][     (4.2) 
( ) ( )tktkeqvv eaeaEPTtEPT 21 211][][ −− −−=      (4.3) 
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where [EPTv](t), [EPTv]eq and [EPTv]0 are the ellipticine concentration in the vesicles at time t, at 
equilibrium and at time zero, respectively; k, k1 and k2 are the rate constants; a1 and a2 are the pre-
exponential factors and a1 + a2 = 1. The particular transfer profile with 0.5 mg/mL EAK16-II was 
fitted with Equation 4.2 where [EPTv]0 ≠ 0 due to an initial burst transfer of ellipticine into the 
vesicles; the other three profiles were fitted well with Equation 3 as the initial transfer in these cases 
was very small and can be negligible. The rate constants are summarized in Table 4.2. Comparing the 
average rate constants for each transfer profile, it can be seen that the rate of transfer of ellipticine 
from the complexes into the vesicles increases with the peptide concentration during the preparation 
of peptide-ellipticine complexes. 
 
Table 4.2 Transfer rates of ellipticine from peptide-ellipticine complexes to EPC liposomes 
 [EAK] 0.5 mg/mL* 0.2 mg/mL 0.1 mg/mL 0.05 mg/mL 
k1 (1/h) 
a1 
3.13 ± 0.14 5.20 ± 0.04 
0.363 ± 0.002 
3.52 ± 0.03 
0.345 ± 0.002 
2.53 ± 0.02 
0.348 ± 0.003 
k2 (1/h) 
a2 
n/a 0.75 ± 0.002 
0.637 ± 0.002 
0.62 ± 0.002 
0.655 ± 0.003 
0.30 ± 0.003 
0.652 ± 0.002 
kavg 3.13 ± 0.14 2.36 ± 0.02 1.62 ± 0.01 1.08 ± 0.01 
R2 0.976 0.999 0.999 0.999 
*Denotes the fitting with Equation 4.2; all others with Equation 4.3. All the fitting parameters are 
significantly different from the statistical analysis. 
kavg = a1k1 + a2k2; a1 + a2 = 1 
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This trend is opposite to that of our previous studies on the pyrene release from the EAK16-II 
coatings into the EPC vesicles.51 The higher EAK16-II concentration used to form peptide-pyrene 
complexes results in a thicker coating on the pyrene microcrystals, which in turn causes a slower 
release rate. In the present case of ellipticine, the higher peptide concentration induces the protonation 
of ellipticine and formation of smaller complexes as visualized by the SEM images in Figure 4.10. 
The size of the complexes with 0.5 mg/mL EAK16-II (Figure 4.10a) is much smaller than that with 
0.2 mg/mL EAK16-II (Figure 4.10b). Further decrease in the peptide concentration (0.05 mg/mL) 
will result in a bigger size of the complexes as shown in Figure 4.10c. Since the ellipticine in the 
vesicles is molecularly solubilized, the transfer process must involve the release of individual 
ellipticine molecules from the complexes; the bigger the complexes are, the longer the release of 
ellipticine from the complexes will be. Therefore, a slower transfer rate of ellipticine was observed at 
low peptide concentrations. 
This study demonstrates that a self-assembling, ionic-complementary peptide, EAK16-II, can 
stabilize the hydrophobic anticancer agent ellipticine in aqueous solution. Different combinations of 
peptide and ellipticine concentrations can stabilize either protonated ellipticine or ellipticine 
microcrystals for an extended time. The ellipticine can be released from the complexes into a cell 
membrane mimic. The release rate is related to the peptide concentration used in the complexation. 
By optimizing the process of complex formation, one could obtain desired complex dimensions and 








Figure 4.10 SEM images of the peptide-ellipticine complexes with 0.1 mg/mL (0.4 mM) ellipticine 
and different EAK16-II concentrations: (a) 0.5 mg/mL (0.3 mM), (b) 0.2 mg/mL (0.12 mM) and (c) 
0.05 mg/mL (0.03 mM). 
 
The results obtained here will be important in the next phase studies on the peptide-based 
delivery of ellipticine in vitro and in vivo. First, the size of the peptide-ellipticine complexes can be 
manipulated from micrometers to hundreds of nanometers. The particle size will significantly affect 
the circulation in the blood stream, the binding to the cells and the uptake by the cells.233-236 Second, 
the different states of stabilized ellipticine in solution can be obtained depending on the peptide and 
ellipticine concentrations in the formulation. This will have a varying impact on the anticancer 





tuned, in relation to the size of the complex and the state of stabilized ellipticine. The cellular toxicity 
and uptake as well as in vivo animal studies are currently under investigation. 
4.4 Conclusions 
The ionic-complementary self-assembling peptide EAK16-II was found to be able to stabilize the 
hydrophobic anticancer agent ellipticine in aqueous solution. Both microcrystal and protonated forms 
of ellipticine can be obtained. The formation of peptide-ellipticine suspensions in water is peptide 
concentration-dependent. The equilibration time can be as short as 5 h when the peptide concentration 
is close to its critical aggregation concentration (~0.1 mg/mL). At higher and lower peptide 
concentrations, the time required to reach equilibrium is much longer. High peptide concentrations (> 
0.1 mg/mL) facilitate the formation of protonated ellipticine during the complexation. With a 
combination of 0.1 mg/mL ellipticine and 0.5 mg/mL EAK16-II, protonated ellipticine can be 
stabilized at equilibrium. The transfer rate of ellipticine from its peptide complexes into EPC vesicles 
is highly dependent on the peptide concentration used in the formulation. A higher peptide 
concentration results in a faster release rate. This relates to the fact that a higher peptide concentration 
favors the protonation of ellipticine and the formation of smaller complexes. In addition, the peptide-
ellipticine complex size can be tuned with the concentration ratio in the formulation. This study 
demonstrates an excellent potential of ionic-complementary, self-assembling peptides as carriers for 





Chapter 5*                                                                   
Cellular Toxicity and Uptake of EAK16-II-Ellipticine Complexes 
5.1 Introduction 
The self-assembling peptide EAK16-II has recently shown its potential for the delivery of 
hydrophobic compounds.51,56 Further studies have demonstrated that EAK16-II can stabilize a 
hydrophobic anticancer agent, ellipticine, in either protonated or crystalline form (Chapter 4). The 
release kinetics of ellipticine can be tuned by adjusting the peptide-to-ellipticine ratio during 
formulation. It will be critical to further evaluate the therapeutic effect of the formulated peptide-drug 
complexes in vitro in order to develop self-assembling peptide-based delivery of hydrophobic 
anticancer drugs. 
Here we investigate the cellular toxicity and uptake of the EAK16-II-ellipticine complexes. 
Two cancer cell lines, the non-small cell lung cancer cell A549 and breast cancer cell MCF-7, were 
used in this study. The complexes were first prepared at five different peptide-to-ellipticine ratios, 
where either protonated or crystalline ellipticine was stabilized. Their toxicity to both cell lines was 
then tested in relation to the cell viability obtained from the MTT assay. The complex stability upon 
dilution was also studied since such information is essential for future preclinical tests. To better 
understand the therapeutic effect of the two molecular states of ellipticine in complexes, cellular 
uptake experiments were performed by a fluorescence imaging technique based on the well-
characterized ellipticine fluorescence properties (Chapter 3). The measurements were conducted in 
different time periods and at different temperatures in order to characterize the internalization 
pathway. This research will provide important information on drug formulation and design of peptide 
nanocarriers. 
*The cellular uptake experiments of this chapter were done and contributed by our collaborators at the University of 
Toronto, P. Tang, R. Bawa, B. Han and M. Liu. 
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5.2 Materials and Methods 
5.2.1 Materials 
The self-assembling ionic-complementary peptide EAK16-II (Mw = 1657 g/mol, crude) was obtained 
from CanPeptide Inc. (Pointe-Claire, Quebec, Canada) and used without further purification. It has an 
amino acid sequence: n-AEAEAKAKAEAEAKAK-c, where A corresponds to alanine, E to glutamic 
acid and K to lysine. The N-terminus and C-terminus of the peptide were protected by acetyl and 
amino groups, respectively. At pH~7, A is neutral, while E and K are negatively and positively 
charged, respectively. The anticancer agent ellipticine (99.8% pure) was purchased from Sigma-
Aldrich (Oakville, ON, Canada) and used as received. Paraformaldehyde (PFA, reagent grade) was 
obtained from Sigma-Aldrich (Oakville, ON, Canada). Cell culture reagents including Dulbecco’s 
modified eagle medium (DMEM), fetal bovine serum (FBS) and trypsin-ETDA were purchased from 
Invitrogen Canada Inc. (Burlington, ON, Canada). Phosphate buffer saline (PBS) and penicillin-
streptomycin (p/s, 10000 U) were obtained from MP Biomedicals Inc. (Solon, OH, USA). 
5.2.2 Sample Preparation 
Fresh EAK16-II solutions were prepared in pure water (18 MΩ; Millipore Milli-Q system) at 
concentrations of 0.02, 0.1, 0.2, 0.5 and 1.0 mg/ml. The solution was then sonicated in a bath 
sonicator (Branson, model 2510) for 10 min to ensure complete dissolution of the peptide powders. 
Appropriate amounts of the fresh peptide solutions at each concentration were added into a glass vial 
containing ellipticine crystals to yield an ellipticine concentration of 0.1 mg/mL, generating five 
peptide-to-ellipticine ratios of 10:1, 5:1, 2:1, 1:1 and 1:5 (by mass). The EAK16-II-ellipticine 
mixtures were under mechanical stirring at 900 rpm for 24 h to allow the complex formation. An 
ellipticine control in pure water (with the absence of EAK16-II) at the same ellipticine concentration 
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was prepared for comparison, following the same procedure. The complexes at a 5:1 ratio were 
diluted serially (2x, 4x, 8x and 16x) in pure water to study the complex stability. All vials and 
solvents were sterilized and the samples were prepared in a biological safety cabinet to avoid possible 
contamination. The complexes were photographed with a digital camera (Cannon PowerShot A95); 
the appearance of the peptide-ellipticine suspensions could reveal certain information on the 
molecular states of ellipticine in the complexes. 
5.2.3 Cellular Toxicity Tests 
Two cancer cell lines, non-small cell lung cancer cell A549 and breast cancer cell MCF-7 (courtesy 
from Dr. Mingyao Liu at the University of Toronto), were used for in vitro cellular toxicity studies on 
the EAK16-II-ellipticine complexes. The cells were cultured in DMEM containing 10% FBS and 1% 
p/s at 37°C and with 5% CO2. When the cells grew to reach ~95% confluence, they were detached 
from the cell culture dishes with trypsin-EDTA, centrifuged at 500 rpm for 5 minutes, and 
resuspended in fresh cell culture media at concentrations of 5 × 104 and 1 × 105 cells/mL for A549 
and MCF-7 cells, respectively. For each type of cell, 200 μL of the cell suspensions were added into 
each well of a clear, flat bottom 96-well plate (Costar) and incubated for ~24 h. The old media were 
taken out and replaced with 150 μL fresh culture media, followed by an addition of 50 μL treatments 
(including the complexes and control samples) into each well, resulting in a 4-fold dilution of the 
treatments. The plates were incubated for 4, 8, 12, 24 and 48 h prior to performing the cell viability 
assay. The experimental setup contained several control groups for each plate, including negative 
control (medium), solvent control, peptide control and drug control.  
MTT assay (TOX1 from Sigma-Aldrich, Oakville, ON, Canada) was used to determine the cell 
viability after different treatments. 5 mg of solid MTT was first dissolved in 3 mL PBS solution, 
followed by a 10-time dilution in the culture medium. All the treatments were taken out, and 100 μL 
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of the MTT solution was then added to each well of the treated plates. The plates were incubated for 4 
h prior to the addition of 100 μL solubilization solution (anhydrous isopropanol with 0.1 N HCl and 
10% Triton X-100). After overnight incubation, the absorbance at 570 nm was collected on a 
microplate reader (BMG FLUOstar OPTIMA) and subtracted by the background signals at 690 nm. 
The absorption intensities were averaged from 4 replicates for each treatment and normalized to that 
obtained from the untreated cells (negative control) to generate the cell viability (i.e., the cell viability 
of the negative control is 1). 
5.2.4 Cellular Uptake Studies 
Two cancer cell lines, A549 and MCF-7 (from ATCC), were used to investigate the uptake of 
EAK16-II-ellipitcine complexes in vitro. They were cultured in DMEM with 10% FBS at 37 °C with 
5% CO2. The cells were then seeded on a 12-well plate with cell densities of 5 × 104 and 1 × 105 
cells/well for A549 and MCF-7, respectively, followed by 48 h incubation prior to the treatments. The 
prolonged incubation time was to enhance the cell adhesion and avoid significant cell loss under 
intensive rinsing during the subsequent cell fixing procedure. The treatments were added into each 
well and incubated for 5, 15 and 30 min. Four treatments were tested: the complexes at two peptide-
to-ellipticine ratios, 5:1 (125 μg/mL:25 μg/mL) and 1:1 (25 μg/mL:25 μg/mL), the ellipticine control 
(25 μg/mL), and the peptide control (125 μg/mL). The treated cells were washed with PBS 3 times, 
and fixed with 4% PFA in PBS, followed by another 3 times washing with PBS. The cells were 
examined with a fluorescence microscope (Nikon Eclipse 80i); a green fluorescence filter was used to 
collect the fluorescence signals of ellipticine, and phase contrast images were acquired to observe the 
cell morphology. 
The temperature-dependent cellular uptake of ellipticine was conducted at 37 °C and 4 °C to 
examine whether the internalization of ellipticine occurs through an endocytosis pathway.239,240 The 
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same cell density (as above) was used for cell seeding with 48 h incubation. Prior to treating the cells, 
the plates were incubated at 37 °C or 4 °C for 30 min, allowing the culture media to reach the 
equilibrium temperature. The same treatments (two complexes, ellipticine control and peptide 
control) were applied with an incubation time of 30 min. The cells were then fixed following the 
same procedure as before, and examined with the fluorescence microscope. 
5.3 Results and Discussion 
The previous studies (Chapter 4) have shown that EAK16-II can stabilize ellipticine in protonated or 
crystalline form in aqueous solution, depending on the peptide and ellipticine concentrations. 
Protonated ellipticine can be stabilized in the complexes formulated with a combination of 0.5 mg/mL 
EAK16-II and 0.1 mg/mL ellipticine. When the ratio of peptide-to-ellipticine is smaller than 5:1 (by 
mass), the stabilized ellipticine is predominantly in crystalline form in the complexes. This may 
indicate that 5:1 ratio is important in determining the molecular states of ellipticine in the complexes. 
Here we report a series of peptide-to-ellipticine ratios (at a fixed ellipticine concentration of 0.1 
mg/mL) on their complex formation and in vitro therapeutic effect against two cancer cell lines, A549 
and MCF-7. Figure 5.1 shows the photographs of the EAK16-II-ellipticine complexes at different 
peptide-to-ellipticine ratios. It is clearly seen that the solutions turn yellow and transparent at ratios of 
5:1 and 10:1, indicating the formation of protonated ellipticine in the complexes. At ratios below 5:1, 
the solutions appear to be turbid as the stabilized ellipticine is predominantly in crystalline form. 
However, the ellipticine control sample remains transparent with chunks of ellipticine crystals 
floating on top or at the bottom of the vial (far right), owing to its extreme hydrophobicity with a very 
low solubility in water (~0.6 μM).71 These results confirm our previous observations (Chapter 4, 
Figure 4.7a) and provide evidence that whether protonated or crystalline ellipticine can be stabilized 




 10:1 5:1 2:1 1:1 1:5 EPT-H2O  
Figure 5.1 Photographs of EAK16-II-ellipticine complexes at different peptide-to-ellipticine ratios 
(by mass). The ellipticine concentration is fixed at 0.1 mg/mL. An ellipticine control in pure water 
(EPT-H2O) is also tested for comparison. 
 
5.3.1 Cellular Toxicity of EAK16-II-Ellipticine Complexes 
The toxicity of the complexes at different peptide-to-ellipticine ratios against both A549 and MCF-7 
cells is shown in Figure 5.2a. The complexes at the ratios of 5:1 and 10:1 are effective at killing both 
cancer cells, leading to low cell viability (less than 0.25). Below the 5:1 ratio, the anticancer activity 
of the complexes decreases significantly, and is similar to the ellipticine control. The dramatic change 
in the complex toxicity is probably related to the molecular state of ellipticine in the complexes. The 
protonated ellipticine appears to be more effective at killing cancer cells than crystalline ellipticine. 
This may be due to fast release kinetics of protonated ellipticine from the complexes (Chapter 4, 
Figure 4.9). In addition, protonated ellipticine tends to interact with negatively charged cell 
membranes, and accumulate at the membrane surface; the hydrophobic moiety of ellipticine further 
helps it cross the cell membrane. This also implies that the internalization of ellipticine may not be 








































Figure 5.2 Viability of MCF-7 and A549 cells treated with the complexes at different peptide-to-
ellipticine ratios (a) and upon serial dilution (b). The complex at 5:1 ratio was used for the serial 
dilution. The complexes were prepared with a fixed ellipticine concentration of 0.1 mg/mL (0.4 mM) 




Note that the protonated ellipticine seems to be more active at killing MCF-7 cells than A549 
cells, causing an almost zero MCF-7 cell viability. Such an effect may be due to the fact that MCF-7 
cells are more sensitive to protonated ellipticine. Thus, these results may lead to a notion of selecting 
appropriate formulations to treat different cancer cells. By adjusting the mass ratio of EAK16-II 
versus ellipticine, one can obtain different molecular states of ellipticine in the complexes as well as 
the complex dimensions (Chapter 4, Figure 4.10), for specific cancer cells. 
The stability of a given formulation upon dilution is an important factor in determining its 
applicability in clinical usage.241 Since the complexes at 5:1 ratio show a good anticancer activity 
against both cancer cell lines, we further carry out serial dilution of such complexes in pure water and 
test their stability in relation to the cellular toxicity. Figure 5.2b shows the toxicity of the complex at 
5:1 ratio and its serial dilution in water (2, 4, 8 and 16 times). The 2 times dilution does not affect the 
toxicity of the complex significantly for both cells. Further dilution greatly reduces the complex 
toxicity against MCF-7 cells; it also decreases the toxicity against A549 cells, but to a lesser degree. 
Normally, the decrease in cell viability should be gradual and smooth due to the decrease in drug 
concentration upon dilution. However, the observed trend is not gradual, but rather has a dramatic 
change at a more than 2x dilution. This may be related to the instability of the complexes upon 
dilution in water. One possible reason is that the complex containing protonated ellipticine is pH 
sensitive; extensive dilution is expected to increase the solution pH, leading to the deprotonation of 
ellipticine to form ellipticine microcrystals. As a result, the toxicity of the diluted complexes reduces, 
similar to that of the complexes at a lower peptide-to-ellipticine ratio. A drastic decrease in complex 
toxicity upon dilution for MCF-7 cells provides additional evidence that MCF-7 cells are more 
sensitive to protonated ellipticine. 
In order to find a proper time-window for cellular uptake, time-dependent toxicity tests are 
conducted. In principle, a proper time-window should allow drug to enter the cells but not cause cell 
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death. The time-dependent toxicity of the complexes is shown in Figure 5.3. Two ratios, 1:1 (squares) 
and 5:1 (circles), are used to examine the difference in toxicity of crystalline and protonated 
ellipticine, respectively. They are compared with the ellipticine control (crosses) in the absence of 
EAK16-II. It can be seen that the two different cell lines exhibit different patterns in the time-
dependent viability in response to the treatments. For MCF-7 cells (Figure 5.3a), the complexes at the 
5:1 ratio are so effective that the cell viability decreases to less than 0.5 after 4 h treatment; it 
decreases further to almost zero after 24 h treatment. Meanwhile, the complexes at the 1:1 ratio and 
ellipticine control have almost no effect at 4 h, before gradually decreasing the viability to about 0.5 
by 48 h. On the other hand, no distinguishable difference in cell viability can be observed among the 
three treatments at 4 h for A549 cells (Figure 5.3b); with time, all treatments cause significant cell 
death, although the effect is more pronounced for the complexes at 5:1 ratio. Almost zero viability is 

































Figure 5.3 Time-dependent toxicity of the EAK16-II-ellipticine complexes against MCF-7 (a) and 




The above results indicate that the appropriate time-window for cellular uptake should be 
within 4 h. In addition, MCF-7 cells are very sensitive to protonated ellipticine while both protonated 
and crystalline ellipticine are effective at killing A549 cells (Figure 5.2). However, the reason behind 
this is still unclear. One may speculate that such a phenomenon probably results from the differences 
in uptake of the complexes by A549 and MCF-7. To clarify this, fluorescence imaging technique is 
applied to characterize the internalization of ellipticine by the two cell lines. 
5.3.2 Cellular Uptake of Ellipticine in A549 and MCF-7 Cells 
The uptake of ellipticine by the two cell lines is shown in Figure 5.4. The cells are treated with 
complexes at two ratios of 5:1 and 1:1, the ellipticine control and the peptide control for 5, 15 and 30 
min. For A549 cells (Figure 5.4a), the treatment with peptide alone does not exhibit any fluorescence 
(1st column, insets), which is reasonable since there is no ellipticine in the system and EAK16-II is 
not fluorescent. When the cells are treated with ellipticine control, the fluorescence signals are too 
dim to be seen initially, but increase with time. A stronger fluorescence signal can be observed for the 
treatments of complexes at 5 min and become more pronounced at later times. After 30 min treatment 
of the complexes at the 5:1 ratio, the ellipticine fluorescence seems to accumulate in the cell nuclei. 
Similar phenomena are observed for MCF-7 cells (Figure 5.4b).  
These results show that the uptake of ellipticine is fast. This is likely because ellipticine is a 
small hydrophobic molecule, and can easily cross the cell membrane barrier once reaching its outer 
surface. However, the presence of peptides appears to enhance the rate of uptake. One reason is that 
peptides can stabilize large amounts of protonated or crystalline ellipticine in aqueous solution. The 
high concentration of ellipticine in solution facilitates its diffusion into the cells. In addition, 
protonated ellipticine seems to have a much stronger tendency to be taken up by both cell lines, 
especially MCF-7 cells. This may due to a stronger interaction between positively charged ellipticine 
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and negatively charged cell membranes. Besides, protonated ellipticine is released much faster from 
the complexes than crystalline ellipticine (Chapter 4, Figure 4.9). It is worth noting that the subtle 
difference in ellipticine uptake from the complexes at two different ratios cannot explain the much 
higher toxicity of the complexes at the 5:1 ratio over the other as shown in Figure 5.2a. Other factors 
may determine the toxicity of protonated and crystalline ellipticine. The toxicity difference may be 
related to variations in the amount of ellipticine uptaken at the two ratios, although it is not directly 







Figure 5.4 Fluorescence images showing cellular uptake of ellipticine in A549 (a) and MCF-7 (b) 
cells. Green color is from ellipticine fluorescence. The first column shows the phase contrast images 
with corresponding fluorescence images as the insets. * denotes half exposure time. 
 
To confirm whether the internalization of ellipticine is through direct permeation across the cell 
membranes, the uptake of ellipticine is conducted at two different temperatures, 37 °C and 4 °C. Most 
cellular uptake through the endocytosis pathway is energy dependent, which can be blocked at a 
temperature as low as 4 °C.224,225,242 As shown in Figure 5.5, the uptake of ellipticine in both cancer 
cells can be observed after 30 min treatments with the complexes as well as the ellipticine control. 
Evidently, there are no significant differences in ellipticine uptake between 37 °C and 4 °C, although 
the ellipticine fluorescence is weak at 4 °C for the treatment of ellipticine control. The temperature-
independent uptake of ellipticine indicates that the passive diffusion of ellipticine into the cells is 




Figure 5.5 Fluorescence images showing cellular uptake of ellipticine at 37 °C and 4 °C in A549 and 
MCF-7 cells with different treatments. Green color represents ellipticine fluorescence. First column 
shows phase contrast images, and the insets are the corresponding fluorescence images. 
 
From these results, the complexation of ellipticine with EAK16-II seems not to alter the 
internalization pathway of ellipticine; however, it enhances the rate of cellular uptake by increasing 
the amount of ellipticine suspended in solution. Note that such a fast and unspecific cellular uptake 
may not be ideal for anticancer drug delivery as it would cause harmful side effects to healthy tissue 
during delivery. To overcome this problem, one could increase the interaction between ellipticine and 
peptides to slow the release process. For example, one could increase the hydrophobicity of the 
peptide through sequence design, which may increase the interaction between the hydrophobic 
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ellipticine and peptides. On the other hand, unspecific uptake may be solved by introducing cell 
targeting moieties onto the peptide sequence to achieve active targeting. An example is the cyclic 
peptide motif c-NGRGEQ-c, which has been found to strongly bind to several non-small cell lung 
cancer cell lines including A549, Calu-1 and H178.112 A vasoactive intestinal peptide (VIP) can 
selectively bind to many breast cancer cell lines such as MCF-7.171,193 Thus, a proper design of 
peptide sequence becomes very important in the development of self-assembling peptide-mediated 
delivery for hydrophobic anticancer drugs. 
5.4 Conclusions 
From this study, it can be concluded that EAK16-II is capable of stabilizing protonated or crystalline 
ellipticine in aqueous solution depending on the peptide-to-ellipticine ratio during the formulation. 
Above the ratio of 5:1 (by weight), the stabilized ellipticine is protonated; below this ratio ellipticine 
is in crystalline form in the complexes. The two molecular states of stabilized ellipticine in the 
complexes exhibit different toxicity against two cancer cell lines, A549 and MCF-7, with the 
protonated being more toxic. Such an effect is more pronounced for MCF-7 cells than for A549 cells. 
This is probably due to the fact that MCF-7 cells are more sensitive to protonated ellipticine. The 
complexes with protonated ellipticine are not stable upon dilution in water. The uptake of ellipticine 
in both cell lines appears to follow a diffusion mechanism. It is found that ellipticine can still be taken 
up by both cancer cells at 4 °C, where the energy-dependent endocytosis pathway is blocked. The 
complexation of ellipticine with EAK16-II seems not to alter the internalization pathway of 
ellipticine. However, it significantly enhances the uptake over a shorter time period (~5 min). These 
results demonstrate that the EAK16-II-ellipticine complexes with protonated ellipticine are effective 
at killing cancer cells in vitro; the existence of some unfavorable properties of the complexes, such as 
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unspecific cellular uptake, suggests that appropriate design of the peptide sequence is essential for 

















Chapter 6*                                                                    
Sequence Effect of Self-Assembling Peptides on the Complexation 
and In Vitro Delivery of the Hydrophobic Anticancer Drug Ellipticine 
6.1 Introduction 
Self-assembling peptides are emerging nano-biomaterials with promising biomedical and 
bioengineering applications.59,116,243 Among them is a special class of ionic-complementary peptides 
discovered from a yeast Z-DNA binding protein.61 These peptides have a unique amphiphilic 
structure resulting from an alternative arrangement of hydrophobic and hydrophilic amino acids in 
sequence. They also consist of alternating positive and negative charges under physiological 
conditions, resulting in ionic complementarity. These peptides are capable of self-assembling into 
very stable nanostructures or macroscopic membranes, which can withstand high temperature, 
extreme pH, many digesting enzymes and denaturation agents.61,62 Moreover, they exhibit good 
biocompatibility with many cultured mammalian cells64 and do not have detectable immune responses 
when introduced into animals61,63,244 These properties make them ideal materials for tissue 
scaffolding,134,135,245 regenerative medicine63,126,244 and drug delivery.51,57,58,154 
 The ionic-complementary self-assembling peptides have recently been used as novel nano-
biomaterials in the local delivery of hydrophilic peptide/protein drugs57,58 and the formulation of 
hydrophobic chemotherapeutics.56 The biotinylated, self-assembling peptide RADA16-II was found 
to be able to locally deliver insulin-like growth factor 1 (IGF-1) to the myocardium, and provide 
sustained release of IGF-1 for 28 days.58 These peptide nanofibers can also bind with a human platelet 
derived growth factor (PDGF-BB) and deliver it in vivo with sustained release to successfully 
decrease cardiomyocyte death and preserve systolic function.57 In addition to the delivery of 
peptide/protein drugs, it has recently been demonstrated that a self-assembling peptide, EAK16-II, 
*This chapter is based on a paper draft “S.Y. Fung, H. Yang and P. Chen, Sequence effect of self-assembling peptides on 
the complexation and in vitro delivery of the hydrophobic anticancer agent ellipticine, accepted by PLoS ONE,  2008”. 
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can stabilize hydrophobic compounds in aqueous solution and release them into a cell membrane 
mimic in a controlled manner.51,56 Further studies revealed that such a peptide can stabilize the 
hydrophobic anticancer agent ellipticine with different molecular states in aqueous solution 
depending on the peptide and ellipticine concentration, which in turn affects the ellipticine release 
from the complexes (Chapter 4). These studies have shown great potential for the use of the self-
assembling peptides in drug delivery. 
 However, current studies of using self-assembling peptides for drug delivery are still at their 
early stage. The development of a self-assembling peptide-based delivery system requires better 
design of peptide sequences for specific delivery goals. Previous studies have shown that a difference 
in the charge distribution of the self-assembling peptides significantly alters the nanostructure of the 
peptide assemblies.45,46 In addition, the charge distribution affects the peptide assemblies in response 
to solution pH.45 The variations in peptide length, hydrophobicity and ionic complementarity have 
been applied to control the formation of self-assembling peptide matrices.128 The resulting structure of 
peptide assemblies will impact the design of delivery vehicles for different therapeutics. For example, 
delivery of protein or siRNA drugs requires cell penetration while cell recognition is critical to 
achieve targeted delivery of anticancer therapeutics.15,225,226 Therefore, proper design of peptide 
sequences becomes crucial to build functional peptide-based carriers for effective drug delivery. 
In this work, we carry out the study of peptide sequence effects on the drug formulation and in 
vitro delivery. Three self-assembling peptides, EAK16-II, EAK16-IV and EFK16-II, are chosen to 
investigate the effects of charge distribution (type II vs. type IV) and hydrophobicity (alanine A vs. 
phenylalanine F). A hydrophobic anticancer agent, ellipticine, is selected as a model drug, following 
our early studies. The self-assembled nanostructures of these peptides are first characterized by 
atomic force microscopy (AFM); the hydrophobicity of the peptides dissolved in aqueous solution is 
studied via surface tension measurements, and fluorescence spectroscopy using a hydrophobic 
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fluorescent probe. These characteristics of the three peptides are expected to impact their 
complexation with ellipticine, in terms of ellipticine molecular states and the size of the resulting 
complexes. The anticancer activity of the formulation is tested in vitro against two cancer cell lines: 
non-small cell lung cancer cell A549 and breast cancer cell MCF-7. The stability of the complexes 
after serial dilutions in aqueous solution is further investigated. The information obtained in this study 
is aimed at providing appropriate design principles for selecting peptide sequences and fabricating 
advanced functional peptide carriers for anticancer drug delivery. 
6.2 Materials and Methods 
6.2.1 Materials 
Three self-assembling, ionic-complementary peptides EAK16-II (Mw = 1657 g/mol, crude), EAK16-
IV (Mw = 1657 g/mol, crude) and EFK16-II (Mw = 2265 g/mol, crude) were obtained from 
CanPeptide Inc. (Pointe-Claire, Quebec, Canada) and used without further purification. Their 
sequences and molecular structures are shown in Figure 6.1, where A corresponds to alanine, F to 
phenylalanine, E to glutamic acid and K to lysine. The N-terminus and C-terminus of the peptide 
were protected by acetyl and amino groups, respectively. At pH~7, A and F are neutral, while E and 
K are negatively and positively charged, respectively. The anticancer agent ellipticine (99.8% pure) 
and 1-anilinonaphthalene-8-sulfonic acid (ANS) were purchased from Sigma-Aldrich (Oakville, ON, 
Canada) and used as received. Tetrahydrofuran (THF, reagent grade 99%) and dimethyl sulfoxide 
(DMSO, spectral grade 99+%) were acquired from Caledon Laboratories Ltd. (Georgetown, ON, 
Canada) and Sigma-Aldrich (Oakville, ON, Canada), respectively. Cell culture reagents including 
Dulbecco’s modified eagle medium (DMEM), fetal bovine serum (FBS) and trypsin-ETDA were 
purchased from Invitrogen Canada Inc. (Burlington, ON, Canada). Phosphate buffer saline (PBS) and 































































































































































Figure 6.1 Molecular structures and sequences of EAK16-II, EAK16-IV and EFK16-II. N and C 
termini are protected by acetylation and amidation, respectively. 
 
6.2.2 Sample Preparation 
Appropriate amounts of the peptide powder were first dissolved in pure water (18 MΩ; Millipore 
Milli-Q system) to obtain fresh peptide solutions at concentrations of 0.5, 0.2 and 0.04 mg/ml. The 
solution was then sonicated in a bath sonicator (Branson, model 2510) for 10 min. The peptide 
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solution at a concentration of 0.5 mg/mL was used to study the differences among the three peptides 
in terms of their self-assembled nanostructures, hydrophobicity and surface activity. 
The peptide-ellipticine complexes were prepared by adding 1 mL of the fresh peptide solution 
into a glass vial containing a thin film of 0.04 mg ellipticine at the bottom, followed by mechanical 
stirring at 900 rpm for 24 h. 1 mL of pure water, instead of peptide solution, was also added to 
another vial to make a control sample. The purpose of using a relatively low ellipticine concentration 
of 0.04 mg/mL in this study was to obtain more distinguishable cellular toxicity levels in the 
complexes and the control sample. To make a thin film of ellipticine at the bottom of the vials, 100 
μL of 0.4 mg/mL ellipticine stock solution in THF was transferred to the vials, and dried by gently 
blowing filtered air (0.22 μm pore size filter) for ~5 min. All the vials and solvents were sterilized 
and the samples were prepared in a biological safety cabinet to avoid possible contamination, for 
especially cell culture experiments. For dynamic light scattering (DLS) measurements, the solvents 
were filtered, and the samples were made in the biosafety cabinet to eliminate potential dust 
contamination. The complexes were photographed with a digital camera (Cannon PowerShot A95) 
and characterized using several techniques to obtain complex dimensions and molecular states of the 
ellipticine in the complexes. 
6.2.3 Determining the Maximum Suspension Concentration of Ellipticine 
The amount of suspended ellipticine in solution was determined by UV-absorption. The peptide-
ellipticine suspension was diluted 20 times in DMSO (resulting in a solvent mixture of 95% DMSO 
and 5% water by volume) to dissolve ellipticine from the complexes. 80 μL of the solution were then 
transferred to a quartz microcell (70 μL) with a 1 cm light path and tested on a UV-Vis 
spectrophotometer (Biochrom Ultraspec 4300 Pro, Cambridge, England). The absorbance at 295 nm 
was converted to the ellipticine concentration using Beer-Lambert’s law: absorbance (Abs) = εcd, 
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where ε is the molar extinction coefficient, c is the molar concentration of ellipticine, and d is the 
optical path length (cm).202 The extinction coefficient was determined to be 59000 ± 1100 (R2 > 
0.995) from the linear fitting of ellipticine absorption as a function of ellipticine concentration (2-20 
μM) prepared in a mixture of 95% DMSO and 5% water. The suspension concentration of ellipticine 
was averaged from 3 measurements, and compared with the given ellipticine concentration of 0.04 
mg/mL. Since not all ellipticine in the thin film at the bottom of the vials could be stabilized and 
suspended in solution, the comparison of the suspension concentration with the given ellipticine 
concentration (0.04 mg/mL) would thus provide the maximum percentage of the ellipticine 
suspension at each formulation condition. 
6.2.4 Atomic Force Microscopy (AFM) 
The self-assembled peptide nanostructures were imaged on a PicoScanTM AFM (Molecular Imaging, 
Phoenix, AZ) in pure water. The samples were prepared with the following procedure: 10 μL of 0.5 
mg/mL peptide solution were put on a freshly cleaved mica substrate, which was fixed on an AFM 
sample plate; a custom made AFM liquid cell was fastened on top of the mica substrate. The solution 
was incubated for 10 s to allow the peptide assemblies to adhere to the mica surface. The surface was 
then washed with pure water 15 times, before adding 500 μL of pure water into the cell prior to AFM 
imaging. A scanner with a maximum scan area of 6 × 6 μm2 was used to acquire the AFM images. It 
was operated with a tapping mode using silicon nitride cantilevers with a nominal spring constant of 
0.58 N/m (DNP-S, Digital Instruments, Santa Barbara, CA) and a typical tip radius of 10 nm. For the 
best imaging quality, the tapping frequency was typically set between 16 kHz and 18 kHz and the 
scan rates controlled between 0.8 and 1 line/s. The experiments were conducted in an 
environmentally-controlled chamber at room temperature to avoid evaporation of the solution. All 
AFM images were obtained at a resolution of 256 × 256 pixels. 
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6.2.5 Surface Tension Measurements 
The dynamic surface tension of fresh peptide solutions was measured over a period of 2 h using the 
Axisymmetric Drop Shape Analysis-Profile (ADSA-P) technique. The experimental setup and 
operation of ADSA-P were described in an earlier publication41 and references therein. 
6.2.6 Fluorescence Spectroscopy 
The hydrophobicity of the three peptides and their assemblies was investigated via ANS 
fluorescence.246,247 10 μM ANS solution was prepared in a 10 mM phosphate buffer at pH 6. The 
fresh peptide solutions were mixed with the same volume of the ANS solution on a vortex mixer for 
10 s. The ANS solution was also mixed with the same volume of pure water as a control sample. 60 
μL of the mixed solution were transferred to a quartz microcell and tested on a spectrofluorometer 
(Photon Technology International, Type QM4-SE, London, Canada) with a continuous xenon lamp as 
the light source. The sample was excited at 360 nm and the emission spectra were collected at 
wavelengths from 420 to 670 nm. The excitation and emission slit widths were set at 0.5 mm and 1.25 
mm, respectively (0.5 and 1.25 mm corresponds to 2 and 5 nm band path). The spectra were 
normalized with the intensity of light scattering of air at 360 nm, to correct for the lamp fluctuations.  
To study the molecular states of ellipticine in the complexes, 60 μL of the peptide-ellipticine 
suspensions were transferred to a microcell and tested on the spectrofluorometer. The excitation 
wavelength was set to be 294 nm and the emission was collected from 320 to 650 nm. The excitation 
and emission slit widths were set at 0.5 mm and 0.25 mm, respectively. The intensities were corrected 
with an ellipticine standard (2 μM in ethanol, sealed and degassed), to account for lamp fluctuations. 
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6.2.7 Dynamic Light Scattering (DLS) 
The dimension of the peptide assemblies (0.5 mg/mL) and the complexes from the peptide-ellipticine 
suspensions was measured with a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, U.K.) 
with appropriate viscosity and refractive index settings. The temperature was maintained at 25 °C 
during the measurement. A quartz microcell (45 μL) with a 3 mm light path was used. The scattered 
light intensities of the samples at the angle of 173° were collected. The intensity-based size 
distribution was obtained with the multimodal algorithm CONTIN,229 provided in the software 
package Dispersion Technology Software 5.0 (Malvern Instruments, Worcestershire, U.K.). Each of 
the intensity-based size distribution reported herein corresponds to the average of three replicate 
measurements. 
6.2.8 Scanning Electron Microscopy (SEM) 
A LEO model 1530 field emission SEM (GmbH, Oberkochen, Germany) was employed to study the 
morphology and dimensions of the peptide-ellipticine complexes. The SEM sample was prepared by 
depositing 10 μL of the peptide-ellipticine suspensions on a freshly cleaved mica surface. The mica 
was affixed on an SEM stub using conductive carbon tape. The sample was placed under a Petridish-
cover for 10 min to allow the complexes to adhere onto the mica surface. It was then washed once 
with a total of 100 μL pure water and air-dried in a dessicator overnight. All samples were coated 
with a 20 nm thick gold layer prior to SEM imaging; the images were acquired using the secondary 
electron (SE2) mode at 5 kV. 
6.2.9 In Vitro Cell Viability Studies 
Two types of cancer cells, non-small cell lung cancer cell A549 and breast cancer cell MCF-7 
(courtesy from Dr. Mingyao Liu at the University of Toronto), were used for in vitro cellular toxicity 
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studies on the peptide-ellipticine complexes. The cells were cultured in DMEM containing 10% FBS 
and 1% p/s at 37°C and with 5% CO2. When cells grew to reach ~95% confluence, they were 
detached from the cell culture flasks with trypsin-EDTA and resuspended in the cell culture media at 
concentrations of 5 × 104 and 1 × 105 cells/mL for A549 and MCF-7 cells, respectively. For each type 
of cell, 200 μL of the cell suspensions were added into each well of a clear, flat bottom 96-well plate 
(Costar) and incubated overnight. 50 μL of the treatments (including the complexes and control 
samples) were then added to the wells each containing 150 μL of fresh culture media. The plates were 
incubated for 48 h prior to perform the cell viability assay.  
MTT assay was used to determine the cell viability after different treatments. 5 mg of solid 
MTT was dissolved in 3 mL PBS solution, followed by 10-fold dilution in the culture medium. All 
the treatments were taken out before 100 μL of the MTT solution was added to each well of the 
treated plates. The plates were incubated for 4 h prior to the addition of 100 μL of the solubilization 
solution (anhydrous isopropanol with 0.1 N HCl and 10% Triton X-100). After overnight incubation, 
the absorbance at 570 nm was recorded on a microplate reader (BMG FLUOstar OPTIMA) and 
subtracted by the background signals at 690 nm. The absorption intensities were averaged from 4 
replicates for each treatment and normalized to that obtained from the untreated cells (negative 
control) to generate the cell viability. 
6.3 Results and Discussion 
The self-assembling peptide EAK16-II has been found to be able to stabilize the hydrophobic 
anticancer agent ellipticine in aqueous solution;56 the ellipticine release kinetics from the complexes 
into a cell membrane mimic has also been determined (Chapter 4). Here, we report how the subtle 
differences in the peptide sequence affect the properties of the peptide assemblies, the formation of 
the peptide-ellipticine complexes, and the cellular toxicity of the complexes. 
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6.3.1 Sequence Effect on the Peptide Assemblies 
Three self-assembling, ionic-complementary peptides, EAK16-II, EAK16-IV and EFK16-II, are used 
in this study. The latter two peptides are derived from the first one EAK16-II. All three peptides have 
16 amino acids in sequence with 3 amino acid components: E, K and A or F, as shown in Figure 6.1. 
EAK16-IV has a different charge distribution of type IV ( ++++−−−− ) from EAK16-II as type II 
( ++−−++−− ), while the difference between EFK16-II and EAK16-II is a more hydrophobic 
residue F replacing A in EAK16-II. The slight differences in sequence among the three peptides may 
significantly affect their assemblies and further complexation with the hydrophobic molecules.  
First, the self-assembled nanostructures formed by these peptides are found to be different. The 
distribution of negative and positive charges towards the two ends of an EAK16-IV molecule at 
neutral pH is reported to cause the folding of the peptide molecule to form a β-turn structure, 
resulting in the formation of globular nanostructures.45,46 EAK16-II, on the other hand, has the 
preference for a stretched molecular structure and likely self-assembles into β-sheet rich nanofibers.46 
The nanostructures of the two peptides are shown in Figure 6.2a and b at a peptide concentration of 
0.5 mg/mL. EAK16-II forms straight nanofibers, connecting to networks (Figure 6.2a), whereas 
EAK16-IV self-assembles into many more globular aggregates and some short nanofibers (Figure 
6.2b). The formation of short nanofibers of EAK16-IV may be due to a relatively low pH (< 5) at 
such a high peptide concentration: when the pH is low enough, some of the negatively charged 
residues can be neutralized so that the intramolecular ionic interaction is weakened. Thus, some 










Figure 6.2 AFM images of the peptide nanostructures: (a) EAK16-II; (b) EAK16-IV; (c) EFK16-II. 
The peptide concentration is 0.5 mg/mL. The scale bar is 200 nm. 
 
The nanostructures of EFK16-II are also different from those of EAK16-II as shown in Figure 
6.2. EFK16-II forms predominant nanofibers and these fibers tend to aggregate into fiber clusters. 
This aggregation of nanofibers is probably due to a stronger hydrophobic interaction between them. 
Such a stronger hydrophobic interaction is expected to come from the more hydrophobic 
phenylalanine (F) residues in the EFK16-II sequence than the alanine (A) residues in EAK16-II. This 
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is probably why the nanofibers of EFK16-II tend to form fiber clusters, but those of EAK16-II are 
dispersed and form fiber networks. 
The hydrophobicity of the three peptides and their assemblies is further characterized by 
surface activity and fluorescence measurements, as shown in Figure 6.3. Figure 6.3a shows the 
surface tension as a function of time for the three peptides at a peptide concentration of 0.5 mg/mL. 
For each profile, the surface tension decreases fast initially before slowly approaching equilibrium. 
This change with time corresponds to the dynamic process of the adsorption of peptide 
molecules/assemblies at the air-liquid interface, leading to the decrease in surface tension.248 
Comparing the surface tensions of the three profiles at 2 h (near equilibrium), they follow a trend: 
EAK16-II > EAK16-IV > EFK16-II. In general, the lower the surface tension is, the more 
hydrophobic is the molecule. Thus, the hydrophobicity of the three peptides and their assemblies 
(coexisting in solution) has a reversed trend: EFK16-II > EAK16-IV > EAK16-II. This is reasonable 
that EFK16-II is the most hydrophobic peptide among the three since it contains phenylalanine 
residues, which are more hydrophobic than alanine residues in EAK16-II and EAK16-IV. The reason 
why EAK16-IV has a lower equilibrium surface tension than EAK16-II is probably due to the 
formation of a β-turn structure through the intramolecular ionic interactions in EAK16-IV. This 
conformational change may cause the exposure of hydrophobic alanine residues toward the aqueous 















































Figure 6.3 The hydrophobicity of the three peptides and their assemblies by dynamic surface tension 
(a) and ANS fluorescence (b). The inset is the ANS fluorescence control with the absence of peptides. 







Figure 6.3b shows the fluorescence spectra of the ANS probe in the three peptide solutions 
compared to that in pure water (black line and the inset). The normalized fluorescence intensities of 
ANS in different solutions follow the trend: EFK16-II >> EAK16-II ≈ EAK16-IV > H2O. Meanwhile, 
the peak positions of the spectra are different; it locates at ~520 nm in pure water (inset), but shifts to 
~485 nm in EAK16-II and EAK16-IV solutions. The ANS fluorescence spectrum has a peak of ~470 
nm in the EFK16-II solution. The changes in ANS fluorescence intensity and peak position indicate 
that the ANS probe is in different environments. ANS is a widely used probe to study protein 
aggregation as well as cell membrane composition and function due to its extreme sensitivity to the 
changes in the polarity of the probed environment.246,249,250 A less polar environment will cause a shift 
of the fluorescence spectrum of ANS toward lower wavelengths (blue shift) and a significant increase 
in the fluorescence quantum yield.246 Thus, the changes in ANS fluorescence in different peptide 
solutions (Figure 6.3b) can be related to the hydrophobicity of the local environment where ANS 
resides. This leads to a conclusion that EFK16-II provides a more hydrophobic environment for ANS 
than the other two peptides. These results also suggest that EFK16-II may have different impacts on 
the complexation with the hydrophobic anticancer agent ellipticine, compared with EAK16-II and 
EAK16-IV. 
It is worth noting that the hydrophobicity determined by the two methods may correspond to 
two different situations. Surface tension is a property based on the molecular adsorption at the air-
solution interface, affecting the surface free energy. Usually, the adsorption process favors small 
molecules due to their fast diffusion from bulk to the interface. Thus, in self-assembling peptide 
systems, the surface tension may reflect predominantly the properties of peptide monomers and small 
peptide assemblies, rather than those of the large peptide aggregates. On the other hand, ANS 
fluorescence depends predominantly on the local probe environment. The binding of ANS to peptide 
monomers may not significantly affect its fluorescence properties as it still “feels” surrounding 
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solvent molecules (i.e., water in this case). Only when the ANS probe is enclosed in a different 
environment from the solvent does its fluorescence greatly change. Therefore, the observed changes 
in ANS fluorescence in Figure 6.3b should result from the properties of peptide 
assemblies/aggregates. This is probably why the difference in surface tension measurements in 
EAK16-II and EAK16-IV solutions is not observed in the case of ANS fluorescence measurements. 
6.3.2 Sequence Effect on the Complex Formation 
Since the different peptide sequences affect the peptide assemblies and their properties, they should 
further influence the formation of peptide-ellipticine complexes. The results are shown in Figure 6.4. 
The differences among the complexes made of the three peptides can be directly visualized from the 
appearance of the suspensions (Figure 6.4a). For EAK16-II, the peptide-ellipticine solutions appear to 
be slightly turbid at peptide concentrations of 0.2 and 0.04 mg/mL, indicating the formation of large 
colloidal suspensions. However, at a concentration of 0.5 mg/mL, the solution becomes clearer with a 
light yellow color (far left vial). Similar appearances of the peptide-ellipticine solutions are found for 
EAK16-IV (central three vials) except that the solution looks less yellow at a peptide concentration of 
0.5 mg/mL. For EFK16-II, all solutions appear cloudy. Compared with the control sample (with the 
absence of peptides, far right vial) that remains colorless and transparent, the changes in the solution 
appearance of the peptide-ellipticine samples reveal that ellipticine has been uptaken by the peptides 
and stabilized in solution. 
The different appearances of the solutions may indicate different molecular states of ellipticine 
in the complexes. Recent studies on the complexation of EAK16-II with ellipticine have 
demonstrated that two molecular states of ellipticine, either protonated or crystalline, can be obtained 
in the complexes depending on the peptide and ellipticine concentrations (Chapter 4). The protonation 
of ellipticine usually occurs at a higher peptide concentration, related to a relatively low solution pH 
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(< 5, pKa of ellipticine is ~6);73 protonated ellipticine can be stabilized by ionic interaction with the 
negatively charged residues (glutamic acid E in this case) of the peptide. The ellipticine microcrystals 
are stabilized by peptide assemblies coating on the surface (Chapter 4).56 When ellipticine is 
protonated, it can dissolve in aqueous solution and cause the solution to have a yellow, transparent 
appearance. On the other hand, the suspended ellipticine microcrystals make the solution turbid and 
cloudy. Thus, by looking at the appearance of the samples, one can possibly predict that EAK16-II 
and EAK16-IV can stabilize protonated or crystalline ellipticine while ellipticine stabilized by 





























































Figure 6.4 The formation of peptide-ellipticine complexes. (a) Photographs of the complexes with the 
three peptides at different peptide concentrations and the ellipticine in pure water as a control. The 
normalized fluorescence spectra of ellipticine in the complexes with EAK16-II (b), EAK16-IV (c) 
and EFK16-II (d). The insets show the spectra of the complexes with low peptide concentrations. The 
ellipticine concentration was fixed at 0.04 mg/mL (0.16 mM). 
 
The molecular state of ellipticine can be further elucidated by the ellipticine fluorescence 
spectra. It has been found that protonated ellipticine molecules have a fluorescence peak at ~520 nm 
while the fluorescence peak at ~430 nm is attributed to neutral ellipticine molecules (Chapter 3); 
crystalline ellipticine exhibits a fluorescence peak at ~470 nm with an extremely low intensity.56 The 
fluorescence spectra of the complexes with the three peptides, EAK16-II, EAK16-IV and EFK16-II, 
are shown in Figure 6.4b, c and d, respectively. For EAK16-II and EAK16-IV, the complexes with 
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0.5 mg/mL peptide have a fluorescence peak located ~520 nm, indicating that ellipticine is 
protonated. At peptide concentrations below 0.5 mg/mL, the spectra have a peak close to 470 nm with 
an extremely low intensity (insets in Figure 6.4b and c), representing crystalline ellipticine. 
Interestingly, the complexes with EFK16-II exhibit a fluorescence spectrum with a major peak 
located at ~435 nm and a small shoulder covering the wavelengths from 470 to 570 nm (Figure 6.4d), 
very different from those of protonated and crystalline ellipticine. The peak located at ~435 nm 
represents neutral (non-charged) ellipticine, present as individual molecules in a much less polar 
environment (Chapter 3). The peak intensity is proportional to the EFK16-II concentration. These 
results indicate that EFK16-II can stabilize neutral, molecular ellipticine in aqueous solution; in 
contrast, the other two molecular states of ellipticine, protonated and crystalline, can be formed in the 
complexes with EAK16-II and EAK16-IV. EFK16-II assemblies provide a more hydrophobic 
environment than those of EAK16-II and EAK16-IV as shown in Figure 6.3b, possibly facilitating the 
stabilization of neutral ellipticine molecules. Note that in addition to neutral ellipticine, crystalline 
and protonated ellipticine can coexist in the suspensions as indicated by the turbid appearance of the 
suspensions and a shoulder from the fluorescence spectra. The fluorescence signals from crystalline 
ellipticine, however, are too small to be seen compared to those of neutral ellipticine. The different 
quantum yields and overlapping of the fluorescence signals from the three molecular states of 
ellipticine make it difficult to determine the percentage of each state among the three in the 
complexes. However, the total amount of stabilized ellipticine can be obtained. 
To determine how much ellipticine can be stabilized in solution by the peptides, aliquots of the 
peptide-ellipticine suspensions were diluted in DMSO, and the UV absorption of ellipticine was 
collected in the resulting mixture. The ellipticine absorbance was then converted to corresponding 
ellipticine concentration in the suspensions. This concentration was compared with the given 
ellipticine concentration (0.04 mg/mL) to obtain the maximum suspension (%) as shown in Figure 
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6.5. Initially in the preparation, ellipticine is in solid form as a thin film at the bottom of the vial. With 
the help of the peptides and mechanical stirring over time, ellipticine can be uptaken and stabilized in 
the solution as protonated, neutral or crystalline ellipticine. Not all given ellipticine can be stabilized 
and suspended in solution; the deposition of ellipticine thin film can still be observed at the bottom of 
most sample vials. The amount of stabilized ellipticine varies with peptide type and concentration. 
The maximum amount of ellipticine in suspension is found to be ~71% (by wt.) at 0.5 mg/mL 
EAK16-II. At the same peptide concentration, such a value decreases to ~56% for EAK16-IV and to 
~46% for EFK16-II. The lowest maximum suspension appears to be ~13% by 0.04 mg/mL EAK16-
IV, which is 3 fold higher than the control (~4.5%) with the absence of peptides. The amount of 
ellipticine suspended by the peptide in water is found to be much higher than the reported solubility in 
water (~0.6 μM)71. With the peptide concentration, the maximum suspension varies largely for 
EAK16-II and EAK16-IV but less so for EFK16-II. Overall, EAK16-II appears to be the most 
effective peptide among the three at stabilizing protonated ellipticine (at a high peptide concentration 
of 0.5 mg/mL); EFK16-II, on the other hand, can stabilize neutral ellipticine (in addition to crystalline 

























Figure 6.5 The maximum suspension (%) of ellipticine in aqueous solution stabilized by the three 
peptides and with the absence of peptides. 0.04 mg/mL (0.16 mM) of ellipticine was used in the 
sample preparation. 
 
6.3.3 Size of the Complexes 
The size distribution of the peptide assemblies and complexes at a peptide concentration of 0.5 
mg/mL is shown in Figure 6.6. For all three peptides, the peptide assemblies have a broad size 
distribution from 10 to several hundred nanometers (Figure 6.6a). They all have a major size 
population around 30 nm and a second one corresponding to a shoulder located at ~300 nm, 100 nm 
and 200 nm for EAK16-II, EAK16-IV and EFK16-II, respectively. The size distribution of EAK16-II 
obtained here correlates well with our earlier findings, and the two populations represent short peptide 
nanofibers and fiber clusters.68 When the peptides interact with ellipticine to form complexes, the size 
distributions change significantly as shown in Figure 6.6b. Note that only the size distributions of the 
complexes with EAK16-II and EAK16-IV are shown in the plot because the size of the complexes 
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with EFK16-II is very polydispersed, and goes beyond the detection limit of the instrument. The 
EAK16-II-ellipticine complexes have a relatively wider size distribution than EAK16-IV-ellipticine 
complexes; two size populations with one centered at about 90 nm and the other at about 500 nm can 



































Figure 6.6 The size distribution of the three peptides at 0.5 mg/mL (0.3 mM) in pure water (a) and 




SEM imaging was applied as a complementary method to examine the size and morphology of 
the complexes for the three peptides at different peptide concentrations. The representative images are 
shown in Figure 6.7. It is clearly seen that the dimensions of the complexes with 0.5 mg/mL EAK16-
II and EAK16-IV are in the range of ~100-200 nm. For these two peptides, at peptide concentrations 
below 0.5 mg/mL, the size of the complexes can be as large as several micrometers. These complexes 
tend to have a rod-like or fiber-like structure, aggregating into bundles or entanglements. Such 
structures are very different from ellipticine crystals suspended in water (control). 
For EFK16-II, the dimensions of the complexes range from hundreds of nanometers to several 
micrometers regardless of the peptide concentrations. However, the morphology of these complexes 
looks different according to the peptide concentration. At 0.04 mg/mL, the majority of the complexes 
are also rod-like although they seem to be shorter and more dispersed than those with EAK16-II and 
EAK16-IV; at higher peptide concentrations, the complexes appear to have irregular shapes. In 
addition, more membrane-like structures are observed in the background with the increase in EFK16-
II concentration. These membrane-like EFK16-II assemblies could play an important role in 
stabilizing neutral ellipticine molecules. This may explain the increase in the fluorescence intensity of 
neutral ellipticine as a function of EFK16-II concentration shown in Figure 6.4d. Meanwhile, the 
ellipticine microcrystals could be stabilized by the amphiphilic EFK16-II monomers and small 
assemblies via forming peptide coatings on the surface of the crystals, leading to the formation of 





Figure 6.7 SEM images of the complexes with the three peptides at different peptide concentrations 
and ellipticine crystals in pure water as the control. 0.04 mg/mL (0.16 mM) ellipticine was used for 





6.3.4 Cellular Toxicity of the Complexes and Their Dilutions  
From the characterization of the complexes above, it can be summarized that peptide sequence will 
affect the molecular state of ellipticine in the peptide-ellipticine complexes/assemblies. EAK16-II and 
EAK16-IV can solubilize protonated ellipticine or encapsulate ellipticine microcrystals, depending on 
the peptide concentration. EFK16-II, on the other hand, can stabilize neutral ellipticine molecules in 
addition to the other two states in aqueous solution; the amount of neutral ellipticine that can be 
carried by EFK16-II assemblies is peptide concentration dependent. The size and structure of the 
complexes also depend on the type of peptide and peptide concentration. To gain more insight 
concerning these differences in the molecular state of ellipticine as well as the size and structure of 
the complexes, we investigated their cellular toxicity against two cancer cell lines and the stability of 
the complexes upon dilution in water. The information regarding the complex stability after dilution 
would be useful for later animal studies and preclinical experiments.  
Figure 6.8 shows the viability of both A549 and MCF-7 cancer cells upon being treated with 
peptide-ellipticine complexes for 48 h. For A549 cells (Figure 6.8a), all peptide-ellipticine complexes 
reduce the cell viability to less than 0.3 compared with the viability of non-treated cells (viability is 
1). The toxicity of complexes is 2-fold higher than that of the ellipticine control with the absence of 
peptides (light green bar). The peptide controls exhibit some toxicity to the cells, causing the decrease 
of viability to the values between 0.6 and 0.8. The much lower cell viability resulted from the 
peptide-ellipticine complexes compared with that from the ellipticine control is probably due to the 
fact that the peptides can stabilize large amounts of ellipticine in aqueous solution as shown in Figure 
6.5. Interestingly, the cells treated with the complexes formulated with 0.5 mg/mL EAK16-II and 
EAK16-IV have almost zero viability. This may indicate that protonated ellipticine is more effective 
at killing A549 cells than other forms of ellipticine in the complexes. Such a result seems to 
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Figure 6.8 Cellular toxicity of the peptides and their complexes with ellipticine for A549 cells (a) and 
MCF-7 cells (b). The viability of non-treated cells is 1 (M: cells were treated with culture medium). 
For the solvent control, cells were treated with pure water (dark green bar); for the drug control, cells 
were treated with ellipticine in pure water (light green bar). The numbers represent different final 
peptide concentration in μg/mL. The final ellipticine concentration is 10 μg/mL. 
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The high efficacy of protonated ellipticine against cancer cells may be explained in the 
following. First, the protonated ellipticine has a positive charge, which can interact with a negatively 
charged cell membrane surface, leading to accumulation of ellipticine at the cell membrane surface. 
In addition, such a small hydrophobic molecule is expected to cross the cell membrane easily into the 
cytoplasm. Second, the protonated ellipticine molecules release much faster from the complexes 
compared with that from ellipticine microcrystals, due to the differences in complex size and a 
relatively weak interaction between protonated ellipticine and the peptide in the complexes (Chapter 
4). This accelerates the diffusion speed of ellipticine from the complexes to the cells, facilitating a 
fast cellular uptake of ellipticine. Third, although EFK16-II is capable of stabilizing neutral ellipticine 
molecules, the amount of stabilized molecules are probably low; the release rate may be slow due to 
the likely stronger hydrophobic interaction between neutral ellipticine and EFK16-II in the 
complexes. This is probably why the complex prepared with 0.5 mg/mL EFK16-II has much less 
effect on the cellular toxicity than protonated ellipticine stabilized by EAK16-II and EAK16-IV at the 
same peptide concentration. 
For MCF-7 cells, the efficacy of protonated ellipticine on anti-proliferation of the cells 
becomes more significant when compared with the other forms of ellipticine (Figure 6.8b). The 
lowest cell viability for the complexes with neutral ellipticine and/or ellipticine crystals is around 0.5, 
which is about 70% of the viability for the ellipticine control (~0.7). This percentage can be as low as 
~25% in the case of A549 cells. Such a difference may imply that the peptide-ellipticine suspensions 
act less effectively on MCF-7 cells than on A549 cells. However, the complexes with protonated 
ellipticine have similar efficacy at killing both cells, although the reason behind is still unclear. It 
could be related to the different sensitivity, internalization pathway and/or cell defense mechanism of 
the two cells in response to ellipticine. Nevertheless, these results provide evidence that the molecular 
state of ellipticine in the complexes significantly affects their cellular toxicity. Accordingly, one 
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should be aware that selection of an appropriate formulation method is important in treating different 
cancer cells. 
Figure 6.9 shows the toxicity of the complexes with 0.5 mg/mL EAK16-II, EAK16-IV and 
EFK16-II upon serial dilution in water against both cell lines. The ellipticine control is diluted the 
same way for comparison. It is clearly seen that dilution has a significant effect on the toxicity of the 
complexes with EAK16-II and EAK16-IV, where ellipticine is stabilized in protonated form. For 
A549 cells (Figure 6.9a), the cell viability is very low and less than 0.05 in the presence of these 
complexes before dilution; it increases largely to above 0.6 for 16-fold dilution of the complexes. A 
similar trend is found for MCF-7 cells as the viability increases from less than 0.05 to above 0.7 
(Figure 6.9b). Such changes imply that the complexes may not be stable, altering the protonated form 
of ellipticine after dilution in water. This instability of complexes is probably due to the rise in 
solution pH, leading to the deprotonation of ellipticine and the formation of ellipticine microcrystals 
after dilution. This may explain why a sudden increase in cell viability occurs upon 2-time dilution 
for MCF-7 cells as they seem to be more sensitive to protonated ellipticine than ellipticine 
microcrystals. 
The EFK16-II-ellipticine complexes, on the other hand, exhibit good stability upon dilution in 
water. The viability increases from ~0.25 to ~0.5 for A549 cells; for MCF-7 cells, it remains 
unchanged at ~0.57 up to 4-time dilution and then slightly increases to ~0.65 for 16-time dilution. 
Such a good stability may result from a stronger interaction between EFK16-II and ellipticine in the 
complexes due to a higher hydrophobicity of the peptide. In addition, a possible increase in solution 
pH after dilution should not affect the state of the stabilized neutral ellipticine molecules or ellipticine 
microcrystals. It is worth noting that although these complexes are not as effective as protonated 
ellipticine at killing cancer cells, their stability is much better, which is especially important for 
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Figure 6.9 Cellular toxicity of the complexes formulated with the three peptides at a peptide 
concentration of 0.5 mg/mL (0.3 mM) and their serial dilutions in water for A549 cells (a) and MCF-
7 cells (b). EPT: ellipticine. 
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Overall, this study has demonstrated the effect of peptide sequence on its ability to stabilize 
hydrophobic ellipticine in protonated, neutral as well as crystalline forms in aqueous solution. The 
difference in charge distribution (type II vs. type IV) on the peptide sequence seems not to have much 
effect on the complex formation and the molecular state of ellipticine in the complexes. The size, 
anticancer activity and stability of the complexes are very similar, although the charge distribution 
does affect, to some degree, the peptide assemblies: nanofibers vs. globular aggregates. It may be 
because the complexation of ellipticine with EAK16-II and EAK16-IV is mainly based on the peptide 
monomers but not on the peptide assemblies. The increase in hydrophobicity of the peptide by 
replacing alanine (A) with phenylalanine (F), however, significantly alters the molecular state of 
ellipticine in the complexes, the complex stability and its therapeutic effect due to the following 
reasons: (i) the EFK16-II assemblies provide a more hydrophobic, enclosed environment where 
neutral ellipticine molecules can be solubilized; (ii) a stronger hydrophobic interaction between 
ellipticine and EFK16-II may further enhance the stability of the complexes upon dilution. 
Different peptide sequences have different advantages in formulating the ellipticine drug. For 
example, 0.5 mg/mL EAK16-II (or EAK16-IV) can solubilize protonated ellipticine in nanoscale 
complexes with high anticancer activity against both A549 and MCF-7 cells, but these complexes are 
pH sensitive and not very stable after dilution. In contrast, the complexes formulated with 0.5 mg/mL 
EFK16-II are more stable upon dilution, but most of their sizes are in the micrometer range and their 
anticancer activity is relatively low. Nevertheless, these results provide essential information to 
design an appropriate peptide sequence that would optimize the delivery of hydrophobic anticancer 
drugs. One could utilize the advantages of different molecular states of ellipticine to improve the 
delivery efficacy, through a proper peptide design to form a stable, peptide nanocarriers, which can 
encapsulate neutral or crystalline ellipticine; if such a carrier enters cells through endocytosis, the 
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encapsulated ellipticine becomes protonated at low pH in the lysosomes, and the protonated 
ellipticine can be released and cross the lysosome membrane into cytoplasm. 
6.4 Conclusions 
Three ionic-complementary self-assembling peptides, EAK16-II, EAK16-IV and EFK16-II, with 
different charge distributions and hydrophobicities were found to be able to stabilize the hydrophobic 
anticancer agent ellipticine in aqueous solution. Ellipticine was stabilized in the form of 
microcrystals, protonated and neutral molecules depending on the peptide sequence and the peptide 
concentration. 0.5 mg/mL EAK16-II and EAK16-IV stabilized protonated ellipticine to form nano-
complexes while crystalline ellipticine was obtained in the complexes with these peptides at lower 
peptide concentrations. On the other hand, EFK16-II was able to stabilize both neutral and crystalline 
ellipticine within the range of tested peptide concentrations; the amount of neutral ellipticine that can 
be stabilized was proportional to the peptide concentration. The different molecular states of 
stabilized ellipticine in the complexes greatly affected the anticancer activity of the complexes and 
their stability upon dilution in water. The complexes with protonated ellipticine were found to be very 
effective at killing both A549 and MCF-7 cells with a cell viability close to zero; however, these 
complexes were not very stable and their anticancer activity reduced significantly after serial dilution 
in water. The complexes formulated with EFK16-II (containing neutral ellipticine and ellipticine 
microcrystals), on the contrary, appeared to be stable after serial dilution, although their original 
anticancer activity was relatively low. These results showed that the differences in charge distribution 
of the peptides did not have much effect on the complex formation and their cellular toxicity, whereas 
the increase in peptide hydrophobicity could strengthen the interaction between the peptide and 
ellipticine, which gives the stability of their complexes upon dilution. This study provides necessary 
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information on peptide sequence design to construct functional peptide carriers for hydrophobic 






Chapter 7                                                                     
Original Contributions and Recommendations 
7.1 Original Contributions to Research: 
This thesis presented the potential of self-assembling peptides as carriers for hydrophobic drug 
delivery. We explored a special class of self-assembling, ionic-complementary peptides for the 
delivery of a hydrophobic anticancer agent, ellipticine. The thesis includes the following parts: (i) 
systematic study the photophysical properties of ellipticine in different solution environments; (ii) 
characterization of the complex formation of ellipticine with a self-assembling peptide and the release 
kinetics of ellipticine from the complexes; (iii) investigation of the therapeutic effect of the 
complexes in vitro and the ellipticine uptake into two cancer cell lines; (iv) study of the peptide 
sequence effect on the complex formation and the in vitro delivery for future design of appropriate 
self-assembling peptide-based delivery vehicles for hydrophobic anticancer drugs. The original 
contributions to research of each part are summarized in the following sections.     
Solvent Effect on Photophysical Properties of Ellipticine. The photophysical properties of the 
anticancer agent ellipticine were systematically studied in different solution environments, including 
16 organic solvents, some of their mixtures and lipid vesicles. The UV absorption and fluorescence 
emission of ellipticine were found to be solvent/environment dependent. As the solvent polarity 
increased, ellipticine exhibited a spectral shift to the red (lower energy) for both absorption and 
emission. The spectral shifts could be correlated with the solvent dielectric constants and the solvent 
polarity using the Lippert-Mataga equation. The presence of a non-linear trend in the Lippert-Mataga 
plot indicated the existence of specific solvent effects. Such effects were related to intramolecular 
charge transfer (ICT) due to the large dipole moment difference between the ground state and the 
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excited state as well as the hydrogen bonding between the solvent and ellipticine. The formation of 
stronger hydrogen bonds in alcohols led to larger extinction coefficients and longer lifetimes, 
although methanol was an exception. In EPC liposome suspensions, ellipticine exhibited an emission 
band at 436 nm, indicating that ellipticine was located in a rather polar environment, close to the 
hydrophilic surface of the liposomes rather than buried in the hydrophobic interior of the lipid 
bilayers. This study not only provides detailed information on the photophysical properties of 
ellipticine in various environments, but also suggests that the dependence of the spectral shift of 
ellipticine with its local environment can be a good indicator of where ellipticine is located in a 
heterogeneous medium like EPC liposomes or cultured cells. 
Complexation and Release of Ellipticine with EAK16-II. A model self-assembling, ionic-
complementary peptide, EAK16-II, was found to be able to stabilize the hydrophobic anticancer agent 
ellipticine in aqueous solution. Both crystalline and protonated forms of ellipticine can be obtained in 
the EAK16-II-ellipticine complexes. The complex formation in water is peptide concentration-
dependent. When the peptide concentration was close to its critical aggregation concentration (~0.1 
mg/mL), the equilibration time for complex formation could be as short as 5 h. At higher and lower 
peptide concentrations, the time required to reach equilibrium became much longer. High peptide 
concentrations (> 0.1 mg/mL) facilitated the formation of protonated ellipticine during the 
complexation while low peptide concentrations favored crystalline ellipticine formation. With a 
combination of 0.1 mg/mL ellipticine and 0.5 mg/mL EAK16-II, protonated ellipticine could be 
stabilized at equilibrium.  
The transfer rate of ellipticine from the complexes into EPC liposomes (cell membrane 
mimics) was dependent on the peptide concentration used during formulation. A higher peptide 
concentration resulted in a faster release rate, related to the fact that higher peptide concentrations 
favor the protonation of ellipticine and the formation of smaller complexes. In addition, the size of the 
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EAK16-II-ellipticine complexes could be tuned by adjusting the peptide-to-ellipticine ratio (by mass) 
during formulation. This study demonstrates the capability of self-assembling, ionic-complementary 
peptides as carriers for hydrophobic anticancer drug delivery. 
In Vitro Delivery of EAK16-II-Ellipticine Complexes. EAK16-II was able to stabilize protonated or 
crystalline ellipticine in aqueous solution depending on the peptide-to-ellipticine ratio (by mass). At 
an ellipticine concentration of 0.1 mg/mL, the stabilized ellipticine was protonated at and above the 
ratio of 5:1; below this ratio, ellipticine was mostly in crystalline form in the complexes. These two 
molecular states of ellipticine in the complexes exhibited different toxicity against two cancer cell 
lines, A549 and MCF-7, with protonated ellipticine being more toxic. Such an effect became more 
pronounced for MCF-7 cells than for A549 cells. The time-dependent toxicity showed that the 
complexes with protonated ellipticine reduced the cell viability of MCF-7 cells to ~50% at 4 h, 
whereas 12 h treatment was required in order to achieve the same effect for A549 cells. This may be 
due to that MCF-7 cells were more sensitive to protonated ellipticine. Although the complexes with 
protonated ellipticine showed high toxicity to both cancer cells, they were not stable upon dilution in 
water.  
The uptake of ellipticine in both cell lines appeared to follow a diffusion mechanism. It was 
found that both cancer cells exhibited strong ellipticine fluorescence at 4 °C, indicating the uptake is 
energy-independent (i.e., not through endocytosis). The complexation of ellipticine with EAK16-II 
seemed not to alter the internalization pathway of ellipticine. However, it significantly enhanced the 
uptake over a shorter time period (~5 min). These results demonstrate that the EAK16-II-ellipticine 
complexes with protonated ellipticine are effective at killing cancer cells in vitro; the existence of 
some unfavorable properties of the complexes, such as unspecific cellular uptake, suggests that an 




Peptide Sequence Effect on the Complexation and In Vitro Delivery of Ellipticine. Three 
self-assembling ionic-complementary peptides, EAK16-II, EAK16-IV and EFK16-II (with different 
charge distributions and hydrophobicities), were found to be able to stabilize ellipticine in aqueous 
solution in the form of crystalline, protonated and/or neutral molecules, depending on the peptide 
sequence and the peptide concentration. 0.5 mg/mL EAK16-II and EAK16-IV stabilized protonated 
ellipticine to form nano-complexes while crystalline ellipticine was stabilized at lower peptide 
concentrations. On the other hand, EFK16-II was able to stabilize mainly neutral ellipticine molecules 
and ellipticine microcrystals; the amount of neutral ellipticine that can be stabilized was proportional 
to the peptide concentration.  
The different molecular states of stabilized ellipticine in the complexes greatly affected the 
anticancer activity of the complexes and their stability upon dilution in water. The complexes with 
protonated ellipticine were found to be effective at killing both A549 and MCF-7 cells (with a cell 
viability close to zero); however, these complexes were not very stable and their anticancer activity 
reduced significantly after serial dilution in water. The complexes formulated with EFK16-II 
(containing neutral ellipticine and ellipticine microcrystals), on the contrary, appeared to be stable 
after serial dilution, although their original anticancer activity was relatively low.  
These results showed that the differences in charge distribution of the peptides did not have 
much effect on the complex formation and their cellular toxicity, whereas the increase in peptide 
hydrophobicity could strengthen the interaction between the peptide and ellipticine, leading to a high 
stability of their complexes upon dilution. Although the three peptides had different nanostructures 
owing to the peptide propensity, the difference in nanostructures may not be a necessary factor 
affecting the complexation and cellular delivery of ellipticine. This study provides useful information 





Recommended future work to develop self-assembling peptide-based nanocarriers for hydrophobic 
anticancer drug delivery can be divided into three major parts: (a) optimization of the peptide-drug 
formulation; (b) enhancement of the delivery efficacy; (c) evaluation of the complexes in vivo. The 
details in each part are listed in the following: 
Optimize the peptide-drug formulation: 
1. An appropriate peptide design is required to form the complexes with high stability, high 
loading efficiency, controllable release, desired dimension and good biocompatibility. A peptide 
library has been constructed with rational design as shown in Table A1. One should find an optimal 
condition to perform high throughput screening on these peptides; hopefully, several candidate 
sequences can be identified. New peptide library may be built based on the peptide candidates. 
2. Current work has developed a method to approximately estimate the maximum suspension 
concentration of the drugs. However, this concentration does not represent the drug loading capacity, 
which is an important factor determining the drug density in delivery systems so that the drug dosage 
forms and scheduling can be accommodated according to chemotherapy requirements. Quite often, 
large drug doses are required in cancer treatment in order to reduce the number of drug 
administrations and suppress the drug resistance. A new method should be developed to quantify the 
amount of peptides as well as the drugs in the complexes, to determine the amount of the drug loaded 
(encapsulated) in the peptide carrier and obtain the drug-to-peptide ratio. Ultracentrifugation and 
filtration may be suitable for this purpose. 
3. Complete stability studies should be carried out. Once the peptide-anticancer drug 
complexes are formed, it is necessary to ascertain that such peptide-drug formulation can tolerate 
various physiological conditions during delivery. In addition to dilution stability, the complexes 
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should be tested for their stability for long storage (i.e., shelf-life), and in the presence of serum and 
degradation enzymes, including pepsin, trypsin, chymotrypsin, elasterase, carboxypeptidase and 
aminopeptidases. 
4. The peptide-drug complexes circulating in the bloodstream must avoid significant 
complement activation, which is the primary cause of immune response. Thus, the complement-
activating properties of the peptide nanocarriers should be examined. This can be done using existing 
methods.251 Briefly, antibody-sensitized sheep red blood cells are used to monitor the hemolysis 
following the addition of serum. Titration of serum and peptide-drug complexes will allow one to 
determine the amount of serum that causes lysis of 50% of the erythrocytes (CH50). If significant 
complement activation is observed, the use of D-form amino acids in peptide synthesis or PEG 
coatings could be considered. 
5. Different formulation methods can be explored. The complexes can be prepared in an 
appropriate buffer solution (should be clinical approved) to achieve physiological pH for 
administration. Cosolvents or additives can also be introduced to enhance the complex stability and 
biocompatibility, and to possibly control the complex size. 
Enhance the delivery efficacy: 
1. An advance in cancer chemotherapy is to achieve active targeted delivery. This can be done 
by incorporating targeting peptide motifs into self-assembling peptide-based nanocarriers. This 
project would include the following steps: (i) find appropriate targeting peptide sequences from 
published literature; (ii) construct self-assembling peptide nanocarriers based on the accumulated 
knowledge from current work; (iii) incorporate targeting sequences into the nanocarriers; iv) test the 
targeting principles of the peptide vehicles in vitro and in vivo; (v) investigate the delivery efficacy of 
the modified nanocarriers for existing anticancer agents. 
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2. In addition to active targeting, the passive targeting via EPR could be an alternative to 
improve the delivery efficacy. This can be achieved by controlling the dimension of the complexes 
(optimal at ~200 nm) during formulation or through peptide sequence design. Different formulation 
conditions would help control the complex size. For example, cosolvents or clinically approved 
additives can be introduced during formulation. In addition, fundamental studies on peptide self-
assembly should provide important information for proper peptide design. 
3. Detailed cell biology studies on the fate of the complexes should be characterized. For 
instance, the cellular uptake mechanism is important for the design of effective delivery system. In 
addition, identify the apoptotic pathway could provide a tool for in vivo studies. 
Evaluate therapeutic effect of the complex in vivo: 
1. Once a promising peptide-drug complex is identified, it should be tested in vivo using 
appropriate cancer animal models. This can be achieved by seeking collaborators at other universities 
or research institutes. Currently, we have collaborated with Dr. Mingyao Liu (and his group) at the 
University of Toronto for pilot animal studies on the EAK16-II-ellipticine complexes. Successful 
animal studies should rely on the formulation. For example, the formulation should have good 
dilution stability and biocompatibility, and satisfy the conditions for intravenous (i.v.) injection. In 
general, the animal studies should include the complex efficacy (e.g., animal survival), biodistribution, 
pharmacokinetics and pharmacodynamics.  
Other studies: 
1. Ellipticine is selected as a model hydrophobic anticancer drug to test the delivery principles 
using self-assembling peptide-based nanocarriers. The system can be applied to other hydrophobic 
anticancer therapeutics, such as paclitaxel, for which its commercial formulation Cremophor® EL has 
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several undesirable side effects in clinics.35,94 Another fluorescent, pH sensitive anticancer drug, 
camptothecin could also be considered.157,238 
2. Other imaging techniques such as transmission electron microscopy (TEM) can be applied as 
a complement tool to SEM and DLS to study the complex dimension and structure. 
3. In this study, the formation of peptide-ellipticine complexes was confirmed by mainly 
fluorescence spectra and solution appearances in comparison with the drug control (no peptides). 
However, these results provide indirect evidence for complex formation, and other approaches should 
be considered to observe the complexation of ellipticine with the peptide. This may be achieved by 
labeling the peptide with a fluorophore. The interaction of ellipticine with the peptide can then be 
monitored by either the fluorescence resonance energy transfer technique or a fluorescence confocal 
microscopy. These approaches also enable us to investigate the cellular distribution of the peptide 
vehicles.  
4. The “inner filter effect” on the ellipticine fluorescence at higher ellipticine concentrations 
should be characterized further. One could construct a calibration curve of protonated ellipticine in 
acidic solution to obtain the concentration threshold for the inner filter effect. This may also help 
quantify the protonated ellipticine stabilized in the complexes. 
5. One should consider the effect of free drug on cell culture experiments and in vivo studies in 








A. Peptide Library for Hydrophobic Anticancer Drug Delivery 
The designed peptides for hydrophobic anticancer drug delivery are listed in Table A1. 
 





Sequence (n-c)  Charges  at pH 7 
Charges at 
pH~4.5 
16 n-GEGEGKGKGEGEGKGK-c  4+,4- 4+,4- 
16 n-IEIEIKIKIEIEIKIK-c  4+,4- 4+,4- EAK derivatives 
8 n-EEKKEEKK-c  4+,4- 4+,4- 
16 n-EEIIIIEERRIIIIRR-c  4+,4- 4+,4- 
16 n-AAEEAAEEAAKKAAKK-c  4+,4- 4+,4- 
16 n-AAAAEEEEAAAAKKKK-c  4+,4- 4+,4- 
8 n-LLEELLRR-c  2+,2- 2+,2- 
8 n-FFEEFFRR-c  2+,2- 2+,2- 




8 n-EEIIIIRR-c  2+,2- 2+,2- 
2 FF    
3 n-FFR-c  1+ 1+ 
4 FFFF    
2 n-YY-c    
2 YY    
4 YYYY    
Short Peptides 
 
4 n-YYYQ-c    
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2 FF    
4 n-NFFR-c  1+ 1+ 
4 n-NFFQ-c    
8 n-FNFNFRFR-c  2+ 2+ 
8 n-LNLNLRLR-c  2+ 2+ 
8 n-VNVNVRVR-c  2+ 2+ 
8 n-ININIRIR-c  2+ 2+ 
16 n-ININIRIRININIRIR-c  4+ 4+ 
16 n-IINRIINRIINRIINR-c  4+ 4+ 
20 n-WHIHININININIRIRIRIR-c  4+ 6+ 
8 n-IINNIIRR-c  2+ 2+ 
8 n-NNIIIIRR-c  2+ 2+ 
12 n-WNNNIIIIIRRR-c  3+ 3+ 
18 n-WHIINNIIHHIINNIIRR-c  5+ 6+ 
Hydrogen Bonding 
Complementary  
20 n-WHHNNNSINISINISINRRR-c  2+ 5+ 
11 n-WRIRIFININW-c  2+ 2+ 
13 n-WQQQIIIIIRRRH-c  3+ 3+ 
Hydrogen Bonding 
Complementary 
17 n-NNNISISIWININIRRR-c  3+ 3+ 
13 n-NIEIINWRIIRIR-c  3+, 1- 3+, 1- 
17 n-NNNNEIIIWIIIRHHHR-c  2+,1- 5+,1- Mixed Design 
21 n-WHHENNININIFISISIRRRN-c  3+ 5+ 
Note: n- and -c refer to the end protection by acetylation and amidation, respectively. 
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